Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 59
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Scheeren Brum, Wagner|||0000-0002-9777-0559
  • Molfetta, Guglielmo Di
  • Benedet, Andréa Lessa
  • Arslan, Burak
  • Jonaitis, Erin Mc Mullen
  • Langhough, Rebecca E.
  • Cody, Karly Alex
  • Wilson, Rachael E.
  • Carlsson, Cynthia M.
  • Vanmechelen, Eugeen|||0000-0002-9466-5366
  • Montoliu Gaya, Laia|||0000-0001-7684-6318
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Rahmouni, Nesrine
  • Tissot, Cécile
  • Stevenson, Jenna
  • Servaes, Stijn|||0000-0002-4431-957X
  • Therriault, Joseph
  • Pascoal, Tharick|||0000-0001-9057-8014
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Rosa-Neto, Pedro|||0000-0001-9116-1376
  • Johnson, Sterling C.
  • Jeromin, Andreas
  • Blennow, Kaj|||0000-0002-1890-4193
  • Zetterberg, Henrik|||0000-0003-3930-4354
IMPORTANCE Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease (AD) pathology, with p-tau217 considered to have the most utility. However, availability of p-tau217 tests for research and clinical use has been limited. Expanding access to this highly accurate AD biomarker is crucial for wider evaluation and implementation of AD blood tests. OBJECTIVE To determine the utility of a novel and commercially available immunoassay for plasma p-tau217 to detect AD pathology and evaluate reference ranges for abnormal amyloid β (Aβ) and longitudinal change across 3 selected cohorts. DESIGN, SETTING, AND PARTICIPANTS This cohort study examined data from 3 single-center observational cohorts: cross-sectional and longitudinal data from the Translational Biomarkers in Aging and Dementia (TRIAD) cohort (visits October 2017-August 2021) and Wisconsin Registry for Alzheimer's Prevention (WRAP) cohort (visits February 2007-November 2020) and cross-sectional data from the Sant Pau Initiative on Neurodegeneration (SPIN) cohort (baseline visits March 2009-November 2021). Participants included individuals with and without cognitive impairment grouped by amyloid and tau (AT) status using PET or CSF biomarkers. Data were analyzed from February to June 2023. EXPOSURES Magnetic resonance imaging, Aβ positron emission tomography (PET), tau PET, cerebrospinal fluid (CSF) biomarkers (Aβ42/40 and p-tau immunoassays), and plasma p-tau217 (ALZpath pTau217 assay). MAIN OUTCOMES AND MEASURES Accuracy of plasma p-tau217 in detecting abnormal amyloid and tau pathology, longitudinal p-tau217 change according to baseline pathology status. RESULTS The study included 786 participants (mean [SD] age, 66.3 [9.7] years; 504 females [64.1%] and 282 males [35.9%]). High accuracy was observed in identifying elevated Aβ (area under the curve [AUC], 0.92-0.96; 95% CI, 0.89-0.99) and tau pathology (AUC, 0.93-0.97; 95% CI, 0.84-0.99) across all cohorts. These accuracies were comparable with CSF biomarkers in determining abnormal PET signal. The detection of abnormal Aβ pathology using a 3-range reference yielded reproducible results and reduced confirmatory testing by approximately 80%. Longitudinally, plasma p-tau217 values showed an annual increase only in Aβ-positive individuals, with the highest increase observed in those with tau positivity. CONCLUSIONS AND RELEVANCE This study found that a commercially available plasma p-tau217 immunoassay accurately identified biological AD, comparable with results using CSF biomarkers, with reproducible cut-offs across cohorts. It detected longitudinal changes, including at the preclinical stage.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Spontaneous and perturbation-based EEG cortical excitability markers are associated with plasma p-tau181 concentration in healthy middle-aged adults

  • Perellón-Alfonso, Ruben|||0000-0001-8647-3703
  • Abellaneda Pérez, Kilian|||0000-0001-6447-1248
  • Pileckyte, Indre
  • Cabello-Toscano, María|||0000-0001-5066-3476
  • Mulet-Pons, Lídia|||0000-0002-8884-136X
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Cattaneo, Gabriele|||0000-0002-7411-6829
  • Redondo-Camós, María|||0000-0002-3890-5070
  • España-Irla, Goretti|||0000-0003-2525-6523
  • Delgado-Gallen, Selma
  • Solana Sánchez, Javier|||0000-0003-0880-7856
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Tormos, Jose M.|||0000-0002-8764-2289
  • Franzmeier, Nicolai
  • Pascual Leone, Álvaro|||0000-0001-8975-0382
  • Bartrés-Faz, David|||0000-0001-6020-4118
In early-stage Alzheimer's disease (AD) amyloid-β (Aβ) deposition can induce neuronal hyperactivity, thereby potentially triggering activity-dependent neuronal secretion of phosphorylated tau (p-tau), ensuing tau aggregation and spread. Therefore, cortical excitability is a candidate biomarker for early AD detection. Moreover, lowering neuronal excitability could potentially complement strategies to reduce Aβ and tau buildup. There is, however, a lack of understanding of the relationship between cortical excitability and p-tau increase in vivo. Therefore, in a sample of 658 healthy middle-aged (between the ages of 40 and 65) participants of the Barcelona Brain Health Initiative cohort study, we examined the relation of blood-based tau, phosphorylated at amino acid 181 (p-tau181), reflecting neuronal p-tau secretion; neurofilament light chain (NfL), as a passively released control for p-tau181; and electroencephalography (EEG) markers of cortical excitability. A subsample of 47 participants also completed a controlled brain perturbation approach via transcranial magnetic stimulation (TMS) with concurrent EEG. Results show that both spontaneous (i.e., resting-state) and perturbation-based TMS-EEG markers, are associated with blood p-tau181, particularly in older individuals. The perturbation-based marker was a significantly more sensitive predictor of p-tau181 concentration than the spontaneous resting state EEG-based marker. The relationships observed are not present for the NfL control. These results show that relationships between p-tau181 and cortical excitability are present in healthy middle-aged subjects and that p-tau181 increases may reflect activity-dependent secretion.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Plasma profiles of neurology-related proteins in at-risk mental state and first-episode psychosis, Associations with psychotic symptoms and cognitive performance

  • Llaurador-Coll, Martí
  • Montalvo Aguirrezabala, Itziar|||0000-0002-7320-5109
  • Estrada, Francesc
  • Sánchez Gistau, Vanessa|||0000-0002-8635-7144
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Labad, Javier|||0000-0003-2214-1886
  • Benedet, Andrea L.
  • Vilella, Elisabet|||0000-0002-1887-5919
Early diagnosis of psychosis is crucial, and biomarker detection may provide insights into the pathophysiology of psychosis and the potential for the development of early diagnostic tools. In particular, blood-based proteomic profiling has yielded promising results for psychiatric disorders because of the use of novel high-throughput techniques and the feasibility of performing blood extractions in routine clinical practice. Here, we studied 182 participants (33.3 % females, = 24.66 ± 5.05), comprising 50 healthy controls (HCs), 37 patients with an at-risk mental state (ARMS) and 95 patients with a first episode of psychosis (FEP). We used a panel of 92 neurology-related proteins in a multiplex immunoassay to identify the plasma protein profiles of each group, their coexpression patterns and biological relevance, and their associations with psychotic symptoms and cognitive performance. CPA2 was overexpressed in both ARMS participants (β = 0.876, adj. p = 0.009) and FEP participants (β = 0.568, adj. p = 0.011) compared with HCs. In FEP participants, in addition to CPA2, 31 other proteins were overexpressed, with GFRA1 being the most differentially expressed protein (β = 1.159, adj. p.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Associations between objective sleep metrics and brain structure in cognitively unimpaired adults: interactions with sex and Alzheimer's biomarkers

  • Stankeviciute, Laura
  • Tort-Colet, Núria
  • Fernández-Arcos, Ana
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Fauria, Karine
  • Holst, Sebastian Camillo
  • Garcés, Pilar
  • Mueggler, Thomas
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Iranzo, Álex
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
INTRODUCTION: Sleep disturbances are prevalent in Alzheimer's disease (AD), probably emerging during its preclinical stage. Poor subjective sleep quality is linked to reduced brain volume and cortical thickness (CTh), but associations with objective sleep measures, particularly regarding sex and AD pathology, remain unclear. METHODS: We characterized 171 cognitively unimpaired adults from the ALzheimer and FAmilies (ALFA) Sleep study using actigraphy, MRI, amyloid beta 42/40, and phosphorylated tau at threonine 181 in cerebrospinal fluid. RESULTS: Lower sleep efficiency, higher wake after sleep onset (WASO), and sleep fragmentation were associated with lower CTh in the medial temporal lobe and other regions linked with AD and sleep disruption, even after adjusting for AD biomarkers. Sex and AD biomarkers modified these associations, with longer WASO showing a stronger correlation with lower CTh in females. DISCUSSION: Disrupted sleep may reduce cortical integrity independently of AD biomarkers, suggesting alternative pathways. Females appear more vulnerable to impaired sleep, and AD pathology may exacerbate AD-related changes in CTh. Highlights: Poor sleep efficiency, increased WASO, and sleep fragmentation are associated with reduced CTh in regions vulnerable to early AD, independently of amyloid and tau pathology. In the presence of AD pathology, this relationship is altered, with A+T+ individuals exhibiting increased CTh associated with sleep disruption. Sex-specific effects suggest females are more vulnerable to sleep-related cortical thinning. These findings highlight the potential of targeting sleep as a secondary prevention strategy to preserve brain integrity and mitigate neurodegenerative processes in AD-vulnerable regions., The ALFA+ study receives funding from ‘la Caixa’ Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an anonymous international charity foundation through the TriBEKa Imaging Platform project (TriBEKa‑17‑519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under Grant 2017-SGR-892. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (2022-01018 and 2019-02397), the European Union's Horizon Europe Research and Innovation Programme under Grant Agreement 101053962, Swedish State Support for Clinical Research (ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (201809-2016862), the AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270), the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie Grant Agreement 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). K.B. is supported by the Swedish Research Council (2017‑00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (RDAPB‑201809‑2016615); the Swedish Alzheimer Foundation (AF‑742881); Hjärnfonden, Sweden (FO2017‑0243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALF‑agreement (ALFGBG‑715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019‑466‑236); the National Institutes of Health (NIH), USA (Grant 1R01AG068398‑01); and the Alzheimer's Association 2021 Zenith Award (ZEN‑21‑848495). M.S.C. receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (Grant Agreement 948677), the Instituto de Salud Carlos III (PI19/00155, PI22/00456), and from the ERC under the EU's ‘la Caixa’ Foundation (ID 100010434) and from the EU's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant (847648, LCF/BQ/PR21/11840004). J.D.G. is supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054). J.D.G. has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (Grant Agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (Grant Agreement RTI2018‑102261). G.S-B. receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. O.G.R. receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme IJC2020-043417-I).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer's disease

  • González Escalante, Armand
  • Milà Alomà, Marta
  • Brum, Wagner S.
  • Ashton, Nicholas J.
  • Ortiz Romero, Paula, 1994-
  • Shekari, Mahnaz
  • Campo, Marta del
  • Anastasi, Federica
  • Quijano-Rubio, Clara
  • Kollmorgen, Gwendlyn
  • Minguillón, Carolina
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • Gispert, Juan Domingo
  • Zetterberg, Henrik
  • Vilor Tejedor, Natàlia, 1988-
  • Blennow, Kaj
  • Suárez-Calvet, Marc
Background: Plasma biomarkers of Alzheimer's disease (AD) change during preclinical stages, indicating potential for detecting amyloid-β (Aβ) pathology in cognitively unimpaired (CU) individuals. Given the need for accurate, scalable biomarkers, we evaluated a fully automated plasma panel to detect and monitor longitudinal Aβ accumulation in CU individuals. Methods: In this longitudinal study, we examined a plasma panel (Aβ42/40, p-tau181, GFAP, NfL, p-tau217 and ApoE4) in CU participants at risk for AD. We assessed the biomarkers' performance to detect Aβ pathology and the cross-sectional and longitudinal relationships between the biomarkers and Aβ accumulation, neurodegeneration and cognition. Findings: We included 400 middle-aged CU participants, of whom 135 (33.8%) were CSF Aβ-positive. All plasma biomarkers differed between Aβ-positive and -negative individuals, with plasma Aβ42/40, p-tau217, p-tau181/Aβ42, and p-tau217/Aβ42 showing the best performance in detecting A+ CU individuals. However, plasma Aβ42/40 was sensitive to random variability. Plasma p-tau217/Aβ42 had the highest performance in detecting PET A+ individuals (AUC = 0.94). All baseline plasma biomarkers were associated with longitudinal increases in Aβ deposition (mean follow-up [SD]: 3.27 ± 0.5). Longitudinal changes in plasma p-tau217 and p-tau217/Aβ42 were associated with concurrent changes in Aβ (both CSF and PET) and soluble tau pathology. Interpretation: In CU individuals, several plasma biomarkers at baseline detect Aβ accumulation and are associated with its short-term change. Plasma p-tau217, and p-tau217/Aβ42 longitudinal changes reflect concurrent Aβ accumulation during this period. These findings help enrich studies in CU individuals at risk of progressing to AD. Funding: ERC-2020-STG (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (SLD077/21/000001); PI19/00155; PI22/00456, LCF/BQ/PR21/11840004., This publication is part of the ALFA study (ALzheimers and Families). The authors would like to express their most sincere gratitude to the ALFA project participants and relatives without whom this research would not have been possible. The authors thank Roche Diagnostics International Ltd for providing the kits to measure Plasma and CSF biomarkers and GE Healthcare for providing the doses of [18F]flutemetamol PET. The NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use (Roche Diagnostics International Ltd, Rotkreuz, Switzerland). Elecsys Phospho-Tau (181P) CSF and Elecsys Total-Tau CSF assays are approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. We thank the collaborators of the ALFA Study: Alba Cañas, Albina Polo, Ana Fernández-Arcos, Annabella Beteta, Anna Brugulat-Serrat, Anna Soteras, Blanca Rodríguez-Fernández, Carme Deulofeu, Ferran Lugo, Irene Cumplido-Mayoral, Jordi Huguet, Laura Hernández, Maria Emilio, Patricia Genius, Paula Marne, Sandra Pradas, Sherezade Fuentes, and Wiesje Pelkmans. MMA receives funding from the Alzheimer’s Association Research Fellowship Program (AARF-23-1141384). FA receives funding from the JDC2022-049347-I grant, funded by the MCIU/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. GSB is supported by the Agencia Estatal de Investigación AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet contract), co-funded by the European Union (FSE+). OGR’s institution is supported by Roche Pharmaceuticals and Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer’s Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). NVT is supported by the Spanish Ministry of Science and Innovation - State Research Agency (grant RYC2022-038136-I, cofunded by the European Union FSE+ and grant PID2022-143106OA-I00 cofunded by the European Union FEDER). Additionally, NVT is supported by the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative. KB is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022–2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, and Familjen Rönströms Stiftelse, Stockholm, Sweden. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through the project SLD077/21/000001; Project “PI19/00155” and “PI22/00456”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Sex/gender effects of glial reactivity on preclinical Alzheimer's disease pathology

  • Vila-Castelar, Clara
  • Akinci, Muge
  • Palpatzis, Eleni
  • Aguilar Dominguez, Pablo
  • Operto, Grégory
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Falcón, Carles
  • Fauria, Karine
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Glial reactivity may contribute to sex/gender differences in Alzheimer's disease (AD) pathophysiology. Here, we investigated the differential effect of cerebrospinal fluid (CSF) glial markers on AD pathology and neurodegeneration by sex/gender among cognitively unimpaired older adults at increased risk of developing AD. We included 397 participants from the ALFA+ cohort with CSF Aβ42/40, p-tau181, sTREM2, YKL40, and GFAP, magnetic resonance imaging-based hippocampal volume (n = 299), and amyloid burden (centiloids) measured with [18F] flutemetamol positron emission tomography (n = 341). We ran multiple linear regression models to assess the association between glial markers, AD pathology and hippocampal volumes and their interaction with sex/gender, using False Discovery Rate to correct for multiple comparisons. Glial markers significantly contributed to explain amyloid burden, tau pathology, and hippocampal volumes, beyond age and/or primary AD pathology in a sex/gender-specific manner. Compared to men, women showed increased amyloid burden (centiloids) and CSF p-tau181 with increasing levels of sTREM2 and YKL40, and YKL40 and GFAP, respectively. Compared to women, men with greater tau burden showed lower hippocampal volumes as CSF YKL40 levels increased. Overall, our findings suggest that glial reactivity may contribute to sex/gender differences in AD progression, mostly, downstream amyloid. Further research identifying sex/gender-specific temporal dynamics in AD development is warranted to inform clinical trials., This publication is part of the ALFA study (ALzheimer and FAmilies). The authors would like to express their sincerest gratitude to the ALFA project participants, without whom this research would have not been possible. Collaborators of the ALFA study are: Federica Anastasi, Annabella Beteta, Anna Brugulat-Serrat, Raffaele Cacciaglia, Irene Cumplido-Mayoral, Alba Cañas, Marta del Campo, Carme Deulofeu, Ruth Dominguez, Maria Emilio, Ana Fernández-Arcos, Sherezade Fuentes, Patricia Genius, Armand González-Escalante, Laura Hernández, Felipe Hernández-Villamizar, Jordi Huguet, David López-Martos, Ferran Lugo, Paula Marne, Tania Menchón, Carolina Minguillon, Paula Ortiz, Wiesje Pelkmans, Albina Polo, Sandra Pradas, Blanca Rodríguez-Fernandez, Gonzalo Sánchez-Benavides, Mahnaz Shekari, Anna Soteras, Laura Stankeviciute, Marc Vilanova and Natalia Vilor-Tejedor. The authors would like to thank Jordi Huguet (Barcelonaβeta Brain Research Center, Barcelona) and Robin de Flores (INSERM, Caen, France) for their contributions to hippocampal subfield segmentation with Automated Segmentation of Hippocampal Subfields (ASHS). The Roche NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use. Elecsys β-amyloid (1–42) CSF, Elecsys Phospho-Tau (181P) CSF and Elecsys Total-Tau CSF assays are approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. The research leading to these results has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID) to EMA-U. EMA-U is supported by the Spanish Ministry of Science and Innovation - State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EMA-U receives support from EU Joint Programme-Neurodegenerative Disease Research J(PND2022-138). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). OG-R is supported by the Spanish Ministry of Science and Innovation –State Research Agency (IJC2020-043417-I/MCIN/AEI/10.13039/501100011033) and the European Union laquoNextGenerationEUraquo/PRTR. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) “A way to make Europe”), and receives the support of a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). CV-C is supported by a grant from the National Institute on Aging (K99AG073452).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic

  • Anastasi, Federica
  • Fernández-Lebrero, Aida
  • Ortiz Romero, Paula, 1994-
  • Torres-Torronteras, Javier
  • González Escalante, Armand
  • Contador, José
  • García Escobar, Greta
  • Manero, Rosa María
  • Navalpotro-Gómez, Irene
  • Jiménez-Moyano, Esther
  • Grau, Oriol (Grau Rivera)
  • Campo, Marta del
  • Puig-Pijoan, Albert
  • Suárez-Calvet, Marc
Introduction: Blood-based biomarkers for Alzheimer's disease (AD) have been widely studied, but direct comparisons of several biomarkers in clinical settings remain limited. Methods: In this cross-sectional study, plasma biomarkers from 197 participants in the BIODEGMAR cohort (Hospital del Mar, Barcelona) were analyzed. Participants were classified based on AD cerebrospinal fluid (CSF) core biomarkers. We assessed the ability of plasma p-tau181, p-tau217, p-tau231, t-tau, and Aβ42/40 to classify Aβ pathology status. Results: Plasma p-tau biomarkers had a greater diagnostic performance and larger effect sizes compared to t-tau and Aβ42/40 assays in detecting Aβ pathology. Among them, plasma p-tau217 consistently outperformed the others, demonstrating superior area under the curves. Furthermore, p-tau217 showed the strongest correlation between plasma and CSF levels, underscoring its potential as a reliable surrogate for CSF biomarkers. Discussion: Several plasma biomarkers, targeting different epitopes and using different platforms, demonstrated high performance in detecting AD in a memory clinic setting. Highlights: Plasma p-tau biomarkers demonstrated higher diagnostic performance and larger effect sizes than t-tau and Aβ42/40 assays in detecting Alzheimer's disease. Among the p-tau biomarkers, p-tau217 assays consistently outperformed the others, providing superior classification of Aβ pathology status across different phosphorylation sites. p-tau217 assays showed the strongest correlation between plasma and CSF levels, indicating its potential as a reliable surrogate for CSF biomarkers. Several plasma p-tau biomarkers can be used in a specialized memory clinic to accurately detect Alzheimer's disease., Federica Anastasi receives funding from the JDC2022-049347-I grant, funded by the MCIU/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. Henrik Zetterberg is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union's Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through the project SLD077/21/000001; Project “PI19/00155″ and “PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts

  • Lantero Rodríguez, Juan
  • Vrillon, Agathe
  • Fernández-Lebrero, Aida
  • Ortiz Romero, Paula, 1994-
  • Snellman, Anniina
  • Montoliu-Gaya, Laia
  • Brum, Wagner S.
  • Cognat, Emmanuel
  • Dumurgier, Julien
  • Puig-Pijoan, Albert
  • Navalpotro-Gómez, Irene
  • García-Escobar, Greta
  • Karikari, Thomas K.
  • Vanmechelen, Eugeen
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Suárez-Calvet, Marc
  • Paquet, Claire
  • Blennow, Kaj
Background Cerebrospinal fluid (CSF) p-tau235 is a novel biomarker highly specific of Alzheimer’s disease (AD). However, CSF p-tau235 has only been studied in well-characterized research cohorts, which do not fully reflect the patient landscape found in clinical settings. Therefore, in this multicentre study, we investigated the performance of CSF p-tau235 to detect symptomatic AD in clinical settings and compared it with CSF p-tau181, p-tau217 and p-tau231. Methods CSF p-tau235 was measured using an in-house single molecule array (Simoa) assay in two independent memory clinic cohorts: Paris cohort (Lariboisière Fernand-Widal University Hospital Paris, France; n=212) and BIODEGMAR cohort (Hospital del Mar, Barcelona, Spain; n=175). Patients were classified by the syndromic diagnosis (cognitively unimpaired [CU], mild cognitive impairment [MCI] or dementia) and their biological diagnosis (amyloid-beta [Aβ]+ or Aβ ). Both cohorts included detailed cognitive assessments and CSF biomarker measurements (clinically validated core AD biomarkers [Lumipulse CSF Aβ1–42/40 ratio, p-tau181 and t-tau] and in-house developed Simoa CSF p-tau181, p-tau217 and p-tau231). Results High CSF p-tau235 levels were strongly associated with CSF amyloidosis regardless of the clinical diagnosis, being significantly increased in MCI Aβ+ and dementia Aβ+ when compared with all other Aβ− groups (Paris cohort: P ˂0.0001 for all; BIODEGMAR cohort: P ˂0.05 for all). CSF p-tau235 was pronouncedly increased in the A+T+ profile group compared with A−T− and A+T− groups (P ˂0.0001 for all). Moreover, CSF p-tau235 demonstrated high diagnostic accuracies identifying CSF amyloidosis in symptomatic cases (AUCs=0.86 to 0.96) and discriminating AT groups (AUCs=0.79 to 0.98). Overall, CSF p-tau235 showed similar performances to CSF p-tau181 and CSF p-tau231 when discriminating CSF amyloidosis in various scenarios, but lower than CSF p-tau217. Finally, CSF p-tau235 associated with global cognition and memory domain in both cohorts. Conclusions CSF p-tau235 was increased with the presence of CSF amyloidosis in two independent memory clinic cohorts. CSF p-tau235 accurately identified AD in both MCI and dementia patients. Overall, the diagnostic performance of CSF p-tau235 was comparable to that of other CSF p-tau measurements, indicating its suitability to support a biomarker-based AD diagnosis in clinical settings., Open access funding provided by University of Gothenburg. This study was funded by the Swedish Research Council (#2017-00915 and #2022-00732), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236) and the National Institute of Health (NIH), USA, (grant #1R01AG068398-01). AV is supported by Fondation Ophtalmologique Adolphe de Rothschild and Fondation Vaincre Alzheimer. AES was supported by the Paulo Foundation, the Orion Research Foundation sr, and currently holds a postdoctoral fellowship from the Academy of Finland (#341059). TKK was funded by the Swedish Research Council (Vetenskapsrådet #2021-03244), the Alzheimer’s Association Research Fellowship (#AARF-21-850325), the Aina (Ann) Wallströms and Mary-Ann Sjöbloms stiftelsen and the Emil och Wera Cornells stiftelsen. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694) and the UK Dementia Research Institute at UCL (UKDRI-1003). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Immune cell subpopulations and serum neurofilament light chain are associated with increased risk of disease worsening in multiple sclerosis

  • Brune-Ingebretsen, Synne
  • Høgestøl, Einar A.
  • de Rosbo, Nicole Kerlero
  • Berg-Hansen, Pål
  • Brunborg, Cathrine
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Paul, Friedemann
  • Uccelli, Antonio
  • Villoslada, Pablo
  • Harbo, Hanne F.
  • Berge, Tone
Changes is lymphocyte subpopulations in peripheral blood have been proposed as biomarkers for evaluation of disease activity in multiple sclerosis (MS). Serum neurofilament light chain (sNfL) is a biomarker reflecting neuro-axonal injury in MS that could be used to monitor disease activity, response to drugs and to prognosticate disease course. Here we show a moderate correlation between sNfL and lymphocyte cell subpopulations, and our data furthermore suggest that sNfL and specific immune cell subpopulations together could predict future disease worsening in MS., This work was supported by the European Commission (ERACOSYSMED ERA-Net program, Sys4MS project, id:43), Instituto de Salud Carlos III, Spain (AC1500052), the Italian Ministry of Health (WFR-PER-2013-02361136), the German Ministry of Science (Deutsches Teilprojekt B “Förderkennzeichen”: 031L0083B), the Norwegian Research Council (project 257955), the South-Eastern Norway Regional Health Authority (project 2019111) and Biogen Norway. Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, and Swedish State Support for Clinical Research (#ALFGBG-71320).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Longitudinal interplay between subclinical atherosclerosis, cardiovascular risk factors, and cerebral glucose metabolism in midlife: results from the PESA prospective cohort study

  • Tristão Pereira, Catarina
  • Fuster, Valentín
  • Oliva, Belén
  • Moreno Arciniegas, Andrea
  • Garcia-Lunar, Ines
  • Perez-Herreras, Cristina
  • Schöll, Michael
  • Suárez-Calvet, Marc
  • Moro, Maria Angeles
  • Garcia-Alvarez, Ana
  • Fernández Ortiz, Antonio
  • Sánchez González, Javier
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Ibáñez, Borja
  • Gispert, Juan Domingo
  • Cortes-Canteli, Marta
Background: Cardiovascular disease and dementia often coexist at advanced stages. Yet, longitudinal studies examining the interplay between atherosclerosis and its risk factors on brain health in midlife are scarce. We aimed to characterise the longitudinal associations between cerebral glucose metabolism, subclinical atherosclerosis, and cardiovascular risk factors in middle-aged asymptomatic individuals. Methods: The Progression of Early Subclinical Atherosclerosis (PESA) study is a Spanish longitudinal observational cohort study of 4184 asymptomatic individuals aged 40-54 years (NCT01410318). Participants with subclinical atherosclerosis underwent longitudinal cerebral [18F]fluorodeoxyglucose ([18F]FDG)-PET, and annual percentage change in [18F]FDG uptake was assessed (primary outcome). Cardiovascular risk was quantified with SCORE2 and subclinical atherosclerosis with three-dimensional vascular ultrasound (exposures). Multivariate regression and linear mixed effects models were used to assess associations between outcomes and exposures. Additionally, blood-based biomarkers of neuropathology were quantified and mediation analyses were performed. Secondary analyses were corrected for multiple comparisons using the false discovery rate (FDR) approach. Findings: This longitudinal study included a PESA subcohort of 370 participants (median age at baseline 49·8 years [IQR 46·1-52·2]; 309 [84%] men, 61 [16%] women; median follow-up 4·7 years [IQR 4·2-5·2]). Baseline scans took place between March 6, 2013, and Jan 21, 2015, and follow-up scans between Nov 24, 2017, and Aug 7, 2019. Persistent high risk of cardiovascular disease was associated with an accelerated decline of cortical [18F]FDG uptake compared with low risk (β=-0·008 [95% CI -0·013 to -0·002]; pFDR=0·040), with plasma neurofilament light chain, a marker of neurodegeneration, mediating this association by 20% (β=0·198 [0·008 to 0·740]; pFDR=0·050). Moreover, progression of subclinical carotid atherosclerosis was associated with an additional decline in [18F]FDG uptake in Alzheimer's disease brain regions, not explained by cardiovascular risk (β=-0·269 [95% CI -0·509 to -0·027]; p=0·029). Interpretation: Middle-aged asymptomatic individuals with persistent high risk of cardiovascular disease and subclinical carotid atherosclerosis already present brain metabolic decline, suggesting that maintenance of cardiovascular health during midlife could contribute to reductions in neurodegenerative disease burden later in life. Funding: Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III, Santander Bank, Pro-CNIC Foundation, BrightFocus Foundation, BBVA Foundation, "la Caixa" Foundation., We thank the PESA participants and the imaging, administrative, and medical PESA teams. The PESA study is equally co-funded by the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and Santander Bank (Madrid, Spain) and also receives funding from the Instituto de Salud Carlos III (ISCIII), Madrid, Spain (PI15/02019), the European Regional Development Fund (ERDF—A Way to Build Europe), and the European Social Fund (ESF—Investing in Your Future). CNIC is a Severo Ochoa Center of Excellence (CEX2020-001041-S) and is supported by the ISCIII, the Spanish Ministry for Science and Innovation, and the Pro-CNIC Foundation. CT-P was supported by a “la Caixa” Foundation fellowship (ID 100010434, LCF/BQ/DI19/11730052). MC-C was supported by a Miguel Servet type II research contract (ISCIII, CPII21/00007) and the Fondo de Investigación Sanitaria (ISCIII, PI20/00819). We acknowledge the Sephardic Foundation on Aging and other donors of the Alzheimer's Disease Research (grant number A2022034S), a programme of the BrightFocus Foundation, for support of this research. This work was also partially produced with the support of a 2021 Leonardo Grant for Researchers and Cultural Creators from the BBVA Foundation awarded to MC-C (the Foundation takes no responsibility for the opinions, statements, and contents of this project, which are entirely the responsibility of its authors). BI was supported by the European Research Council (ERC-2018-CoG 819775-MATRIX). MS is supported by the Knut and Alice Wallenberg Foundation (Wallenberg Centre for Molecular and Translational Medicine; KAW2014.0363), the Swedish Research Council (2017-02869, 2021-02678, 2021-06545), the Swedish state under the agreement between the Swedish Government and the County Councils, the ALF-agreement (ALFGBG-813971, ALFGBG-965326), the Swedish Brain Foundation (FO2021-0311), and the Swedish Alzheimer Foundation (AF-740191). MS-C receives funding from the European Research Council (grant agreement number 948677), project “PI19/00155”, funded by ISCIII and co-funded by the EU, and a fellowship from “la Caixa” Foundation (ID 100010434) and from the EU's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement number 847648 (LCF/BQ/PR21/11840004). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018), the EU's Horizon Europe research and innovation programme under grant agreement number 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation, USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the EU's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement number 860197 (MIRIADE), the EU Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#2017-00915, #2022-00732), the Swedish state under the agreement between the Swedish Government and the County Councils, the ALF-agreement (#ALFGBG-715986, #ALFGBG-965240), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270), Hjärnfonden, Sweden (#FO2017-0243, #ALZ2022-0006), the Alzheimer's Association 2021 Zenith Award (ZEN-21-848495), and the Alzheimer's Association 2022–2025 grant (SG-23-1038904 QC).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform

  • Palmqvist, Sebastian
  • Anastasi, Federica
  • Puig-Pijoan, Albert
  • Fernández-Lebrero, Aida
  • Contador, José
  • Suárez-Calvet, Marc
  • Hansson, Oskar
Global implementation of blood tests for Alzheimer's disease (AD) would be facilitated by easily scalable, cost-effective and accurate tests. In the present study, we evaluated plasma phospho-tau217 (p-tau217) using predefined biomarker cutoffs. The study included 1,767 participants with cognitive symptoms from 4 independent secondary care cohorts in Malmö (Sweden, n = 337), Gothenburg (Sweden, n = 165), Barcelona (Spain, n = 487) and Brescia (Italy, n = 230), and a primary care cohort in Sweden (n = 548). Plasma p-tau217 was primarily measured using the fully automated, commercially available, Lumipulse immunoassay. The primary outcome was AD pathology defined as abnormal cerebrospinal fluid Aβ42:p-tau181. Plasma p-tau217 detected AD pathology with areas under the receiver operating characteristic curves of 0.93-0.96. In secondary care, the accuracies were 89-91%, the positive predictive values 89-95% and the negative predictive values 77-90%. In primary care, the accuracy was 85%, the positive predictive values 82% and the negative predictive values 88%. Accuracy was lower in participants aged ≥80 years (83%), but was unaffected by chronic kidney disease, diabetes, sex, APOE genotype or cognitive stage. Using a two-cutoff approach, accuracies increased to 92-94% in secondary and primary care, excluding 12-17% with intermediate results. Using the plasma p-tau217:Aβ42 ratio did not improve accuracy but reduced intermediate test results (≤10%). Compared with a high-performing mass-spectrometry-based assay for percentage p-tau217, accuracies were comparable in secondary care. However, percentage p-tau217 had higher accuracy in primary care and was unaffected by age. In conclusion, this fully automated p-tau217 test demonstrates high accuracy for identifying AD pathology. A two-cutoff approach might be necessary to optimize performance across diverse settings and subpopulations., We would like to express our gratitude to the participants, and relatives, in all studies, without whom this research would have not been possible. In addition, we thank B. Arslan for analyzing plasma Aβ in the Gothenburg cohort. The BioFINDER group was supported by the National Institute of Aging (grant no. R01AG083740 to O.H., S.P., R.O. and S.J.), Alzheimer’s Association (grant nos. SG-23-1061717 and ZEN24-1069572 to O.H.), GHR Foundation (O.H. and S.P.), European Research Council (ERC, grant no. ADG-101096455 to O.H.), Swedish Research Council (grant nos. 2023-00356 to O.H., 2021-02219 to N.M.-C. and 2018-02052 to S.P.), ERA PerMed (grant no. ERAPERMED2021-184 to O.H.), the Knut and Alice Wallenberg Foundation (grant no. 2022-0231 to O.H.), the European Union’s (EU’s) Horizon Europe research and innovation program under grant agreement no. 101053962 (to O.H.), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University (to O.H.), the Swedish Alzheimer Foundation (grant nos. AF-1011949 and AF-994075 to S.P., AF-994229 to N.M.-C. and AF-981132 to S.P.), the Swedish Brain Foundation (grant nos. FO2023-0163 to N.M.-C., FO2024-0284 and FO2022-0204 to S.P. and FO2021-0293 to O.H.), the family Rönström’s Foundation (grant nos. FRS-0003 to N.M.-C. and FRS-0004 and FRS-0011 to S.P.), the Berg Family Foundation (O.H.), the Parkinson Foundation of Sweden (grant no. 1412/22 to O.H.), the Cure Alzheimer’s fund (O.H.), the Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (O.H.), the Skåne University Hospital Foundation (grant no. 2020-O000028 to S.P.), EU Joint Programme Neurodegenerative Diseases (grant no. 2019-03401 to N.M.-C.), WASP and DDLS Joint call for research projects (grant no. WASP/DDLS22-066 to N.M.-C.), Regionalt Forskningsstöd (grant no. 2022-1346 to S.P.) and the Swedish Federal Government under the ALF-agreement (grant nos. 2022-Projekt0107 to N.M.-C., 2022-Projekt0080 to O.H. and 2018-Projekt0226 to S.P.). The precursor of [18F]flutemetamol was sponsored by GE Healthcare. For the Gothenburg group, S.K. was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (nos. ALFGBG-1005471, ALFGBG-965923, ALFGBG-81392 and ALFGBG-771071), the Alzheimerfonden (grant nos. AF-842471, AF-737641, AF-929959 and AF-939825), the Swedish Research Council (grant nos. 2019-02075 and 2019-02075_15), Stiftelsen Psykiatriska Forskningsfonden and the Swedish Brain Foundation (grant no. FO2024-0097). A.D. was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (grant no. ALFGBG-984092). H.Z. is a Wallenberg Scholar and a distinguished professor at the Swedish Research Council. K.B. is supported by the Swedish Research Council (grant nos. 2017-00915 and 2022-00732), the Swedish Alzheimer Foundation (grant nos. AF-930351, AF-939721, AF-968270 and AF-994551), Hjärnfonden, Sweden (grant nos. ALZ2022-0006, FO2024-0048-TK-130 and FO2024-0048-HK-24), the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (grant nos. ALFGBG-965240 and ALFGBG-1006418), the Alzheimer’s Association 2022–2025 (grant no. SG-23-1038904 QC), the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden and an anonymous philanthropist and donor. The Barcelona group thanks P. Ortiz-Romero, M. de Diego, E. Jiménez, J. Torres and M. del Campo for technical support. F.A. received funding from grant no. JDC2022-049347-I, funded by the MCIU/AEI/10.13039/501100011033 and the EU NextGeneration EU/PRTR. M.S.-C. received funding from the ERC under the EU’s Horizon 2020 research and innovation program (grant no. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project no. SLD077/21/000001; project PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the EU; and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 847648 (LCF/BQ/PR21/11840004)). For the Brescia group, A. Pilotto has beensupported by grants of Airalzh Foundation AGYR2021) Life-BIO grant, the LIMPE-DISMOV Foundation Segala Grant 2021, the Italian Ministry of University and Research PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast (20202THZAW), the H2020 IMI IDEA-FAST (ID853981) and the Italian Ministry of Health, grant/award nos. RF-2018-12366209 and PNRR-Health PNRR-MAD-2022-12376110. V.Q. was supported by the H2020 IMI IDEA-FAST (grant no. ID853981). C.T. was supported by the PRIN 2021 RePlast (grant no. 20202THZAW). A. Padovani has been supported by grants of the Italian Ministry of University and Research PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast (20202THZAW), the H2020 IMI IDEA-FAST (ID853981) and the Italian Ministry of Health, grant/award nos. RF-2018-12366209, RF-2019 RF-2019-12369272 and PNRR-Health PNRR-MAD-2022-12376110. The funders had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review or approval of the paper and decision to submit the paper for publication.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A blood-based multi-pathway biomarker assay for early detection and staging of Alzheimer's disease across ethnic groups

  • Jiang, Yuanbing
  • Ortiz Romero, Paula, 1994-
  • Puig-Pijoan, Albert
  • Fernández-Lebrero, Aida
  • Contador, José
  • Suárez-Calvet, Marc
  • Ip, Nancy Y.
Introduction: Existing blood-based biomarkers for Alzheimer's disease (AD) mainly focus on its pathological features. However, studies on blood-based biomarkers associated with other biological processes for a comprehensive evaluation of AD status are limited. Methods: We developed a blood-based, multiplex biomarker assay for AD that measures the levels of 21 proteins involved in multiple biological pathways. We evaluated the assay's performance for classifying AD and indicating AD-related endophenotypes in three independent cohorts from Chinese or European-descent populations. Results: The 21-protein assay accurately classified AD (area under the receiver operating characteristic curve [AUC] = 0.9407 to 0.9867) and mild cognitive impairment (MCI; AUC = 0.8434 to 0.8945) while also indicating brain amyloid pathology. Moreover, the assay simultaneously evaluated the changes of five biological processes in individuals and revealed the ethnic-specific dysregulations of biological processes upon AD progression. Discussion: This study demonstrated the utility of a blood-based, multi-pathway biomarker assay for early screening and staging of AD, providing insights for patient stratification and precision medicine. Highlights: The authors developed a blood-based biomarker assay for Alzheimer's disease. The 21-protein assay classifies AD/MCI and indicates brain amyloid pathology. The 21-protein assay can simultaneously assess activities of five biological processes. Ethnic-specific dysregulations of biological processes in AD were revealed., This study was supported in part by the National Key R&D Program of China (2021YFE0203000); the Areas of Excellence Scheme of the University Grants Committee (AoE/M-604/16); the Research Grants Council of Hong Kong (the Collaborative Research Fund [C6027-19GF] and the Theme-Based Research Scheme [T13-605/18 W]); the Innovation and Technology Commission (InnoHK; ITCPD/17-9, INNOHK18SC01, ITS/207/18FP, MRP/042/18X, and MRP/097/20X); Chow Tai Fook Charity Foundation (CTFCF18SC01); the Guangdong Provincial Key S&T Program Grant (2018B030336001); the Guangdong Provincial Fund for Basic and Applied Basic Research (2019B1515130004); and the Fundamental Research Program of Shenzhen Virtual University Park (2021Szvup137). Yuanbing Jiang is a recipient of the Hong Kong Postdoctoral Fellowship Award from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. HKUST PDFS2324-6S04). Marc Suárez-Calvet received funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (Grant Agreement No. 948677); Project “PI19/00155,” co-funded by Instituto de Salud Carlos III (ISCIII) and the European Union; and a fellowship from “La Caixa” Foundation (ID 100010434); and a fellowship from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie Grant Agreement (No. 847648; LCF/BQ/PR21/11840004). Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union's Horizon Europe Research and Innovation Programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Intracellular fluid accumulation underlies brain volume increases in early Alzheimer's disease

  • Kassinopoulos, Michalis
  • Montesinos, Paula
  • Falcon, Carles
  • Huguet, Jordi
  • Minguillón, Carolina
  • Fauria, Karine
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Sánchez González, Javier
  • Gispert, Juan Domingo
  • ALFA Study
Abstract In the preclinical stages of Alzheimer's disease, increased brain volume has been associated with amyloid-beta pathology, particularly in regions that undergo volume reductions as the disease progresses. Glial reactivity and water diffusion alterations have been linked to such macroscopic volumetric changes. Brain volume reductions have also been reported following amyloid-beta removal with anti-amyloid therapies with beneficial clinical effects, but it remains unclear whether these changes result from resolving amyloid-triggered neuroinflammation or neurodegeneration. Intravoxel incoherent motion modelling based on multi-shell diffusion-weighted imaging may provide a better understanding of the processes underlying these paradoxical changes. This study used intravoxel incoherent motion diffusion MRI to examine how alterations in cerebral water pools contribute to increased brain volume linked to amyloid-beta deposition and neuroinflammation in cognitively unimpaired individuals. We developed a three-compartment diffusion MRI model with four parameters of cerebral water diffusion: slow diffusion coefficient, fast diffusion coefficient, slow signal portion, and perfusion fraction. We computed these diffusion parameters in 297 cognitively unimpaired late middle-aged adults, 35% of whom showed evidence of amyloid deposition. We examined their correlation with demographic factors (age, sex, apolipoprotein E status), markers of Alzheimer's disease pathology, neurodegeneration, neuroinflammation, and mean diffusivity. Then, we identified regions showing grey matter volume increases related to amyloid burden and examined the association between grey matter volume and diffusion parameters within these regions. We did not find evidence of associations between diffusion parameters and amyloid-related biomarkers, whether assessed by PET or cerebrospinal fluid measures. In contrast, the four diffusion parameters showed strong and widespread associations with biomarkers of neuroinflammation and neurodegeneration, particularly in frontoparietal and cingulate regions. Additionally, in grey matter regions where volume increases were related to amyloid levels, volumes were negatively correlated with the slow diffusion coefficient (P = 0.001), perfusion fraction (P = 0.036) and mean diffusivity (P = 0.047). These findings indicate that diffusion-derived measures are more sensitive to neuroinflammatory and neurodegenerative processes than to amyloid pathology in cognitively unimpaired individuals. Furthermore, the observed negative association between grey matter volume and slow diffusion coefficient in amyloid-related regions may reflect increased cellular complexity rather than intracellular water accumulation. This interpretation suggests that glial remodelling or microstructural changes could underlie brain volume increases in amyloid-positive individuals without overt neurodegeneration. These results underscore the value of intravoxel incoherent motion-derived metrics for gaining deeper insights into the pathophysiological mechanisms of Alzheimer's disease, influencing brain volume changes as well as those resulting from the response to anti-amyloid therapies., The research leading to these results has received funding from 'la Caixa' Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016–2020 grant# SLT002/16/00201), and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. Henrik Zetterberg is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). Oriol Grau Rivera receives funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644568) and is supported by the Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I). Kaj Blennow is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, and Familjen Rönströms Stiftelse, Stockholm, Sweden. Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant agreement No. 948677) and the Instituto de Salud Carlos III through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund, FEDER, ‘A way to make Europe’). Moreover, Marc Suárez-Calvet receives the support of a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression

  • Pelkmans, Wiesje
  • Shekari, Mahnaz
  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • González Escalante, Armand
  • Kollmorgen, Gwendlyn
  • Carboni, Margherita
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • ALFA Study
Introduction: We studied how biomarkers of reactive astrogliosis mediate the pathogenic cascade in the earliest Alzheimer's disease (AD) stages. Methods: We performed path analysis on data from 384 cognitively unimpaired individuals from the ALzheimer and FAmilies (ALFA)+ study using structural equation modeling to quantify the relationships between biomarkers of reactive astrogliosis and the AD pathological cascade. Results: Cerebrospinal fluid (CSF) amyloid beta (Aβ)42/40 was associated with Aβ aggregation on positron emission tomography (PET) and with CSF p-tau181 , which was in turn directly associated with CSF neurofilament light (NfL). Plasma glial fibrillary acidic protein (GFAP) mediated the relationship between CSF Aβ42/40 and Aβ-PET, and CSF YKL-40 partly explained the association between Aβ-PET, p-tau181 , and NfL. Discussion: Our results suggest that reactive astrogliosis, as indicated by different fluid biomarkers, influences the pathogenic cascade during the preclinical stage of AD. While plasma GFAP mediates the early association between soluble and insoluble Aβ, CSF YKL-40 mediates the latter association between Aβ and downstream Aβ-induced tau pathology and tau-induced neuronal injury. Highlights: Lower CSF Aβ42/40 was directly linked to higher plasma GFAP concentrations. Plasma GFAP partially explained the relationship between soluble Aβ and insoluble Aβ. CSF YKL-40 mediated Aβ-induced tau phosphorylation and tau-induced neuronal injury., The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa‑17‑519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan government under grant no. 2017-SGR-892. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (2022-01018 and 2019-02397), the European Union's Horizon Europe research and innovation program under grant agreement 101053962, Swedish State Support for Clinical Research (ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (201809-2016862), the AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (2017‑00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (RDAPB‑201809‑2016615); the Swedish Alzheimer Foundation (AF‑742881); Hjärnfonden, Sweden (FO2017‑0243); the Swedish state under the agreement between the Swedish government and the county councils, the ALF‑agreement (ALFGBG‑715986); the European Union Joint Programme for Neurodegenerative Disorders (JPND2019‑466‑236); the National Institute of Health (NIH), USA (grant 1R01AG068398‑01); and the Alzheimer's Association 2021 Zenith Award (ZEN‑21‑848495). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement 948677), the Instituto de Salud Carlos III (PI19/00155, PI22/00456), and the ERC under the EU's ‘la Caixa’ Foundation (ID 100010434) and from the EU's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant (847648, LCF/BQ/PR21/11840004). JDG is supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054). JDG has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018‑102261). GS-B receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. OGR receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's disease

  • Warmenhoven, Noëlle
  • Sánchez Benavides, Gonzalo
  • González Escalante, Armand
  • Milà Alomà, Marta
  • Shekari, Mahnaz
  • López-Martos, David
  • Ortiz Romero, Paula, 1994-
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Vilor Tejedor, Natàlia, 1988-
  • Arenaza Urquijo, Eider M.
  • Palpatzis, Eleni
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
Introduction: We examined whether baseline glial markers soluble triggering receptor expressed on myeloid cell 2 (sTREM2), chitinase 3-like protein 1 (YKL-40), and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF), and plasma GFAP are associated with cognitive change in cognitively unimpaired (CU) individuals at risk of Alzheimer's disease (AD). Methods: A total of 353 CU (mean age 60.9 years) participants were included (mean follow-up time 3.28 years). Linear regression models with cognition as outcome were used. We also tested whether amyloid beta (Aβ) status modified these associations. Results: Higher baseline CSF sTREM2 was associated with a positive global cognition (Preclinical Alzheimer's Cognitive Composite) rate of change, and better memory and executive outcomes, independently of AD pathology. Higher baseline plasma GFAP was associated with a decline on attention rate of change. Stratified analyses by Aβ status showed that CSF sTREM2 and YKL-40 were positively associated with executive functioning in amyloid negative (Aβ-) individuals. Discussion: Our results suggest that a TREM2-mediated microglial response may be associated with better longitudinal cognitive performance. Highlights: Higher cerebrospinal fluid (CSF) soluble triggering receptor expressed on myeloid cell 2 (sTREM2) relates to better longitudinal cognitive performance. The association between CSF sTREM2 and cognition is independent of Alzheimer's disease (AD) pathology. Targeting microglial reactivity may be a therapeutic strategy for AD prevention., This publication is part of the ALFA study (ALzheimers and Families). The authors would like to thank the collaborators of the ALFA study. Additionally, the authors would like to express their most sincere gratitude to the ALFA project participants and relatives without whom this research would not have been possible. The authors thank Roche Diagnostics International Ltd for providing the kits to measure CSF biomarkers and GE Healthcare for providing the doses of [18F]flutemetamol PET. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa17519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. GSB is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by the Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet Contract), so-funded by the European Union (FSE+). DLM is supported by the Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 (co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/“Investing in your future”). CM received funding within the context of EURO-FINGERS, a EU Joint Programme – Neurodegenerative Disease Research (JPND) project. The EURO-FINGERS project is supported through the following funding organizations under the aegis of JPND—www.jpnd.eu: Finland: Academy of Finland; Germany: Federal Ministry of Education and Research; Spain: National Institute of Health Carlos III; Luxembourg: National Research Fund; Hungary: National Research, Development and Innovation Office; and The Netherlands: Netherlands Organisation for Health Research and Development (ZonMW-Memorabel no. 733051102). JDG has received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), Innovative Health Initiative PROMINENT (grant agreement 101112145), EIT Digital (Grant 2021), and from the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project RTI2018102261. EAU has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00), the Alzheimer's Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), and the European Union Joint Program for Neurodegenerative Disorders (JPND2022-138, AC22/00060). EAU is also supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#201700915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB2018092016615); the Swedish Alzheimer Foundation (#AF742881); Hjärnfonden, Sweden (#FO20170243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALFagreement (#ALFGBG715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019466236); the National Institute of Health (NIH), USA (grant #1R01AG06839801); and the Alzheimer's Association 2021 Zenith Award (ZEN21848495). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III (ISCIII) through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) “A way to make Europe”), and receives the support of a fellowship funded by “la Caixa” Foundation (ID 100010434), and the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). OGR receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 co-funded by the European Union (FEDER), and from Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project IJC2020-043417-I, co-funded by the European Union “Next GenerationEU”/PRTR. NVT is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project IJDC2020-043216-I, co-funded by the European Union “Next GenerationEU”/PRTR) and project PID2022-143106OA-I00, co-funded by the European Union (FEDER). In addition, NVT receives funding from the Alzheimer's Disease Data Initiative (ADDI) through the Williams H. Gates Sr. Fellowship Program and the Ajuntament de Barcelona in collaboration with “la Caixa” Foundation though the project 23S06083-001.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The potential dual role of tau phosphorylation: plasma phosphorylated-tau217 in newborns and Alzheimer’s disease

  • González Ortiz, Fernando
  • Vávra, Jakub
  • Payne, Emma
  • Kirsebom, Bjørn-Eivind
  • Sjöbom, Ulrika
  • Santos, Cristiano
  • Júlvez Calvo, Jordi
  • Kramer, Kaitlin
  • Zalcberg, David
  • Montoliu-Gaya, Laia
  • Turton, Michael
  • Harrison, Peter
  • Hellström, Ann
  • Zetterberg, Henrik
  • Fladby, Tormod
  • Sanders, Robert D.
  • Blennow, Kaj
Tau phosphorylation plays an important role in brain physiology and pathology. During foetal development, it supports microtubule dynamics and neuroplasticity, whereas in Alzheimer’s disease (AD), it drives pathological tau aggregation and tangle formation. In this multicentre study (n = 462), we measured plasma phosphorylated-tau217 in healthy newborns, premature infants, patients with AD and healthy controls across various age groups. Plasma phosphorylated-tau217 levels were significantly higher in newborns compared to healthy individuals of any age group and even exceeded levels observed in patients with AD. In newborns, plasma phosphorylated-tau217 levels inversely correlated with perinatal factors such as gestational age. Longitudinal analysis of preterm infants demonstrated a decline in serum phosphorylated-tau217 levels over the first months of life, approaching levels observed in young adults. In contrast, elevated plasma phosphorylated-tau217 in older individuals was associated with AD pathology. Our findings corroborate the crucial role of tau phosphorylation in early brain development. However, in AD, tau phosphorylation transitions into a pathological mechanism. The high levels of blood-based phosphorylated-tau217 observed at birth and subsequent clearance might indicate distinct regulatory mechanisms that prevent tau aggregation in early life. Further studies are needed to explore the shared mechanisms of tau phosphorylation in newborns and AD., K.B. is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270 and #AF-994551), Hjärnfonden, Sweden (#ALZ2022-0006 and #FO2024-0048-TK-130), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-965240 and #ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark and Familjen Rönströms Stiftelse, Stockholm, Sweden. The project was funded by the Norwegian Research Council, JPND/PMI-AD (NRC 311993), the National Institute of Health (R01 AG083874-01). F.G.-O. was funded by the Anna Lisa and Brother Björnsson’s Foundation and Emil och Maria Palms Foundation. M.S.-C. receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 948677), Project ‘PI19/00155’, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 847648 (LCF/BQ/PR21/11840004). B.-E.K. was supported by a grant from Helse-Nord (HNF1540-20). H.Z. is a Wallenberg scholar and a distinguished professor at the Swedish Research Council and receives funding from the Swedish Research Council (#2023-00356, #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement no. 101053962 and Swedish State Support for Clinical Research (#ALFGBG-71320).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease

  • González Ortiz, Fernando
  • González Escalante, Armand
  • Ortiz Romero, Paula, 1994-
  • Minguillón, Carolina
  • Contador, José
  • Suárez-Calvet, Marc
  • Blennow, Kaj
Introduction: Detection of Alzheimer's disease (AD) pathophysiology among individuals with mild cognitive changes and those experiencing subjective cognitive decline (SCD) remains challenging. Plasma phosphorylated tau 217 (p-tau217) is one of the most promising of the emerging biomarkers for AD. However, accessible methods are limited. Methods: We employed a novel p-tau217 immunoassay (University of Gothenburg [UGOT] p-tau217) in four independent cohorts (n = 308) including a cerebrospinal fluid (CSF) biomarker-classified cohort (Discovery), two cohorts consisting mostly of cognitively unimpaired (CU) and mild cognitively impaired (MCI) participants (MYHAT and Pittsburgh), and a population-based cohort of individuals with SCD (Barcelonaβeta Brain Research Center's Alzheimer's At-Risk Cohort [β-AARC]). Results: UGOT p-tau217 showed high accuracy (area under the curve [AUC] = 0.80-0.91) identifying amyloid beta (Aβ) pathology, determined either by Aβ positron emission tomography or CSF Aβ42/40 ratio. In individuals experiencing SCD, UGOT p-tau217 showed high accuracy identifying those with a positive CSF Aβ42/40 ratio (AUC = 0.91). Discussion: UGOT p-tau217 can be an easily accessible and efficient way to screen and monitor patients with suspected AD pathophysiology, even in the early stages of the continuum., This publication is part of the BBRC's β-AARC study, the MYHAT study, and the Pittsburgh study. The authors would like to express their most sincere gratitude to the project participants, without whom this research would have not been possible. The authors would like to thank Altoida for kindly supporting the CSF AD core biomarker characterisation of β-AARC study participants. F.G.-O. was funded by the Anna Lisa and Brother Björnsson's Foundation and Emil och Maria Palms Foundation. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation ə under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation ə under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). K.B. is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the Alzheimer's Association 2021 Zenith Award (ZEN-21-848495), and the Alzheimer's Association 2022-2025 Grant (SG-23-1038904 QC). M.S.C. receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). T.K.K. was supported by grants 1 R01 AG083874-01 and 1U24AG082930 from the National Institutes of Health (NIH), the Swedish Research Council (Vetenskåpradet; 2021-03244), the Alzheimer's Association (AARF-21-850325), the Swedish Alzheimer Foundation (Alzheimerfonden), the Aina (Ann) Wallströms and Mary-Ann Sjöbloms Stiftelsen, and the Emil och Wera Cornells stiftelsen. M.G. and the MYHAT study were funded by the NIH (grants AG052521 and R37 AG023651). The other Pittsburgh cohorts were financed by the NIH (grants P30 AG066468, P01AG025204, RF1AG025516, RF1AG052525, R01AG052446, and R01AG052446).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The CSF p-tau/ß-amyloid 42 ratio correlates with brain structure and fibrillary ß-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer's disease

  • Cacciaglia, Raffaele
  • Shekari, Mahnaz
  • Salvadó, Gemma
  • Milà Alomà, Marta
  • Falcón, Carles
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Fauria, Karine
  • Grau, Oriol (Grau Rivera)
  • Molinuevo, José Luis
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Quevenco, Frances-Catherine
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • ALFA Study
CSF concentrations of β-amyloid 42 (Aβ42) and phosphorylated tau (p-tau) are well-established biomarkers of Alzheimer's disease and have been studied in relation to several neuropathological features both in patients and in cognitively unimpaired individuals. The CSF p-tau/Aβ42 ratio, a biomarker combining information from both pathophysiological processes, has emerged as a promising tool for monitoring disease progression, even at pre-clinical stages. Here, we studied the association between the CSF p-tau/Aβ42 ratio with downstream markers of pre-clinical Alzheimer's disease progression including brain structure, glucose metabolism, fibrillary Aβ deposition and cognitive performance in 234 cognitively unimpaired individuals, who underwent cognitive testing, a lumbar puncture, MRI, 18F-fluorodeoxyglucose and 18F-flutemetamol PET scanning. We evaluated both main effects and interactions with Alzheimer's disease risk factors, such as older age, female sex and the apoliporoptein E (APOE)-ɛ4 allele, in a priori defined regions of interest and further examined the associations on the whole-brain using voxel-wise regressions. In addition, as the association between CSF Alzheimer's disease biomarkers and brain structure and function may be non-linear, we tested the interaction between the CSF p-tau/Aβ42 ratio and stages of pre-clinical Alzheimer's disease defined using the amyloid (A) and tau (T) classification. We found significantly positive associations between CSF p-tau/Aβ42 and both cortical Aβ deposition and regional grey matter volume while no effect was observed for brain metabolism. A significant interaction with age indicated that, for the same level of CSF p-tau/Aβ42, older individuals displayed both increased Aβ deposition and lower grey matter volume, in widespread cortical areas. In addition, we found that women compared with men had a greater Aβ fibrillary accumulation in midline cortical areas and inferior temporal regions, for the same level of the CSF biomarker. The impact of CSF p-tau/Aβ42 on grey matter volume was modulated by AT stages, with A+T+ individuals displaying significantly less positive associations in areas of early atrophy in the Alzheimer's continuum. Finally, we found that sex and APOE-ɛ4 modulated the association between the CSF biomarker and episodic memory as well as abstract reasoning, respectively. Our data indicate that the CSF p-tau/Aβ42 ratio is strongly associated with multiple downstream neuropathological events in cognitively unimpaired individuals and may thus serve as a potent biomarker to investigate the earliest changes in pre-clinical Alzheimer's disease. Given that its impact on both Aβ deposition and grey matter volume is modulated by specific risk factors, our results highlight the need to take into account such predisposing variables in both clinical practice and prevention trials., The research leading to these results has received funding from ‘la Caixa’ Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. R.C. receives funding from ‘Ministerio de Ciencia, Innovación y Universidades—Agencia Estatal de Investigación’ MCIN/AEI/10.13039/501100011033/FEDER, EU, through project PID2021-125433OA-100 and support from grant RYC2021-031128-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/Plan de Recuperación, Transformación y Resiliencia (PRTR). H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Union’s Horizon Europe research and innovation programme under grant agreement no. 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694) and the UK Dementia Research Institute at University College London (UCL) (UKDRI-1003). K.B. is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the Avtal om Läkarutbildning och Forskning (ALF) agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Programme for Neurodegenerative Disorders (JPND2019-466-236), the National Institutes of Health (NIH), USA, (grant #1R01AG068398-01), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495) and the Alzheimer’s Association 2022–25 Grant (SG-23-1038904 QC). M.S.-C. receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 948677), Project ‘PI19/00155’, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 847648 (LCF/BQ/PR21/11840004). O.G.-R. is supported by the ‘Ministerio de Ciencia, Innovación y Universidades' (IJC2020-043417-I) and receives funding from the Alzheimer’s Association (2019-AARF-644568) and the Instituto de Salud Carlos III (PI19/00117).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individuals

  • López-Martos, David
  • Suárez-Calvet, Marc
  • Cacciaglia, Raffaele
  • Shekari, Mahnaz
  • González Escalante, Armand
  • Brugulat Serrat, Anna, 1986-
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
Alzheimer's disease (AD) diagnostic guidelines emphasize subjective cognitive decline (SCD) preceding mild cognitive impairment (MCI), implicitly assuming awareness of cognitive decline (ACD) is preserved in preclinical AD. This study aimed to characterize a discrete clinical profile consistent with subtle amnestic anosognosia: decreased ACD, evaluating its association with multimodal core AD biomarkers in cognitively unimpaired (CU) individuals. We analyzed data from CU individuals with baseline CSF biomarkers and 3-year longitudinal neuropsychological assessment (ALFA+ cohort). Decreased ACD was defined by concurrent decline in episodic memory and cognitive awareness using robust longitudinal references (Free and Cued Selective Reminding Test, Memory Binding Test, Wechsler Memory Scale, and Subjective Cognitive Decline Questionnaire). Biomarker outcomes included plasma p-tau181, p-tau181/Aβ42, p-tau217; CSF p-tau181, Aβ42/40, p-tau181/Aβ42, p-tau217; Aβ ([¹⁸F]flutemetamol) and tau PET ([¹⁸F]RO948). Associations of ACD with AD biomarkers were evaluated using linear regression models. Sensitivity analysis was restricted to individuals with memory decline. 350 CU individuals were included (mean age 61 years; 60% female; mean education 14 years; 35% CSF Aβ-positive). Memory decline was identified in 61 (17%) individuals, of whom 25 (41%) exhibited concurrent awareness decline; meeting criteria for decreased ACD. This group demonstrated higher levels of AD pathology compared to the remaining sample. Among fluid biomarkers, CSF p-tau217 showed the strongest association. Neuroimaging revealed elevated frontoparietal Aβ PET, alongside temporal, insular, and frontal tau PET deposition. Sensitivity analysis confirmed that, although less pronounced, this pattern persists at the same threshold of memory decline. This study suggests that assessment of ACD may provide a crucial extension of current AD clinical frameworks., The research leading to these results has received funding from “la Caixa” Foundation under agreement LCF/PR/SC22/68000001, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa−17–519007). RC received funding from the MCIN/AEI/10.13039/501100011033/FEDER, EU, through the project PID2021–125433OA−100 and from the grant RYC2021–031128-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR; MS-C received funding from the ERC under the EU’s Horizon 2020 research and innovation program (grant no. 948677), ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project no. SLD077/21/000001, projects PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the EU (FEDER), and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 847648 (LCF/BQ/PR21/11840004)); AB-S received funding from the Alzheimer's Association Clinician Scientist Fellowship (AACSF) Program, through the grant AACSF−23–1145154; HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023–00356, #2022–01018 and #2019–02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG−71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809–2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF−21–831376-C, #ADSF−21–831381-C, #ADSF−21–831377-C, and #ADSF−24–1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Familjen Beiglers Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022–0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021–00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI−1003), and an anonymous donor; KB is supported by the Swedish Research Council (#2017–00915 and #2022–00732), the Swedish Alzheimer Foundation (#AF−930351, #AF−939721, #AF−968270, and #AF−994551), Hjärnfonden, Sweden (#ALZ2022–0006, #FO2024–0048-TK−130 and FO2024–0048-HK−24), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG−965240 and #ALFGBG−1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019–466–236), the Alzheimer’s Association 2021 Zenith Award (ZEN−21–848495), the Alzheimer’s Association 2022–2025 Grant (SG−23–1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden, and an anonymous philanthropist and donor; JDG was supported by the Spanish Ministry of Science and Innovation (RYC‑2013–13054), received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018–102261); OG-R received support from the grant IJC2020–043417-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR, and receives funding from Instituto de Salud Carlos III (ISCIII) through the projects "PI19/00117" and "PI24/00116", co-funded by the European Union/FEDER, and through the project "CB16/10/00417"; GS-B receives support from the grant CP23/00039 (Miguel Servet), funded by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union/FSE + , and receives funding from the MCIN/AEI/10.13039/501100011033 through the project PID2020–119556RA-I00 and through the project PID2024–163071OB-I00, funded by MICIU/AEI/10.13039/501100011033 and by the European Union FEDER.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Plasma p-tau212 identifies cognitively unimpaired individuals with emerging amyloid-ß pathology

  • Kac, Przemysław R.
  • González Escalante, Armand
  • Milà Alomà, Marta
  • Ashton, Nicholas J.
  • Shekari, Mahnaz
  • Ortiz Romero, Paula, 1994-
  • Turton, Michael
  • Harrison, Peter
  • Zetterberg, Henrik
  • Gispert, Juan Domingo
  • Karikari, Thomas K.
  • Suárez-Calvet, Marc
  • Blennow, Kaj
Plasma phosphorylated-tau (p-tau) biomarkers show high performance as first-in-line tests in the evaluation of patients with cognitive symptoms and have also found utility in clinical trials for anti-amyloid drug therapies for Alzheimer¿s disease (AD). Plasma p-tau212 is a novel blood biomarker that can discriminate cognitively unimpaired (CU) and subjective cognitive decline patients from mild cognitive impairment (MCI)-AD and AD dementia patients in clinical cohorts. Using Simoa technology, we evaluated plasma p-tau212 for its ability to detect emerging amyloid-beta (Aß) pathology in CU individuals with brain amyloidosis from CSF Aß42/40 ratio (n = 317) or Aß PET scans (n = 277). We benchmarked plasma p-tau212 against p-tau181, p-tau217, and p-tau231 by comparing their accuracies and fold changes for detecting brain amyloidosis. Our results showed that all the plasma p-tau biomarkers are increased in the CU CSF Aß + participants, with the highest median fold change observed for plasma p-tau212. Discrimination performance of the biomarkers to differentiate amyloid PET-positive from amyloid PET-negative participants differed between plasma p-tau biomarkers, being higher for plasma p-tau217 and p-tau212 compared to plasma p-tau181 and p-tau231. Furthermore, plasma p-tau212 was elevated in participants with low Aß burden (CSF Aß-positive, amyloid PET-negative), supporting its potential as a cost-effective, easily implemented biomarker for trial recruitment in early stages. Its further increase in Aß PET-positive participants suggests additional utility for monitoring anti-amyloid therapies., Open access funding provided by University of Gothenburg. Demensförbundet, Anna-Lisa och Bror Björnssons Stiftelse, Alzheimer’s Association, AARF-23-1141384,Marta Milà-Alomà, (#ADSF-21-831376-C,Henrik Zetterberg, #ADSF-21-831381-C, Henrik Zetterberg,#ADSF-21-831377-C, Henrik Zetterberg, #ADSF-24-1284328-C, Henrik Zetterberg, ZEN-21-848495, Kaj Blennow, #AARF-21-850325, Thomas K. Karikari, Vetenskapsrådet, #2023-00356, Henrik Zetterberg, #2022-01018, Henrik Zetterberg, #2019-02397, Henrik Zetterberg, #ALFGBG-71320, Henrik Zetterberg, #2017-00915,Kaj Blennow, (#ALFGBG-715986, Kaj Blennow, #ALFGBG-965240, Kaj Blennow, 2021-03244, Thomas K. Karikari, HORIZON EUROPE Reforming and enhancing the European Research and Innovation system, 101053962, Henrik Zetterberg, 948677, Marc Suárez-Calvet, Alzheimer’s Drug Discovery Foundation, 201809-2016862, Henrik Zetterberg, #RDAPB-201809-2016615, Kaj Blennow, European Partnership on Metrology, NEuroBioStand,Henrik Zetterberg, #22HLT07, Henrik Zetterberg, the Bluefield Project, Cure Alzheimer’s Fund, Olav Thon Stiftelsen, Familjen Erling-Perssons Stiftelse, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, #FO2022-0270, Henrik Zetterberg, #FO2017-0243,Kaj Blennow, #ALZ2022-0006, Kaj Blennow, HORIZON EUROPE Marie Sklodowska-Curie Actions, 860197 (MIRIADE), Henrik Zetterberg, No 847648 LCF/BQ/PR21/11840004, Marc Suárez-Calvet, EU Joint Programme – Neurodegenerative Disease Research, JPND2021-00694, Henrik Zetterberg, University College London Hospitals Biomedical Research Centre, UK Dementia Research Institute, UKDRI-1003, Henrik Zetterberg, Departament de Salut, Generalitat de Catalunya, SLD077/21/000001,Marc Suárez-Calvet, PI19/00155,Marc Suárez-Calvet, PI22/00456, Marc Suárez-Calvet,’la Caixa’ Foundation, ID 100010434, Marc Suárez-Calvet, Instituto de Salud Carlos III, Alzheimerfonden, #AF-930351, Kaj Blennow, #AF-939721,Kaj Blennow, #AF-968270, Kaj Blennow, European Union Joint Program for Neurodegenerative Disorders, JPND2019-466-236, Kaj Blennow, National Institute of Health (NIH), #1R01AG068398-01, Kaj Blennow, 1 RF1 AG052525-01A1, Thomas K. Karikari, 5 P30 AG066468-04, Thomas K. Karikari, 5 R01 AG053952-05, Thomas K. Karikari, 3 R01 MH121619-04S1, Thomas K. Karikari, 5 R37 AG023651-18, Thomas K. Karikari, 2 RF1 AG025516-12A1, Thomas K. Karikari, 5 R01 AG073267-02, Thomas K. Karikari, 2 R01 MH108509-06, Thomas K. Karikari, 5 R01 AG075336-02,Thomas K. Karikari, 5 R01 AG072641-02, Thomas K. Karikari, 2 P01 AG025204-16, Thomas K. Karikari, WaAina (Ann) llströms and Mary-Ann Sjöbloms stiftelsen, Emil och Wera Cornells Stiftelse.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Multimodal biomarker characterization of amnestic objective subtle cognitive decline in aging and preclinical Alzheimer's disease

  • López-Martos, David
  • Cacciaglia, Raffaele
  • Suárez-Calvet, Marc
  • Salvadó, Gemma
  • Shekari, Mahnaz
  • González Escalante, Armand
  • Milà Alomà, Marta
  • Brugulat Serrat, Anna, 1986-
  • Minguillón, Carolina
  • Tonietto, Matteo
  • Borroni, Edilio
  • Klein, Gregory
  • Quijano-Rubio, Clara
  • Kollmorgen, Gwendlyn
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • Sánchez Benavides, Gonzalo
  • ALFA Study
Background The objective of this study was to provide a multimodal biomarker characterization of amnestic objective subtle cognitive decline (obj-SCD) in aging and preclinical Alzheimer's disease (AD). Methods Prospective observational study; data from the Alzheimer's and Families+ (ALFAs+) cohort, including cognitively unimpaired (CU) individuals with available baseline CSF biomarkers (normal or AD continuum profiles) and longitudinal neuropsychological assessment (2 time points, 3-year follow-up). Amnestic obj-SCD was defined using robust longitudinal neuropsychological references with multivariate base rate thresholds of significant decline (Free and Cued Selective Reminding Test, Memory Binding Test, Wechsler Memory Scale IV: Logical Memory). Study outcomes included plasma p-tau217, NfL, and GFAP; CSF p-tau181/Aß42, NfL, and GFAP; Aß and tau PET; and MRI Grey Matter volume (GMv). The associations of amnestic obj-SCD with fluid (plasma and CSF) and neuroimaging biomarkers (PET and GMv) were evaluated using mixed-effects and voxel-wise linear regression models, respectively. Results 350 CU individuals were included (mean age 61 years; 60% female; mean education 14 years; 35% CSF Aß-positive). Amnestic obj-SCD was identified in 10% of the sample, associated with greater AD pathology (higher plasma p-tau217, CSF p-tau181/Aß42, global Aß PET, medial temporal tau PET), neurodegeneration (higher plasma and CSF NfL, reduced GMv in cingulate cortex, longitudinal GMv reductions in hippocampus) and inflammation (higher plasma and CSF GFAP, longitudinal GMv increases in neocortical brain regions). Discussion These findings highlight the need for standardized clinical staging criteria to enhance early detection and risk stratification in aging and preclinical AD., The research leading to these results has received funding from “la Caixa” Foundation under agreement LCF/PR/SC22/68000001, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). R.C. received funding from the MCIN/AEI/10.13039/501100011033/FEDER, EU,through the project PID2021-125433OA-100 and from the grant RYC2021-031128-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR; M.S.-C. received funding from the ERC under the EU’s Horizon 2020 research and innovation program (grant no. 948677), ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project no. SLD077/21/000001, projects PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the EU (FEDER), and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 847648 (LCF/BQ/PR21/11840004)); A.B.-S. received funding from the Alzheimer's Association Clinician Scientist Fellowship (AACSF) Program, through the grant AACSF-23-1145154; H.Z. is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356, #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Familjen Beiglers Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI-1003), and an anonymous donor; K.B. is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#ALZ2022-0006, #FO2024-0048-TK-130 and FO2024-0048-HK-24), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-965240 and #ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden, and an anonymous filantropist and donor; J.D.G. was supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054), received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018‑102261); O.G.-R. was supported by the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva program IJC2020-043417-I), funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR, Instituto de Salud Carlos III (ISCIII) through the projects "PI19/00117" and "PI24/00116" and co-funded by the European Union/FEDER. OG-R also receives funding from F. Hoffmann-La Roche Ltd, and has given lectures in symposia sponsored by Roche Diagnostics, S.L.U; G.S.-B. was supported by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union/FSE+, supported by MCIN/AEI/10.13039/501100011033, through the project PID2020-119556RA-I00 and grant CP23/00039.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Blood pressure and Alzheimer's disease biomarkers in cognitively unimpaired adults: a multicenter study

  • Osset-Malla, Mariona
  • Martínez-Velasco, Aitana
  • Sánchez Benavides, Gonzalo
  • Buongiorno, Mariateresa
  • Sierra, Alejandro de la
  • Shekari, Mahnaz
  • Minguillón, Carolina
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Vállez García, David
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • Grau-Rivera, Oriol
  • ALFA Study
BACKGROUND: Hypertension is a modifiable risk factor for dementia, potentially influencing Alzheimer's disease (AD) pathology. Understanding this relationship is essential for developing interventions to reduce dementia risk. OBJECTIVES: We investigated cross-sectional and longitudinal associations between blood pressure and AD biomarkers in cerebrospinal fluid (CSF) and amyloid (Aß) positron emission tomography (PET) in cognitively unimpaired adults. DESIGN: Prospective observational study. SETTING: We analyzed data from cognitively unimpaired participants from three observational prospective European studies: ALFA+ (NCT02485730), EPAD-LCS (NCT02804789), and AMYPAD PNHS (EudraCT: 2018-002,277-22). MEASUREMENTS: ALFA+ participants had either CSF biomarkers (CSF Aß42, Aß40, p-tau181, t-tau) and/or Aß PET data. EPAD participants had CSF biomarkers (CSF Aß42, p-tau181, t-tau), and AMYPAD participants had Aß PET data. All participants had available data about diabetes, use of hypertensive medication, and waist-to-hip ratio. Multivariable linear regression models were used to analyze cross-sectional associations between systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP) with CSF biomarkers or Aß PET (Centiloid units, CL); longitudinal associations were tested by means of delta CL scores between baseline and follow-up to assess Aß PET changes over time. RESULTS: We included 405 participants from ALFA+ (mean age 61.1 years; 60 % female), 1104 from EPAD (mean age 64.8 years; 59.1 % female), and 340 from AMYPAD (mean age 71.8 years; 60 % female). In ALFA+, DBP was negatively associated with CSF Aß40 (p = 0.016) and p-tau181 (p = 0.050), while there was a non-significant trend towards a positive association between SBP and CL over time (p = 0.058). In EPAD, DBP was negatively associated with CSF Aß42 (p < 0.001) and p-tau181 (p = 0.014), while PP was positively associated with CSF Aß42 (p = 0.024). In AMYPAD, SBP (p = 0.002) and PP (p = 0.003) were positively associated with CL at baseline, with a similar non-significant trend being found for DBP (p = 0.089). Higher DBP (p = 0.042) was significantly associated to increased CL over time, with a similar non-significant trend being found for SBP (p = 0.072). We did not find significant associations between blood pressure and longitudinal changes in CSF biomarkers. CONCLUSIONS: Elevated blood pressure was associated with increased Aß PET accumulation in cognitively unimpaired individuals. Further research is warranted to elucidate potential mechanisms underlying the negative associations between DBP and CSF biomarkers, which do not reflect the typical AD molecular signature. These findings highlight the relevance of high blood pressure as a potential risk factor for cognitive decline., The research leading to these results has received funding from “la Caixa” Foundation (ID 100,010,434), under agreement LCF/PR/GN17/50,300,004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17–519,007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00,913. OGR has received funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644,568) and Instituto de Salud Carlos III (PI19/00,117) and receives funding from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme IJC2020–043,417-I). OG-R is supported by the Spanish Ministry of Science and Innovation –State Research Agency (IJC2020–043,417-I/MCIN/AEI/10.13039/501,100,011,033) and the European Union laquoNextGenerationEUraquo/PRTR. GSB receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020–119556RA-I00. MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948,677); ERA PerMed (ERAPERMED2021–184); Project "PI19/00,155″ and “PI22/00,456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ”la Caixa” Foundation (ID 100,010,434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847,648 (LCF/BQ/PR21/11,840,004). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023–00,356; #2022–01,018 and #2019–02,397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101,053,962, Swedish State Support for Clinical Research (#ALFGBG-71,320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201,809–2016,862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21–831,376-C, #ADSF-21–831,381-C, #ADSF-21–831,377-C, and #ADSF-24–1284,328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022–0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860,197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021–00,694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#2017–00,915 and #2022–00,732), the Swedish Alzheimer Foundation (#AF-930,351, #AF-939,721 and #AF-968,270), Hjärnfonden, Sweden (#FO2017–0243 and #ALZ2022–0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715,986 and #ALFGBG-965,240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019–466–236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21–848,495), and the Alzheimer’s Association 2022–2025 Grant (SG-23–1038,904 QC). This work used data and/or samples from the EPAD project which received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement n° 115,736 and an Alzheimer’s Association Grant (SG-21–818,099-EPAD). This work also used data from AMYPAD PNHS that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115,952. This Joint Undertaking received support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Differential effects of sleep on brain structure and metabolism at the preclinical stages of AD

  • Stankeviciute, Laura
  • Falcón, Carles
  • Operto, Grégory
  • Garcia, Marina
  • Shekari, Mahnaz
  • Iranzo, Álex
  • Niñerola-Baizán, Aida
  • Perissinotti, Andrés
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Cacciaglia, Raffaele
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
Introduction: Poor sleep quality is associated with cognitive outcomes in Alzheimer's disease (AD). We analyzed the associations between self-reported sleep quality and brain structure and function in cognitively unimpaired (CU) individuals. Methods: CU adults (N = 339) underwent structural magnetic resonance imaging, lumbar puncture, and the Pittsburgh Sleep Quality Index (PSQI) questionnaire. A subset (N = 295) performed [18F] fluorodeoxyglucose positron emission tomography scans. Voxel-wise associations with gray matter volumes (GMv) and cerebral glucose metabolism (CMRGlu) were performed including interactions with cerebrospinal fluid (CSF) AD biomarkers status. Results: Poorer sleep quality was associated with lower GMv and CMRGlu in the orbitofrontal and cingulate cortices independently of AD pathology. Self-reported sleep quality interacted with altered core AD CSF biomarkers in brain areas known to be affected in preclinical AD stages. Discussion: Poor sleep quality may impact brain structure and function independently from AD pathology. Alternatively, AD-related neurodegeneration in areas involved in sleep-wake regulation may induce or worsen sleep disturbances. Highlights Poor sleep impacts brain structure and function independent of Alzheimer's disease (AD) pathology. Poor sleep exacerbates brain changes observed in preclinical AD. Sleep is an appealing therapeutic strategy for preventing AD., This publication is part of the ALFA study (Alzheimer and Families). The authors would like to express their most sincere gratitude to the ALFA project participants and relatives, without whom this research would have not been possible. The authors thank Roche Diagnostics International Ltd. for providing the kits to measure CSF biomarkers and GE Healthcare for providing the doses for [18F]flutemetamol PET. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712 and #101053962), Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). Collaborators of the ALFA Study are Müge Akinci, Annabella Beteta, Alba Cañas, Irene Cumplido, Carme Deulofeu, Ruth Dominguez, Maria Emilio, Karine Fauria, Sherezade Fuentes, Oriol Grau-Rivera, Laura Hernandez, Gema Huesa, Jordi Huguet, Eider M. Arenaza-Urquijo, Paula Marne, Tania Menchón, Carolina Minguillon, Eva M. Palacios, Eleni Palpatzis, Cleofé Peña-Gómez, Albina Polo, Sandra Pradas, Blanca Rodríguez-Fernández, Aleix Sala-Vila, Gemma Salvadó, Mahnaz Shekari, Anna Soteras, Laura Stankeviciute, Marc Vilanova, and Natalia Vilor-Tejedor. This work was supported by a grant from the Alzheimer's Association (2019-AARF-644568) awarded to O.G.-R. The ALFASleep study also receives funding from the Instituto de Salud Carlos III through the project PI19/00117 (co-funded by European Regional Development Fund; “A way to make Europe”) awarded to OG-R. The ALFA+ study is funded by the “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). O.G.-R. is supported by the Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Awareness of episodic memory and meta-cognitive profiles: associations with cerebrospinal fluid biomarkers at the preclinical stage of the Alzheimer's continuum

  • López-Martos, David
  • Suárez-Calvet, Marc
  • Milà Alomà, Marta
  • Gispert, Juan Domingo
  • Minguillón, Carolina
  • Quijano-Rubio, Clara
  • Kollmorgen, Gwendlyn
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Grau, Oriol (Grau Rivera)
  • Sánchez Benavides, Gonzalo
Introduction: The lack of cognitive awareness, anosognosia, is a clinical deficit in Alzheimer's disease (AD) dementia. However, an increased awareness of cognitive function, hypernosognosia, may serve as a marker in the preclinical stage. Subjective cognitive decline (SCD) might correspond to the initial symptom in the dynamic trajectory of awareness, but SCD might be absent along with low awareness of actual cognitive performance in the preclinical stage. We hypothesized that distinct meta-cognitive profiles, both hypernosognosia and anosognosia, might be identified in preclinical-AD. This research evaluated the association between cerebrospinal fluid (CSF) AD biomarkers and the awareness of episodic memory, further exploring dyadic (participant-partner) SCD reports, in the preclinical Alzheimer's continuum. Methods: We analyzed 314 cognitively unimpaired (CU) middle-aged individuals (mean age: 60, SD: 4) from the ALFA+ cohort study. Episodic memory was evaluated with the delayed recall from the Memory Binding Test (MBT). Awareness of episodic memory, meta-memory, was defined as the normalized discrepancy between objective and subjective performance. SCD was defined using self-report, and dyadic SCD profiles incorporated the study partner's report using parallel SCD-Questionnaires. The relationship between CSF Aβ42/40 and CSF p-tau181 with meta-memory was evaluated with multivariable regression models. The role of SCD and the dyadic contingency was explored with the corresponding stratified analysis. Results: CSF Aβ42/40 was non-linearly associated with meta-memory, showing an increased awareness up to Aβ-positivity and a decreased awareness beyond this threshold. In the non-SCD subset, the non-linear association between CSF Aβ42/40 and meta-memory persisted. In the SCD subset, higher Aβ-pathology was linearly associated with increased awareness. Individuals presenting only study partner's SCD, defined as unaware decliners, exhibited higher levels of CSF p-tau181 correlated with lower meta-memory performance. Discussion: These results suggested that distinct meta-cognitive profiles can be identified in preclinical-AD. While most individuals might experience an increased awareness associated with the entrance in the AD continuum, hypernosognosia, some might be already losing insight and stepping into the anosognosic trajectory. This research reinforced that an early anosognosic profile, although at increased risk of AD-related decline, might be currently overlooked considering actual diagnostic criteria, and therefore its medical attention delayed., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The design and execution of the study were independent of any influence from funding sources. This includes data collection, analysis, interpretation, manuscript preparation, review, and approval. The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. DL-M was supported by Instituto de Salud Carlos III through the project PI19/00117 (Co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/”Investing in your future”). MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project “PI19/00155” and “PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). JG receives funding from the European Comission Innovative Health Initiative (Grant Agreement: 101112145), the BrightFocus Foundation (Grant Reference ID: A2022034S), and La Marató de TV3 (Project: 202318 30-31-32). HZ was a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). KB was supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), and the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC). OG-R was supported by the Spanish Ministry of Science and Innovation –State Research Agency (IJC2020-043417-I/MCIN/AEI/10.13039/501100011033) and the European Union laquoNextGenerationEUraquo/PRTR. GS-B was supported by the Agencia Estatal de Investigación AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet contract), co-funded by the European Union (FSE+).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Time-encoded ASL reveals lower cerebral blood flow in the early AD continuum

  • Falcón, Carles
  • Minguillón, Carolina
  • Fauria, Karine
  • Cascales Lahoz, Diego
  • Contador, José
  • Fernández-Lebrero, Aida
  • Navalpotro-Gómez, Irene
  • Puig-Pijoan, Albert
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
Introduction: Cerebral blood flow (CBF) is reduced in cognitively impaired (CI) Alzheimer's disease (AD) patients. We checked the sensitivity of time-encoded arterial spin labeling (te-ASL) in measuring CBF alterations in individuals with positive AD biomarkers and associations with relevant biomarkers in cognitively unimpaired (CU) individuals. Methods: We compared te-ASL with single-postlabel delay (PLD) ASL in measuring CBF in 59 adults across the AD continuum, classified as CU amyloid beta (Aβ) negative (-), CU Aβ positive (+), and CI Aβ+. We sought associations of CBF with biomarkers of AD, cerebrovascular disease, synaptic dysfunction, neurodegeneration, and cognition in CU participants. Results: te-ASL was more sensitive at detecting CBF reduction in the CU Aβ+ and CI Aβ+ groups. In CU participants, lower CBF was associated with altered biomarkers of Aβ, tau, synaptic dysfunction, and neurodegeneration. Discussion: CBF reduction occurs early in the AD continuum. te-ASL is more sensitive than single-PLD ASL at detecting CBF changes in AD. Highlights: Lower CBF can be detected in CU subjects in the early AD continuum. te-ASL is more sensitive than single-PLD ASL at detecting CBF alterations in AD. CBF is linked to biomarkers of AD, synaptic dysfunction, and neurodegeneration., We want to express our most sincere gratitude to the ALFA project participants and relatives, without whom this research would not have been possible. We thank Roche Diagnostics International Ltd for providing the NeuroToolKit kits to measure CSF biomarkers, Eli Lilly and Company for providing the measurements of the in-house assay for CSF and plasma p-tau217, and GE Healthcare for providing the doses of [18F] flutemetamol PET. Lastly, we would like to thank Valeria Di Giacomo, PhD, and Allison Clark, from ThePaperMill, for providing writing support, funded by The Fundació Pasqual Maragall. Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III (ISCIII) through projects PI19/00155 and PI22/00456 (cofunded by the European Union FEDER), the Department of Research and Universities of the Generalitat de Catalunya through the project 2021 SGR 01137, the HNA Foundation through the project PROAD, and the ERA PerMed ERA-NET and the Department of Health of the Generalitat de Catalunya (DS-CAT) through the project SLD077/21/000001. Moreover, Marc receives support from a fellowship provided by “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant agreement No. 847648 (fellowship code LCF/BQ/PR21/11840004). Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (Nos. 2022-01018 and 2019-02397), the European Union's Horizon Europe research and innovation program under Grant agreement No. 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (No. 201809-2016862), the AD Strategic Fund and the Alzheimer's Association (Nos. ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant agreement No. 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). Oriol Grau-Rivera receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), the Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 (cofunded by the European Unior FEDER), and the MCIN/AEI/10.13039/501100011033 through the project IJC2020-043417-I (cofunded by the European Union NextGenerationEU/PRTR).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Data-driven CSF biomarker profiling: imaging and clinical outcomes in a cohort at risk of Alzheimer's disease

  • Argiris, Georgette
  • Akinci, Muge
  • Peña-Gómez, Cleofé
  • Palpatzis, Eleni
  • Garcia Prat, Marina
  • Shekari, Mahnaz
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Ashton, Nicholas J.
  • Karikari, Thomas K.
  • Brinkmalm-Westman, Ann
  • Lantero Rodriguez, Juan
  • Fauria, Karine
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Background: Cerebrospinal fluid (CSF) biomarkers of synaptic dysfunction, neuroinflammation, and glial response, complementing Alzheimer's disease (AD) core biomarkers, have improved the pathophysiological characterization of the disease. Here, we tested the hypothesis that the co-expression of multiple CSF biomarkers will help the identification of AD-like phenotypes when biomarker positivity thresholds are not met yet. Methods: Two hundred and seventy cognitively unimpaired adults with family history (FH) of sporadic AD (mean age = 60.6 ± 4.85 years, 64.8% women) underwent lumbar puncture, magnetic resonance imaging (n = 266) and positron emission tomography imaging (n = 239) protocols, and clinical evaluations. CSF Aβ42, Aβ40, p-tau181, p-tau217, p-tau231, NfL, neurogranin, sTREM2, YKL40, GFAP, S100, α-Synuclein, SYT1, and SNAP25 were measured. Participants were clustered based on CSF biomarker co-expression with an agglomerative algorithm. The predictive value of the classification against brain and cognitive outcomes was evaluated. Results: Three clusters (C) were identified. Higher Aβ burden and CSF p-tau was the hallmark of C1. The other two clusters showed lower Aβ burden but higher expression of glial (C2) or synaptic markers (C3). Participants in C1 showed an AD-like clinical phenotype, comprising participants with the overall highest percentage of two parent FH and APOE-ε4 carriers, in addition to comprising more females compared to C2. C3 displayed better vascular health compared to C1. C2 were older and comprised a lower percentage of females compared to C3. C1 showed an AD-like gray matter reduction in medial temporal (notably hippocampus) and frontal regions that were not observed in Aβ42/40 + compared with Aβ42/40 - . Furthermore, Aβ42/40 - participants in C1 showed GM reduction in inferior temporal areas compared with Aβ42/40 + participants overall. C1 membership also predicted cognitive decline in executive function, but not memory, beyond Aβ + status, overall suggesting a better prognosis in Aβ42/40 + participants without C1 membership. Additionally, C1 displayed a higher rate of conversion to Aβ + (25%) over time. Conclusions: Our results suggest that examining multiple CSF biomarkers reflecting diverse pathological pathways may complement and/or outperform AD core biomarkers and thresholding approaches to identify individuals showing a clinical and cognitive AD-like phenotype, including higher conversion to Aβ + , GM reductions and cognitive decline. The clinical utility of this approach warrants further investigation and replication in other cohorts., The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17–519007). Support has also been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant no. 2021 SGR 00913. The research leading to these results has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), to EMA-U. EMA-U is supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EMA-U receives support from EU Joint Programme-Neurodegenerative Disease Research (JPND2022-138). E.P is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). GA receives support from the Alzheimer’s Association research fellowship (23AARF-1028873). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022–01018 and #2019–02397), the European Union’s Horizon Europe research and innovation program under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201,809–2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21–831,376-C, #ADSF-21–831,381-C, and #ADSF-21–831,377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Program – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project "PI19/00155″, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
RUA. Repositorio Institucional de la Universidad de Alicante
Publication Otros (Other)

Development and Validation of an ICP-MS/MS Method for the Multielemental Analysis of Cerebrospinal Fluid, Examination of Alzheimer's Disease Samples

  • Pérez Ramírez, Rebeca
  • Cuchillo-Ibáñez, Inmaculada
  • Sánchez, Raquel
  • Beltrán Sanahuja, Ana
  • Escamilla, Sergio
  • Molina-Gasset, Ricardo
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Sáez-Valero, Javier
  • Todolí Torró, José Luis
  • Sánchez, Raquel|||/items/06c6cd36-b88e-43e0-929a-9b92d670da54
  • Beltrán Sanahuja, Ana|||/items/e050de26-d5fa-4bc8-8092-760c0d8865d0
  • Todolí Torró, José Luis|||/items/e63cf980-21e8-48ec-8493-cdb380f1cccc
Multielemental analysis of cerebrospinal fluid (CSF) yields critical insights into the pathophysiology of neurological disorders and holds potential as a diagnostic and predictive tool for Alzheimer's disease (AD). The present work presents the development and validation of an inductively coupled plasma tandem mass spectrometry (ICP-MS/MS) based method for multielemental determination in CSF, including metals and metalloids as analytes. As a proof of concept, the importance of the CSF element determination was evaluated in a cohort of patients with AD (n = 20) and non-AD controls (n = 19) who displayed typical levels of core CSF biomarkers (Aβ42, P-tau, and total-tau). Discrete sample introduction ICP-MS/MS procedure was effective for accurate and precise CSF analysis. The methodology provided better sensitivities and limits of detection than a conventional one based on sample dilution and analysis in continuous sample introduction mode, while only requiring a 20 μL CSF sample volume. A total of 24 elements were encountered and quantified in CSF, with reduced levels of Mn, Cr, Se, Fe, and Zn in the CSF from AD patients and increased levels of Ag and Bi, compared with non-AD patients. Particularly, Mn fully discriminated AD from non-AD subjects, with binary regression analysis indicating that Mn was the most effective element to distinguish between AD and non-AD groups. Furthermore, distinctive correlation profiles were found between AD and non-AD controls for elements with AD core biomarkers and the alternative amyloidogenic sAPPβ fragment. Quantitative determination of metals, metalloids and non-metals displays differences associated with pathological status, serving as additional biomarkers for neurological diseases.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Transient changes in the plasma of astrocytic and neuronal injury biomarkers in COVID-19 patients without neurological syndromes

  • Lennol, Matthew P.
  • Ashton, Nicholas J.
  • Moreno-Pérez, Oscar
  • García-Ayllón, María-Salud
  • Ramos-Rincón, José Manuel
  • Andrés, Mariano
  • León-Ramírez, José Manuel
  • Boix, Vicente
  • Gil, Joan
  • Blennow, Kaj
  • Merino, Esperanza
  • Zetterberg, Henrik
  • Sáez-Valero, Javier
This article belongs to the Special Issue Latest Advances in Neuroscience., The levels of several glial and neuronal plasma biomarkers have been found to increase during the acute phase in COVID-19 patients with neurological symptoms. However, replications in patients with minor or non-neurological symptoms are needed to understand their potential as indicators of CNS injury or vulnerability. Plasma levels of glial fibrillary acidic protein (GFAP), neurofilament light chain protein (NfL), and total Tau (T-tau) were determined by Single molecule array (Simoa) immunoassays in 45 samples from COVID-19 patients in the acute phase of infection [moderate (n = 35), or severe (n = 10)] with minor or non-neurological symptoms; in 26 samples from fully recovered patients after ~2 months of clinical follow-up [moderate (n = 23), or severe (n = 3)]; and in 14 non-infected controls. Plasma levels of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2), were also determined by Western blot. Patients with COVID-19 without substantial neurological symptoms had significantly higher plasma concentrations of GFAP, a marker of astrocytic activation/injury, and of NfL and T-tau, markers of axonal damage and neuronal degeneration, compared with controls. All these biomarkers were correlated in COVID-19 patients at the acute phase. Plasma GFAP, NfL and T-tau levels were all normalized after recovery. Recovery was also observed in the return to normal values of the quotient between the ACE2 fragment and circulating full-length species, following the change noticed in the acute phase of infection. None of these biomarkers displayed differences in plasma samples at the acute phase or recovery when the COVID-19 subjects were sub-grouped according to occurrence of minor symptoms at re-evaluation 3 months after the acute episode (so called post-COVID or “long COVID”), such as asthenia, myalgia/arthralgia, anosmia/ageusia, vision impairment, headache or memory loss. Our study demonstrated altered plasma GFAP, NfL and T-tau levels in COVID-19 patients without substantial neurological manifestation at the acute phase of the disease, providing a suitable indication of CNS vulnerability; but these biomarkers fail to predict the occurrence of delayed minor neurological symptoms., This work was supported by grants from the Fondo de Investigaciones Sanitarias (PI19-01359, co-funded by the Fondo Europeo de Desarrollo Regional, FEDER “Investing in your future”), CIBERNED (Instituto de Salud Carlos III, Spain), by the Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL; grant 2020-0308) and from the Direcció General de Ciència I Investigació, Generalitat Valenciana (AICO/2021/308). MPL is supported by a BEFPI fellowship from the Generalitat Valenciana. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme–Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Neuroinflammation in Alzheimer disease

  • Heneka, Michael T.
  • Flier, Wiesje M. van der
  • Jessen, Frank
  • Hoozemanns, Jeroen
  • Thal, Dietmar Rudolf
  • Boche, Delphine
  • Brosseron, Frederic
  • Teunissen, Charlotte E.
  • Zetterberg, Henrik
  • Jacobs, Andreas H.
  • Edison, Paul
  • RamÍrez, Alfredo
  • Cruchaga, Carlos
  • Lambert, Jean-Charles
  • Ruíz Laza, Agustín
  • Sánchez-Mut, José Vicente
  • Fischer, Andre
  • Castro, Sergio
  • Stein, Thor D.
  • Kleineidam, Luca
  • Wagner, Michael
  • Neher, Jonas J.
  • Cunningham, Colm
  • Singhrao, Sim K.
  • Prinz, Marco
  • Glass, Christopher K.
  • Schlachetzki, Johannes C. M.
  • Butovsky, Oleg
  • Kleemann, Kilian
  • De Jaeger, Philip L.
  • Scheiblich, Hannah
  • Brown, Guy C.
  • Landreth, Gary
  • Moutinho, Miguel
  • Grutzendler, Jaime
  • Gomez-Nicola, Diego
  • McManus, Róisín M.
  • Andreasson, Katrin
  • Ising, Christina
  • Karabag, Deniz
  • Baker, Darren J.
  • Liddelow, Shane A.
  • Verkhratsky, Alexei
  • Tansey, Malu
  • Monsonego, Alon
  • Aigner, Ludwig
  • Dorothée, Guillaume
  • Nave, Klaus-Armin
  • Simons, Mikael
  • Constantin, Gabriela
  • Rosenzweig, Neta
  • Pascual Bravo, Alberto
  • Petzold, Gabor C.
  • Kipnis, Jonathan
  • Venegas, Carmen
  • Colonna, Marco
  • Walter, Jochen
  • Tenner, Andrea J.
  • O'Banion, M. Kerry
  • Steinert, Joern R.
  • Feinstein, Douglas L.
  • Sastre, Magdalena
  • Bhaskar, Kiran
  • Hong, Soyon
  • Schafer, Dorothy P.
  • Golde, Todd
  • Ransohoff, Richard M.
  • Morgan, David
  • Breitner, John
  • Mancuso, Renzo
  • Riechers, Sean-Patrick
Increasing evidence points to a pivotal role of immune processes in the pathogenesis of Alzheimer disease, which is the most prevalent neurodegenerative and dementia-causing disease of our time. Multiple lines of information provided by experimental, epidemiological, neuropathological and genetic studies suggest a pathological role for innate and adaptive immune activation in this disease. Here, we review the cell types and pathological mechanisms involved in disease development as well as the influence of genetics and lifestyle factors. Given the decade-long preclinical stage of Alzheimer disease, these mechanisms and their interactions are driving forces behind the spread and progression of the disease. The identification of treatment opportunities will require a precise understanding of the cells and mechanisms involved as well as a clear definition of their temporal and topographical nature. We will also discuss new therapeutic strategies for targeting neuroinflammation, which are now entering the clinic and showing promise for patients., A.F. received funds from Germany’s Excellence Strategy (EXC 2067/1 390729940). A.J.T. is supported by the National Institutes of Health (NIH) grant (U54 AG054349). D.L.F. is supported by grant IK6BX004852-01 from the Department of Veterans Affairs. D.B. acknowledges support from the Medical Research Council UK, Alzheimer’s Research UK and the European Union. She thanks the UK Brain Banks and BRAIN UK for providing tissue for her studies. D.J.B. is supported by the NIH (R01AG053229, R01AG068076, U54AG079779), the Minnesota Partnership for Biotechnology and Medical Genomics (MNP #18.04), and the Glenn Foundation for Medical Research. C.Cunningham is funded by the Irish Research Council, National Institutes of Health, the Dutch Research Council (ZonMW) and Alzheimer’s Research UK. D.G.-N. was supported by grants from the Medical Research Council (MR/P024572/1, MR/Y004116/1). C.V. was supported by the RYC2022-036191-I, funded by MCIN/AEI/10.13039/501100011033 and European Social Fund Plus. C.T. is supported by the European Commission Marie Curie International Training Network, grant agreement No. 860197 (MIRIADE) and TAME, Innovative Medicines Initiatives 3TR (Horizon 2020, grant No. 831434), EPND (IMI 2 Joint Undertaking (JU), grant No. 101034344) and JPND (bPRIDE, CCAD), European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (22HLT07 NEuroBioStand), CANTATE project funded by the Alzheimer Drug Discovery Foundation, Alzheimer Association, Michael J Fox Foundation, Health Holland, ZonMW, Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, and Alzheimer Netherlands. C.T. is a recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). C.T. is a recipient of TAP-dementia, a ZonMw-funded project (#10510032120003) in the context of the Dutch National Dementia Strategy. D.M. is supported by ZEN24-1070221 from the Alzheimer’s Association and R01 AG055072, R01 AG077651, and P30 AG072931 from NIH. D.R.T. received support from Research Foundation – Flanders (FWO; G065721N), Stichting Alzheimer Onderzoek (SAO/FRA 2023/0009) and Alzheimer’s Association (22-AAIIA-963171). D.S. was supported by NINDS-R01NS117533, NIA-RF1AG068281 and NIH-R24OD036199. G.C. is supported by the NextGenerationEU and National Recovery and Resilience Plan, National Biodiversity Future Center and PE grant MNESYS (PE0000006). G.C.P. received funding from the German Science Foundation (PE1193/6-2), ERA-NET (MICRO-BLEEDs and TACKLE-CSVD), and the Fondation Leducq (Transatlantic Network of Excellence 23CVD03); he is a member of the Deutsche Forschungsgemeinschaft (DFG; German Research Foundation) excellence cluster ImmunoSensation2. G.D. thanks the Agence Nationale de la Recherche (grants #ANR-21-CE17-0054-01; #ANR-24-CE18-2770-02), Fondation Alzheimer, Fondation pour la Recherche Médicale, Fondation Pierre Deniker, Association France Alzheimer and Fondation Vaincre Alzheimer for funding his research. H.Z. is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe Research and Innovation Programme under grant agreement No. 101053962, and Swedish State Support for Clinical Research (#ALFGBG-71320). J.B. was supported by a research grant from the Canada Institute for Health Research. J.G. was funded by the JPB Foundation, the Cure Alzheimers Fund and The Alzheimer’s Association. J.C.M.S. is supported by a clinical fellowship from the Alzheimer’s Association (AACSF). J.V.S.-M. is supported by grants from the Pasqual Maragall Foundation (PMRP/2022/1184) and Spanish (PID2022-143263OB-I00) and Valencian (PROMETEO/2021/045) governments. K.-A.N. has been supported by grants from the DFG (TRR274), European Research Council (ERC; AdG MyeliNANO) and the Adelson Medical Research Foundation (AMRF). K.B. was funded by the NIH grant RF1NS083704. L.A. is supppoted by the Austrian Science Fund FWF Project #P35417-B. K.A. is the Edward F. and Irene Thiele Pimley Professor of Neurology and Neurological Sciences and is supported by NIH grants RF1 AG070839, RF1 AG079131, and RF1 AG080742, the Wu Tsai Neurosciences Institute Knight Initiative for Brain Resilience at Stanford University, and she is a Chan Zuckerberg Biohub-San Francisco Investigator. M.K.O. is supported by grant 80NSSC21K0542 from NASA. O.B. is funded by grants from NIH-STTR (R41AG073059), Cure Alzheimer Fund, BrightFocus Foundation (2020A016806), NIH/NIA (R01 AG051812), NIH (R01 AG054672), NIH (R01 AG075509), NIH (R01 NS088137-10), NIH (R21AG076982), and NIH/NINDS (R01 NS088137). R.Mancuso has funding from the ERC under the European Union’s Horizon 2020 Research and Innovation Programme (project no. 101041867 - XenoMicrogliaAD), Fonds voor Wetenschappelijk Onderzoek (grants No. G0C9219N, G056022N and G0K9422N), the Alzheimer’s Association USA (2018-AARF-591110, 2018-AARF-591110-RAPID, E2A-23-1148152, ABA-22-968700). He also receives funding from BrightFocus Foundation (A2021034S), SAO-FRA (grants No. 2021/0021 and SAO-FRA 20230019) and the University of Antwerp (BOF-TOP 2022-2025). R.McManus is supported by grants from the European Union Joint Programme Neurodegenerative Disease (JPND) (01ED2409B), the Alzheimer’s Association (24AARF-1243474) and from the DFG, under Germany’s Excellence Strategy – EXC2151 – 390873048, along with Project-ID 432325352 – SFB 1454. S.C.G. is supported by the Alzheimer Forschung Initiative e.V (Grant 21060), the Hertie Network of Excellence in Clinical Neuroscience (Grant 2021-1A-12), the Bonn Neuroscience Clinician Scientist Program (Neuro-aCSis), and the DFG (EXC2151–390873048). S.H. is supported by the UK Dementia Research Institute (UKDRI-1011) and the Chan Zuckerberg Initiative Neurodegeneration Network. J.J.N. is currently supported through Germany’s Excellence Strategy (EXC 2145 SyNergy– ID 390857198), the Else Kröner-Fresenius Stiftung (2018-A158), the Charitable Hertie Foundation (P1200024), the BrightFocus Foundation (A2021035S) and Alzheimer’s Association (ADSF-24-1345513-C). W.M.vdF. performs research at the Alzheimer Center Amsterdam as part of the neurodegeneration research programme of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting Steun Alzheimercentrum Amsterdam. The chair held by W.M.vdF. is supported by the Pasman Stichting. W.M.vdF. is a recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). W.M.vdF. is a recipient of TAP-dementia (www.tap-dementia.nl), receiving funding from ZonMw (#10510032120003)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Alterations of NMDAR Subunits in the Cerebrospinal Fluid Across Neurodegenerative and Immunological Disorders

  • Escamilla, Sergio
  • Pérez-González, Rocío
  • Márquez Marco, Carmen
  • Camporesi, Elena
  • Brinkmalm, Gunnar
  • Padovani, Alessandro
  • Pilotto, Andrea
  • Tolassi, Chiara
  • Arici, Davide
  • Volonghi, Irene
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Perez-Perez, Jesús
  • Kulisevsky, Jaime
  • Cuchillo-Ibáñez, Inmaculada
  • Sáez-Valero, Javier
N-methyl-D-aspartate receptors (NMDARs) are glutamate-binding calcium channels that play a key role in brain function and have been linked to many neurological disorders. NMDARs are multi-pass membrane heterotetrameric complexes composed of two compulsory GluN1 subunits and two GluN2 (A-D) or GluN3 (A-B) subunits, from which GluN1, GluN2B, GluN2A, and GluN3A are widely expressed in the adult brain. This study assesses the presence of GluN1, GluN2B, GluN2A, and GluN3A in the cerebrospinal fluid (CSF) from healthy individuals, viral and autoimmune encephalitis, Huntington's disease (HD) and Alzheimer's disease (AD) patients. Samples were run in SDS-PAGE under reducing conditions and resolved with different anti-ectodomain and anti-C-terminal antibodies that combined with immunoprecipitation analyses, served to demonstrate the presence of full-length GluN1, GluN2A, GluN2B, and GluN3A in CSF. These NMDAR subunit complexes are not associated with extracellular vesicles. As a proof of concept of the identity of NMDAR subunits in the CSF, we demonstrated reduced levels of GluN1 in the CSF from patients with autoimmune encephalitis caused by anti-GluN1 antibodies compared with other causes of encephalitis; and showed a depletion of CSF GluN3A in a Grin3a knockout mouse model. Moreover, we observed higher GluN3A levels in CSF in both asymptomatic and symptomatic HD patients; while GluN2A levels were lower in CSF from AD patients. In conclusion, here we demonstrate the presence of NMDAR full-length subunits in CSF and that changes in NMDAR subunits balance could serve to identify alterations related to pathological conditions., This work was supported by Fondo de Investigaciones Sanitarias (PI22/01329) and Direcció General de Ciència i Investigació, Generalitat Valenciana (AICO/2021/308)., We thank Prof. I. Pérez-Otaño (Instituto de Neurociencias de Alicante, CSIC-Universidad Miguel Hernández, Spain) for advice and the generous gift of the Grin3a knockout mouse. We also thank Prof. John J. Woodward (University of South Carolina, South Carolina, USA) and Juan Lerma (Instituto de Neurociencias de Alicante, CSIC-Universidad Miguel Hernández, Spain) for the generous gift of NMDA constructs; and Dr. Ricardo Rodrigues (CNC-UC-Center for Neuroscience and Cell Biology, University of Coimbra, Portugal) and Ana V. Paternain (Instituto de Neurociencias de Alicante, CSIC-Universidad Miguel Hernández, Spain) for guidance with the constructs and transfection. We thank Dr. A. Sogorb-Esteve (UK Dementia Research Institute at UCL, London) for assistance with mouse CSF extraction. This work was supported by grants from the Fondo de Investigaciones Sanitarias (PI22/01329, co-funded by the Fondo Europeo de Desarrollo Regional, FEDER “Investing in your future”), CIBERNED (Instituto de Salud Carlos III, Spain), and from the Direcció General de Ciència i Investigació, Generalitat Valenciana (AICO/2021/308) and “Severo Ochoa” Program for Centers of Excellence in R&D (CEX2021-001165-S). S.E. is supported by a PFIS fellowship from the ISC-III. APa has been supported by grants of the Italian Ministry of University and Research PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast (20202THZAW), the H2020 IMI IDEA-FAST (ID853981), Italian Ministry of Health, Grant/Award Number: RF-2018-12366209, RF-2019-12369272 and PNRR-Health PNRR-MAD-2022-12376110. APi has been supported by grants of Airalzh Foundation AGYR2021 Life-Bio Grant, The LIMPE-DISMOV Foundation Segala Grant 2021, the Italian Ministry of University and Research PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast (20202THZAW), the H2020 IMI IDEA-FAST (ID853981), Italian Ministry of Health, Grant/Award Number: RF-2018-12366209 and PNRR-Health PNRR-MAD-2022-12376110. C.T. is supported by the Ministry of Health PRIN 2021 RePlast. H.Z. is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356, #2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union's Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI-1003), and an anonymous donor., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Development and Validation of an ICP-MS/MS Method for the Multielemental Analysis of Cerebrospinal Fluid, Examination of Alzheimer's Disease Samples

  • Pérez-Ramírez, Rebeca
  • Cuchillo-Ibáñez, Inmaculada
  • Sánchez-Romero, Raquel
  • Beltrán-Sanahuja, Ana
  • Escamilla, Sergio
  • Molina-Gasset, Ricardo
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Sáez-Valero, Javier
  • Todolí-Torró, José Luis
Multielemental analysis of cerebrospinal fluid (CSF) yields critical insights into the pathophysiology of neurological disorders and holds potential as a diagnostic and predictive tool for Alzheimer's disease (AD). The present work presents the development and validation of an inductively coupled plasma tandem mass spectrometry (ICP-MS/MS) based method for multielemental determination in CSF, including metals and metalloids as analytes. As a proof of concept, the importance of the CSF element determination was evaluated in a cohort of patients with AD (n = 20) and non-AD controls (n = 19) who displayed typical levels of core CSF biomarkers (Aβ42, P-tau, and total-tau). Discrete sample introduction ICP-MS/MS procedure was effective for accurate and precise CSF analysis. The methodology provided better sensitivities and limits of detection than a conventional one based on sample dilution and analysis in continuous sample introduction mode, while only requiring a 20 μL CSF sample volume. A total of 24 elements were encountered and quantified in CSF, with reduced levels of Mn, Cr, Se, Fe, and Zn in the CSF from AD patients and increased levels of Ag and Bi, compared with non-AD patients. Particularly, Mn fully discriminated AD from non-AD subjects, with binary regression analysis indicating that Mn was the most effective element to distinguish between AD and non-AD groups. Furthermore, distinctive correlation profiles were found between AD and non-AD controls for elements with AD core biomarkers and the alternative amyloidogenic sAPPβ fragment. Quantitative determination of metals, metalloids and non-metals displays differences associated with pathological status, serving as additional biomarkers for neurological diseases., The authors wish to thank the Spanish State Research Agency (AEI) from the Ministry of Science, Innovation, and Universities for the financial support (Project Ref. PID2021-127566NB-I00). This work was also supported by grants from the Fondo de Investigaciones Sanitarias (PI22/01329, co-funded by the Fondo Europeo de Desarrollo Regional, FEDER “Investing in your future”), CIBERNED (Instituto de Salud Carlos III, Spain), the Direcció General de Ciència i Investigació, Generalitat Valenciana (AICO/2021/308) and by the Spanish State Research Agency (AEI/10.13039/501100011033), through the “Severo Ochoa” Center of Excellence grant to the IN (CEX2021-001165-S). SE is supported by a PFIS fellowship from the ISC-III. H.Z. is a Wallenberg scholar and a distinguished professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356, #2022-01018, and #2019-02397), the European Union's Horizon Europe research and innovation program under grant agreement No 101053962, and Swedish State Support for Clinical Research (#ALFGBG-71320)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

GluN2A-mediated currents and calcium signal in human iPSC-derived neurons

  • Escamilla, Sergio
  • Avilés-Granados, Carlos3
  • Peralta, Francisco Andrés
  • Paternain, Ana V.
  • Cortés‐Gómez, Maria‐Angeles
  • Zetterberg, Henrik
  • Peña, Elvira de la
  • Salas-Lucia, Federico
  • Sáez-Valero, Javier
  • Cuchillo-Ibáñez, Inmaculada
Gene expression data indicate that during human brain development, neurons change the NMDA receptor (NMDAR) subunit composition to modulate their function, favouring the GluN2A subunit over GluN2B-a hallmark of neuronal maturation. However, evidence supporting this phenomenon in human iPSC-derived neurons remains elusive. Here, using two differentiation methods in parallel (BrainPhys Neuronal Medium, BPM, and Neural Maintenance Medium, NMM), we provide evidence of increased synaptic localization of NMDARs during neuronal maturation and that GluN2A subunit is crucial for the NMDA physiological function-inducing inward currents and calcium entrance at 60 days of differentiation. Calcium responses to specific agonists, particularly NMDA, were elevated in cells cultured under BPM conditions. This is likely attributable to their more mature neuronal phenotype and the RNA-seq identified upregulation of genes involved in intracellular calcium signaling proteins. Our results offer insight into how glutamate receptor subunits mature during brain development, delineating approaches to study NMDAR activity in health and disease., This work was supported by grants from the Fondo de Investigaciones Sanitarias (PI22/01329, co-funded by the Fondo Europeo de Desarrollo Regional, FEDER “Investing in your future”), CIBERNED (Instituto de Salud Carlos III, Spain), the Instituto de Investigación Sanitaria y Biomédica de Alicante (Isabial), Direcció General de Ciència i Investigació, Generalitat Valenciana (CIAICO/2024/313) and “Severo Ochoa” Program for Centers of Excellence in R&D (CEX2021-001165-S). SE is supported by a PFIS fellowship from the ISC‐III. CAG is supported by a predoctoral contract. (PRE2022-104182) funded by the Agencia Estatal de Investigación (AEI) and the Ministerio de Ciencia e Innovación (MCIN) under the Plan Estatal de I + D+I 2021–2023, co-funded by the European Social Fund (FSE). FS-L is supported by University of Chicago start-up funds. AVP is supported by the Spanish Agency of Research (AEI) under the grants PID2022-136741NB-100 and by the Generalitat Valenciana through the program PROMETEO/2019/014 and CIPROM/2022/08 to Juan Lerma. EDLP and FAP are supported by grant PID2022-140961OB-100 (MCIN/AEI/https://doi.org/10.13039/501100011033), grant PROMETEO/2021/031 (Generalitat Valenciana Government) and “Severo Ochoa” Program for Centers of Excellence in R&D (CEX2021-001165-S). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023 − 00356, #2022 − 01018 and #2019–02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, and Swedish State Support for Clinical Research (#ALFGBG-71320)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer's disease patients

  • Gea-González, Adriana
  • Valle-Pedroso, Renata
  • López-Font, Inmaculada
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Sáez-Valero, Javier
  • García-Ayllón, María-Salud
ADAM10 and ADAM17, members of the membrane-bound disintegrin metalloproteinase (ADAM) family, act as α-secretases in the non-amyloidogenic processing of the amyloid precursor protein. While alterations in ADAM10, the primary α-secretase, have been reported in Alzheimer’s disease (AD), with certain controversy between studies, ADAM17 changes remain less understood. Both enzymes display a complex pattern of expression that includes immature zymogen and mature full-length, assigned as the active form, and soluble cleaved species. We reported for the first time that ADAM10 is present in human cerebrospinal fluid (CSF), and levels of the full-length and soluble fragments decrease in samples from AD patients., This work was supported by grants from Fundació para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (UGP-21-217 to M-S.G-A.); Fondo de Investigaciones Sanitarias (PI22/01329 to J.S-V and PI24/01421 to M-S.G-A)co-funded by the Fondo Europeo de Desarrollo Regional, FEDER “Investing in your future”); CIBERNED (Instituto de Salud Carlos III, Spain); Direcció General de Ciència i Investigació, Generalitat Valenciana (CIAICO/2024/313 to J.S-V). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023 − 00356, #2022 − 01018 and #2019–02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809–2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI-1003), and an anonymous donor. KB is supported by the Swedish Research Council (#2017 − 00915 and #2022 − 00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#ALZ2022-0006, #FO2024-0048-TK-130 and FO2024-0048-HK-24), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-965240 and #ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022–2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden. R-V.P. was supported by São Paulo Research Foundation (FAPESP, grants 2019/20110-1 and #2017/18808-5). A.G-G. was supported by a PhD fellowship (grant CIACIF/2021/426) funded by the Conselleria of Education, Culture, Universities and Employment (Generalitat Valenciana) and co-funded by the European Union through the Fondo Social Europeo (FSE)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cerebrospinal fluid and frontal cortex TMPRSS2 and ACE2 protein levels differ in Down syndrome and Alzheimer's disease

  • Avilés-Granados, Carlos
  • Gea-González, Adriana
  • Sáez-Leyva, Jorge
  • Pérez, Sylvia E.
  • Mufson, Elliott J.
  • Granholm, Ann-Charlotte
  • Carmona-Iragui, María
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Fortea, Juan
  • García-Ayllón, María-Salud
  • Sáez-Valero, Javier
Individuals with Down syndrome (DS) and Alzheimer’s disease (AD) are vulnerable to COVID-19, but whether alterations in ACE2, the viral receptor, and TMPRSS2, the spike-priming protease for SARS-CoV-2, differ between these disorders is unknown. We analyzed cleaved fragments and full-length species of ACE2 and TMPRSS2 in the cerebrospinal fluid (CSF) from non-infected individuals with DS (n = 9) without memory decline (nDS), DS with dementia (dDS; n = 10) and aged matched controls (n = 10). CSF levels were compared to levels in frozen postmortem frontal cortex in nDS (n = 4), dDS (n = 8) and 11 controls using quantitative fluorescent western blotting. We also examined CSF (19 AD and 19 age-matched non-AD controls) and frontal cortex from 30 AD cases and 7 non-disease controls. CSF and frontal cortex TMPRSS2 full-length zymogen and active protease-domain fragment were significantly increased in nDS, but not in dDS despite elevated zymogen. In contrast, AD CSF and frontal cortex levels of the TMPRSS2 protease fragment and zymogen remained unchanged. Regarding the viral receptor, an ~ 80 kDa fragment of ACE2 was significantly reduced in nDS CSF compared to controls, whereas there was a significant decrease in an ACE2 fragment/full-length quotient in both nDS and dDS. In frontal cortex, full-length ACE2 levels were preserved in nDS compared to controls, but several ACE2 species (120 and 110 kDa full-length, and 80 kDa fragment) were significantly decreased in dDS compared to nDS and controls. In contrast, CSF ACE2 130 kDa full-length levels were decreased compared to an increase in the fragment/full-length ratio in AD compared to controls, opposite to DS. In AD, frontal cortex levels of the 150 kDa ACE2 full-length species was significantly reduced across all Braak stages. ACE2 immunohistochemistry and immunofluorescence of frontal cortex sections revealed positive puncta in the neuropil, astrocytes and blood vessels in AD and DS with or without dementia. Overall, we found an increase in active TMPRSS2 and reduced soluble ACE2 fragments individuals with DS, particularly those without dementia, which differs from that observed in AD that may differentially affect susceptibility to COVID-19 viral infection in these conditions., This work was supported by grants from the Fondo de Investigaciones Sanitarias (PI22/01329, co-funded by the Fondo Europeo de Desarrollo Regional, FEDER “Investing in your future”), CIBERNED (Instituto de Salud Carlos III, Spain), from the Direcció General de Ciència i Investigació, Generalitat Valenciana (CIAICO/2024/313) and “Severo Ochoa” Program for Centers of Excellence in R&D (CEX2021-001165-S). CAG is supported by a predoctoral contract (PRE2022-104182) funded by the Agencia Estatal de Investigación (AEI) and the Ministerio de Ciencia e Innovación (MCIN) under the Plan Estatal de I + D+I 2021–2023, co-funded by the European Social Fund (FSE). A.G-G. was supported by a PhD fellowship (grant CIACIF/2021/426) funded by the Conselleria of Education, Culture, Universities and Employment (Generalitat Valenciana) and co-funded by the European Union through the Fondo Social Europeo (FSE). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023 − 00356, #2022 − 01018 and #2019–02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809–2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#2017 − 00915 and #2022 − 00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#ALZ2022-0006, #FO2024-0048-TK-130 and FO2024-0048-HK-24), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-965240 and #ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022–2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden. EM and SEP are supported by grants from the NIA PO1AG014449, RF1AG081286, R01AG061566), BrightFocus Foundation (CA2018010), Arizona Alzheimer’s Consortium, Barrow Neurological Foundation. ACG was supported by NIH grants (5 R01 AG071228-02, R01AG070153, 1U24AG092191-01, and 5 R01 AG061566) and by a Foundation Lejeune grant to the DSBC brain bank consortium (GRT-2023b/2277). The researchers also acknowledge the support of anonymous philanthropists and donors., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Meprin-β levels are increased in the brain and the cerebrospinal fluid of Alzheimer's disease patients

  • Escamilla, Sergio
  • Avilés-Granados, Carlos
  • Márquez Marco, Carmen
  • Keller, Maximilian
  • Sánchez-Domínguez, Irene
  • Cuchillo-Ibáñez, Inmaculada
  • Aguado, Fernando
  • Zetterberg, Henrik
  • Pietrzik, Claus U.
  • Sáez-Valero, Javier
The aim of this study is to assess the levels of meprin-β, an alternative β-secretase in the brain and cerebrospinal fluid of subjects suffering Alzheimer's disease. The full-length zymogen and the active species of meprin-β were characterized by immunoblotting and immunoprecipitation using ectodomain N-terminal and C-terminal antibodies. We examined meprin-β changes in extracts from Alzheimer's frontal cortex (n = 13, Braak stages I-II; n = 12, Braak stages III-IV; n = 12, Braak stages V-VI) compared with controls (n = 14), as well as in cerebrospinal fluid samples from Alzheimer's patients (n = 15) or non-Alzheimer's controls (n = 15). Cerebrospinal fluid meprin-β levels were also determined in 19-month old TgF344-AD and wild-type rats. Brain and cerebrospinal fluid from a Mep1b-null mouse served to characterize the specificity of the immunoreactive bands for meprin-β. Human induced pluripotent stem cell (iPSC)-derived neuronal cultures were treated with 2 μM Aβ42 for 24 h. We found that meprin-β is present in human brain extracts and cerebrospinal fluid as several distinct species, attributed to the zymogen and the mature species. These species were absent in brain and cerebrospinal fluid from a Mep1b-null mouse. No fragments of meprin-β were detected in brain extract, either in cerebrospinal fluid. Only the mature forms of meprin-β are increased in frontal cortex extracts (from Braak V-VI), but not the zymogen. The MEP1-B mRNA levels are increased in Braaks III-IV and V-VI compared with controls. The meprin-β species are increased in human neuronal cultures treated with Aβ42. Finally, we demonstrated elevated levels of the mature meprin-β in the cerebrospinal fluid of patients with Alzheimer's disease and in TgF344-AD rats. Our data support a role of meprin-β in Alzheimer's pathology., This work was supported by grants from the Fondo de Investigaciones Sanitarias (PI22/01329, co-funded by the Fondo Europeo de Desarrollo Regional, FEDER “Investing in your future”), CIBERNED (Instituto de Salud Carlos III, Spain), from the Direcció General de Ciència i Investigació, Generalitat Valenciana (CIAICO/2024/313), and “Severo Ochoa” Program for Centers of Excellence in R&D (CEX2021-001165-S). SE is funded by the Instituto de Salud Carlos III (PFIS fellowship). This study was also supported by the by the Spanish Ministry of Science, Innovation and Universities MICINN/FEDER (PID2022-142187OB-I00), to FA. CAG is supported by a predoctoral contract (PRE2022-104182) funded by the Agencia Estatal de Investigación (AEI) and the Ministerio de Ciencia e Innovación (MCIN) under the Plan Estatal de I + D + I 2021–2023, co-funded by the European Social Fund (FSE). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023–00356, #2022–01018 and #2019–02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201,809–2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21–831,376-C, #ADSF-21–831,381-C, #ADSF-21–831,377-C, and #ADSF-24–1,284,328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI-1003)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Time-encoded ASL reveals lower cerebral blood flow in the early AD continuum

  • Falcón, Carles
  • Minguillón, Carolina
  • Fauria, Karine
  • Cascales Lahoz, Diego
  • Contador, Jose
  • Fernández-Lebrero, Aida
  • Navalpotro-Gómez, Irene
  • Puig-Pijoan, Albert
  • Grau-Rivera, Oriol
  • Suárez-Calvet, Marc
  • Gispert López, Juan Domingo
Introduction: Cerebral blood flow (CBF) is reduced in cognitively impaired (CI) Alzheimer's disease (AD) patients. We checked the sensitivity of time-encoded arterial spin labeling (te-ASL) in measuring CBF alterations in individuals with positive AD biomarkers and associations with relevant biomarkers in cognitively unimpaired (CU) individuals. Methods: We compared te-ASL with single-postlabel delay (PLD) ASL in measuring CBF in 59 adults across the AD continuum, classified as CU amyloid beta (Aβ) negative (-), CU Aβ positive (+), and CI Aβ+. We sought associations of CBF with biomarkers of AD, cerebrovascular disease, synaptic dysfunction, neurodegeneration, and cognition in CU participants. Results: te-ASL was more sensitive at detecting CBF reduction in the CU Aβ+ and CI Aβ+ groups. In CU participants, lower CBF was associated with altered biomarkers of Aβ, tau, synaptic dysfunction, and neurodegeneration. Discussion: CBF reduction occurs early in the AD continuum. te-ASL is more sensitive than single-PLD ASL at detecting CBF changes in AD. Highlights: Lower CBF can be detected in CU subjects in the early AD continuum. te-ASL is more sensitive than single-PLD ASL at detecting CBF alterations in AD. CBF is linked to biomarkers of AD, synaptic dysfunction, and neurodegeneration., We want to express our most sincere gratitude to the ALFA project participants and relatives, without whom this research would not have been possible. We thank Roche Diagnostics International Ltd for providing the NeuroToolKit kits to measure CSF biomarkers, Eli Lilly and Company for providing the measurements of the in-house assay for CSF and plasma p-tau217, and GE Healthcare for providing the doses of [18F] flutemetamol PET. Lastly, we would like to thank Valeria Di Giacomo, PhD, and Allison Clark, from ThePaperMill, for providing writing support, funded by The Fundació Pasqual Maragall. Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III (ISCIII) through projects PI19/00155 and PI22/00456 (cofunded by the European Union FEDER), the Department of Research and Universities of the Generalitat de Catalunya through the project 2021 SGR 01137, the HNA Foundation through the project PROAD, and the ERA PerMed ERA-NET and the Department of Health of the Generalitat de Catalunya (DS-CAT) through the project SLD077/21/000001. Moreover, Marc receives support from a fellowship provided by “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant agreement No. 847648 (fellowship code LCF/BQ/PR21/11840004). Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (Nos. 2022-01018 and 2019-02397), the European Union's Horizon Europe research and innovation program under Grant agreement No. 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (No. 201809-2016862), the AD Strategic Fund and the Alzheimer's Association (Nos. ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant agreement No. 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). Oriol Grau-Rivera receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), the Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 (cofunded by the European Unior FEDER), and the MCIN/AEI/10.13039/501100011033 through the project IJC2020-043417-I (cofunded by the European Union NextGenerationEU/PRTR).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression

  • Pelkmans, Wiesje
  • Shekari, Mahnaz
  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • González Escalante, Armand
  • Kollmorgen, Gwendlyn
  • Carboni, Margherita
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • ALFA Study
Introduction: We studied how biomarkers of reactive astrogliosis mediate the pathogenic cascade in the earliest Alzheimer's disease (AD) stages. Methods: We performed path analysis on data from 384 cognitively unimpaired individuals from the ALzheimer and FAmilies (ALFA)+ study using structural equation modeling to quantify the relationships between biomarkers of reactive astrogliosis and the AD pathological cascade. Results: Cerebrospinal fluid (CSF) amyloid beta (Aβ)42/40 was associated with Aβ aggregation on positron emission tomography (PET) and with CSF p-tau181 , which was in turn directly associated with CSF neurofilament light (NfL). Plasma glial fibrillary acidic protein (GFAP) mediated the relationship between CSF Aβ42/40 and Aβ-PET, and CSF YKL-40 partly explained the association between Aβ-PET, p-tau181 , and NfL. Discussion: Our results suggest that reactive astrogliosis, as indicated by different fluid biomarkers, influences the pathogenic cascade during the preclinical stage of AD. While plasma GFAP mediates the early association between soluble and insoluble Aβ, CSF YKL-40 mediates the latter association between Aβ and downstream Aβ-induced tau pathology and tau-induced neuronal injury. Highlights: Lower CSF Aβ42/40 was directly linked to higher plasma GFAP concentrations. Plasma GFAP partially explained the relationship between soluble Aβ and insoluble Aβ. CSF YKL-40 mediated Aβ-induced tau phosphorylation and tau-induced neuronal injury., The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa‑17‑519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan government under grant no. 2017-SGR-892. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (2022-01018 and 2019-02397), the European Union's Horizon Europe research and innovation program under grant agreement 101053962, Swedish State Support for Clinical Research (ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (201809-2016862), the AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (2017‑00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (RDAPB‑201809‑2016615); the Swedish Alzheimer Foundation (AF‑742881); Hjärnfonden, Sweden (FO2017‑0243); the Swedish state under the agreement between the Swedish government and the county councils, the ALF‑agreement (ALFGBG‑715986); the European Union Joint Programme for Neurodegenerative Disorders (JPND2019‑466‑236); the National Institute of Health (NIH), USA (grant 1R01AG068398‑01); and the Alzheimer's Association 2021 Zenith Award (ZEN‑21‑848495). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement 948677), the Instituto de Salud Carlos III (PI19/00155, PI22/00456), and the ERC under the EU's ‘la Caixa’ Foundation (ID 100010434) and from the EU's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant (847648, LCF/BQ/PR21/11840004). JDG is supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054). JDG has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018‑102261). GS-B receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. OGR receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Data-driven CSF biomarker profiling: imaging and clinical outcomes in a cohort at risk of Alzheimer's disease

  • Argiris, Georgette
  • Akinci, Muge
  • Peña-Gómez, Cleofé
  • Palpatzis, Eleni
  • Garcia Prat, Marina
  • Shekari, Mahnaz
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Ashton, Nicholas J.
  • Karikari, Thomas K.
  • Brinkmalm-Westman, Ann
  • Lantero Rodriguez, Juan
  • Fauria, Karine
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Background: Cerebrospinal fluid (CSF) biomarkers of synaptic dysfunction, neuroinflammation, and glial response, complementing Alzheimer's disease (AD) core biomarkers, have improved the pathophysiological characterization of the disease. Here, we tested the hypothesis that the co-expression of multiple CSF biomarkers will help the identification of AD-like phenotypes when biomarker positivity thresholds are not met yet. Methods: Two hundred and seventy cognitively unimpaired adults with family history (FH) of sporadic AD (mean age = 60.6 ± 4.85 years, 64.8% women) underwent lumbar puncture, magnetic resonance imaging (n = 266) and positron emission tomography imaging (n = 239) protocols, and clinical evaluations. CSF Aβ42, Aβ40, p-tau181, p-tau217, p-tau231, NfL, neurogranin, sTREM2, YKL40, GFAP, S100, α-Synuclein, SYT1, and SNAP25 were measured. Participants were clustered based on CSF biomarker co-expression with an agglomerative algorithm. The predictive value of the classification against brain and cognitive outcomes was evaluated. Results: Three clusters (C) were identified. Higher Aβ burden and CSF p-tau was the hallmark of C1. The other two clusters showed lower Aβ burden but higher expression of glial (C2) or synaptic markers (C3). Participants in C1 showed an AD-like clinical phenotype, comprising participants with the overall highest percentage of two parent FH and APOE-ε4 carriers, in addition to comprising more females compared to C2. C3 displayed better vascular health compared to C1. C2 were older and comprised a lower percentage of females compared to C3. C1 showed an AD-like gray matter reduction in medial temporal (notably hippocampus) and frontal regions that were not observed in Aβ42/40 + compared with Aβ42/40 - . Furthermore, Aβ42/40 - participants in C1 showed GM reduction in inferior temporal areas compared with Aβ42/40 + participants overall. C1 membership also predicted cognitive decline in executive function, but not memory, beyond Aβ + status, overall suggesting a better prognosis in Aβ42/40 + participants without C1 membership. Additionally, C1 displayed a higher rate of conversion to Aβ + (25%) over time. Conclusions: Our results suggest that examining multiple CSF biomarkers reflecting diverse pathological pathways may complement and/or outperform AD core biomarkers and thresholding approaches to identify individuals showing a clinical and cognitive AD-like phenotype, including higher conversion to Aβ + , GM reductions and cognitive decline. The clinical utility of this approach warrants further investigation and replication in other cohorts., The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17–519007). Support has also been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant no. 2021 SGR 00913. The research leading to these results has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), to EMA-U. EMA-U is supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EMA-U receives support from EU Joint Programme-Neurodegenerative Disease Research (JPND2022-138). E.P is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). GA receives support from the Alzheimer’s Association research fellowship (23AARF-1028873). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022–01018 and #2019–02397), the European Union’s Horizon Europe research and innovation program under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201,809–2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21–831,376-C, #ADSF-21–831,381-C, and #ADSF-21–831,377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Program – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project "PI19/00155″, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The potential dual role of tau phosphorylation: plasma phosphorylated-tau217 in newborns and Alzheimer’s disease

  • González Ortiz, Fernando
  • Vávra, Jakub
  • Payne, Emma
  • Kirsebom, Bjørn-Eivind
  • Sjöbom, Ulrika
  • Santos, Cristiano
  • Júlvez Calvo, Jordi
  • Kramer, Kaitlin
  • Zalcberg, David
  • Montoliu-Gaya, Laia
  • Turton, Michael
  • Harrison, Peter
  • Hellström, Ann
  • Zetterberg, Henrik
  • Fladby, Tormod
  • Sanders, Robert D.
  • Blennow, Kaj
Tau phosphorylation plays an important role in brain physiology and pathology. During foetal development, it supports microtubule dynamics and neuroplasticity, whereas in Alzheimer’s disease (AD), it drives pathological tau aggregation and tangle formation. In this multicentre study (n = 462), we measured plasma phosphorylated-tau217 in healthy newborns, premature infants, patients with AD and healthy controls across various age groups. Plasma phosphorylated-tau217 levels were significantly higher in newborns compared to healthy individuals of any age group and even exceeded levels observed in patients with AD. In newborns, plasma phosphorylated-tau217 levels inversely correlated with perinatal factors such as gestational age. Longitudinal analysis of preterm infants demonstrated a decline in serum phosphorylated-tau217 levels over the first months of life, approaching levels observed in young adults. In contrast, elevated plasma phosphorylated-tau217 in older individuals was associated with AD pathology. Our findings corroborate the crucial role of tau phosphorylation in early brain development. However, in AD, tau phosphorylation transitions into a pathological mechanism. The high levels of blood-based phosphorylated-tau217 observed at birth and subsequent clearance might indicate distinct regulatory mechanisms that prevent tau aggregation in early life. Further studies are needed to explore the shared mechanisms of tau phosphorylation in newborns and AD., K.B. is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270 and #AF-994551), Hjärnfonden, Sweden (#ALZ2022-0006 and #FO2024-0048-TK-130), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-965240 and #ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark and Familjen Rönströms Stiftelse, Stockholm, Sweden. The project was funded by the Norwegian Research Council, JPND/PMI-AD (NRC 311993), the National Institute of Health (R01 AG083874-01). F.G.-O. was funded by the Anna Lisa and Brother Björnsson’s Foundation and Emil och Maria Palms Foundation. M.S.-C. receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 948677), Project ‘PI19/00155’, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 847648 (LCF/BQ/PR21/11840004). B.-E.K. was supported by a grant from Helse-Nord (HNF1540-20). H.Z. is a Wallenberg scholar and a distinguished professor at the Swedish Research Council and receives funding from the Swedish Research Council (#2023-00356, #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement no. 101053962 and Swedish State Support for Clinical Research (#ALFGBG-71320).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer's disease

  • González Escalante, Armand
  • Milà Alomà, Marta
  • Brum, Wagner S.
  • Ashton, Nicholas J.
  • Ortiz Romero, Paula, 1994-
  • Shekari, Mahnaz
  • Campo, Marta del
  • Anastasi, Federica
  • Quijano-Rubio, Clara
  • Kollmorgen, Gwendlyn
  • Minguillón, Carolina
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • Gispert, Juan Domingo
  • Zetterberg, Henrik
  • Vilor Tejedor, Natàlia, 1988-
  • Blennow, Kaj
  • Suárez-Calvet, Marc
Background: Plasma biomarkers of Alzheimer's disease (AD) change during preclinical stages, indicating potential for detecting amyloid-β (Aβ) pathology in cognitively unimpaired (CU) individuals. Given the need for accurate, scalable biomarkers, we evaluated a fully automated plasma panel to detect and monitor longitudinal Aβ accumulation in CU individuals. Methods: In this longitudinal study, we examined a plasma panel (Aβ42/40, p-tau181, GFAP, NfL, p-tau217 and ApoE4) in CU participants at risk for AD. We assessed the biomarkers' performance to detect Aβ pathology and the cross-sectional and longitudinal relationships between the biomarkers and Aβ accumulation, neurodegeneration and cognition. Findings: We included 400 middle-aged CU participants, of whom 135 (33.8%) were CSF Aβ-positive. All plasma biomarkers differed between Aβ-positive and -negative individuals, with plasma Aβ42/40, p-tau217, p-tau181/Aβ42, and p-tau217/Aβ42 showing the best performance in detecting A+ CU individuals. However, plasma Aβ42/40 was sensitive to random variability. Plasma p-tau217/Aβ42 had the highest performance in detecting PET A+ individuals (AUC = 0.94). All baseline plasma biomarkers were associated with longitudinal increases in Aβ deposition (mean follow-up [SD]: 3.27 ± 0.5). Longitudinal changes in plasma p-tau217 and p-tau217/Aβ42 were associated with concurrent changes in Aβ (both CSF and PET) and soluble tau pathology. Interpretation: In CU individuals, several plasma biomarkers at baseline detect Aβ accumulation and are associated with its short-term change. Plasma p-tau217, and p-tau217/Aβ42 longitudinal changes reflect concurrent Aβ accumulation during this period. These findings help enrich studies in CU individuals at risk of progressing to AD. Funding: ERC-2020-STG (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (SLD077/21/000001); PI19/00155; PI22/00456, LCF/BQ/PR21/11840004., This publication is part of the ALFA study (ALzheimers and Families). The authors would like to express their most sincere gratitude to the ALFA project participants and relatives without whom this research would not have been possible. The authors thank Roche Diagnostics International Ltd for providing the kits to measure Plasma and CSF biomarkers and GE Healthcare for providing the doses of [18F]flutemetamol PET. The NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use (Roche Diagnostics International Ltd, Rotkreuz, Switzerland). Elecsys Phospho-Tau (181P) CSF and Elecsys Total-Tau CSF assays are approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. We thank the collaborators of the ALFA Study: Alba Cañas, Albina Polo, Ana Fernández-Arcos, Annabella Beteta, Anna Brugulat-Serrat, Anna Soteras, Blanca Rodríguez-Fernández, Carme Deulofeu, Ferran Lugo, Irene Cumplido-Mayoral, Jordi Huguet, Laura Hernández, Maria Emilio, Patricia Genius, Paula Marne, Sandra Pradas, Sherezade Fuentes, and Wiesje Pelkmans. MMA receives funding from the Alzheimer’s Association Research Fellowship Program (AARF-23-1141384). FA receives funding from the JDC2022-049347-I grant, funded by the MCIU/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. GSB is supported by the Agencia Estatal de Investigación AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet contract), co-funded by the European Union (FSE+). OGR’s institution is supported by Roche Pharmaceuticals and Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer’s Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). NVT is supported by the Spanish Ministry of Science and Innovation - State Research Agency (grant RYC2022-038136-I, cofunded by the European Union FSE+ and grant PID2022-143106OA-I00 cofunded by the European Union FEDER). Additionally, NVT is supported by the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative. KB is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022–2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, and Familjen Rönströms Stiftelse, Stockholm, Sweden. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through the project SLD077/21/000001; Project “PI19/00155” and “PI22/00456”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's disease

  • Warmenhoven, Noëlle
  • Sánchez Benavides, Gonzalo
  • González Escalante, Armand
  • Milà Alomà, Marta
  • Shekari, Mahnaz
  • López-Martos, David
  • Ortiz Romero, Paula, 1994-
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Vilor Tejedor, Natàlia, 1988-
  • Arenaza Urquijo, Eider M.
  • Palpatzis, Eleni
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
Introduction: We examined whether baseline glial markers soluble triggering receptor expressed on myeloid cell 2 (sTREM2), chitinase 3-like protein 1 (YKL-40), and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF), and plasma GFAP are associated with cognitive change in cognitively unimpaired (CU) individuals at risk of Alzheimer's disease (AD). Methods: A total of 353 CU (mean age 60.9 years) participants were included (mean follow-up time 3.28 years). Linear regression models with cognition as outcome were used. We also tested whether amyloid beta (Aβ) status modified these associations. Results: Higher baseline CSF sTREM2 was associated with a positive global cognition (Preclinical Alzheimer's Cognitive Composite) rate of change, and better memory and executive outcomes, independently of AD pathology. Higher baseline plasma GFAP was associated with a decline on attention rate of change. Stratified analyses by Aβ status showed that CSF sTREM2 and YKL-40 were positively associated with executive functioning in amyloid negative (Aβ-) individuals. Discussion: Our results suggest that a TREM2-mediated microglial response may be associated with better longitudinal cognitive performance. Highlights: Higher cerebrospinal fluid (CSF) soluble triggering receptor expressed on myeloid cell 2 (sTREM2) relates to better longitudinal cognitive performance. The association between CSF sTREM2 and cognition is independent of Alzheimer's disease (AD) pathology. Targeting microglial reactivity may be a therapeutic strategy for AD prevention., This publication is part of the ALFA study (ALzheimers and Families). The authors would like to thank the collaborators of the ALFA study. Additionally, the authors would like to express their most sincere gratitude to the ALFA project participants and relatives without whom this research would not have been possible. The authors thank Roche Diagnostics International Ltd for providing the kits to measure CSF biomarkers and GE Healthcare for providing the doses of [18F]flutemetamol PET. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa17519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. GSB is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by the Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet Contract), so-funded by the European Union (FSE+). DLM is supported by the Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 (co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/“Investing in your future”). CM received funding within the context of EURO-FINGERS, a EU Joint Programme – Neurodegenerative Disease Research (JPND) project. The EURO-FINGERS project is supported through the following funding organizations under the aegis of JPND—www.jpnd.eu: Finland: Academy of Finland; Germany: Federal Ministry of Education and Research; Spain: National Institute of Health Carlos III; Luxembourg: National Research Fund; Hungary: National Research, Development and Innovation Office; and The Netherlands: Netherlands Organisation for Health Research and Development (ZonMW-Memorabel no. 733051102). JDG has received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), Innovative Health Initiative PROMINENT (grant agreement 101112145), EIT Digital (Grant 2021), and from the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project RTI2018102261. EAU has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00), the Alzheimer's Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), and the European Union Joint Program for Neurodegenerative Disorders (JPND2022-138, AC22/00060). EAU is also supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#201700915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB2018092016615); the Swedish Alzheimer Foundation (#AF742881); Hjärnfonden, Sweden (#FO20170243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALFagreement (#ALFGBG715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019466236); the National Institute of Health (NIH), USA (grant #1R01AG06839801); and the Alzheimer's Association 2021 Zenith Award (ZEN21848495). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III (ISCIII) through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) “A way to make Europe”), and receives the support of a fellowship funded by “la Caixa” Foundation (ID 100010434), and the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). OGR receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 co-funded by the European Union (FEDER), and from Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project IJC2020-043417-I, co-funded by the European Union “Next GenerationEU”/PRTR. NVT is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project IJDC2020-043216-I, co-funded by the European Union “Next GenerationEU”/PRTR) and project PID2022-143106OA-I00, co-funded by the European Union (FEDER). In addition, NVT receives funding from the Alzheimer's Disease Data Initiative (ADDI) through the Williams H. Gates Sr. Fellowship Program and the Ajuntament de Barcelona in collaboration with “la Caixa” Foundation though the project 23S06083-001.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Intracellular fluid accumulation underlies brain volume increases in early Alzheimer's disease

  • Kassinopoulos, Michalis
  • Montesinos, Paula
  • Falcon, Carles
  • Huguet, Jordi
  • Minguillón, Carolina
  • Fauria, Karine
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Sánchez González, Javier
  • Gispert, Juan Domingo
  • ALFA Study
Abstract In the preclinical stages of Alzheimer's disease, increased brain volume has been associated with amyloid-beta pathology, particularly in regions that undergo volume reductions as the disease progresses. Glial reactivity and water diffusion alterations have been linked to such macroscopic volumetric changes. Brain volume reductions have also been reported following amyloid-beta removal with anti-amyloid therapies with beneficial clinical effects, but it remains unclear whether these changes result from resolving amyloid-triggered neuroinflammation or neurodegeneration. Intravoxel incoherent motion modelling based on multi-shell diffusion-weighted imaging may provide a better understanding of the processes underlying these paradoxical changes. This study used intravoxel incoherent motion diffusion MRI to examine how alterations in cerebral water pools contribute to increased brain volume linked to amyloid-beta deposition and neuroinflammation in cognitively unimpaired individuals. We developed a three-compartment diffusion MRI model with four parameters of cerebral water diffusion: slow diffusion coefficient, fast diffusion coefficient, slow signal portion, and perfusion fraction. We computed these diffusion parameters in 297 cognitively unimpaired late middle-aged adults, 35% of whom showed evidence of amyloid deposition. We examined their correlation with demographic factors (age, sex, apolipoprotein E status), markers of Alzheimer's disease pathology, neurodegeneration, neuroinflammation, and mean diffusivity. Then, we identified regions showing grey matter volume increases related to amyloid burden and examined the association between grey matter volume and diffusion parameters within these regions. We did not find evidence of associations between diffusion parameters and amyloid-related biomarkers, whether assessed by PET or cerebrospinal fluid measures. In contrast, the four diffusion parameters showed strong and widespread associations with biomarkers of neuroinflammation and neurodegeneration, particularly in frontoparietal and cingulate regions. Additionally, in grey matter regions where volume increases were related to amyloid levels, volumes were negatively correlated with the slow diffusion coefficient (P = 0.001), perfusion fraction (P = 0.036) and mean diffusivity (P = 0.047). These findings indicate that diffusion-derived measures are more sensitive to neuroinflammatory and neurodegenerative processes than to amyloid pathology in cognitively unimpaired individuals. Furthermore, the observed negative association between grey matter volume and slow diffusion coefficient in amyloid-related regions may reflect increased cellular complexity rather than intracellular water accumulation. This interpretation suggests that glial remodelling or microstructural changes could underlie brain volume increases in amyloid-positive individuals without overt neurodegeneration. These results underscore the value of intravoxel incoherent motion-derived metrics for gaining deeper insights into the pathophysiological mechanisms of Alzheimer's disease, influencing brain volume changes as well as those resulting from the response to anti-amyloid therapies., The research leading to these results has received funding from 'la Caixa' Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016–2020 grant# SLT002/16/00201), and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. Henrik Zetterberg is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). Oriol Grau Rivera receives funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644568) and is supported by the Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I). Kaj Blennow is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, and Familjen Rönströms Stiftelse, Stockholm, Sweden. Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant agreement No. 948677) and the Instituto de Salud Carlos III through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund, FEDER, ‘A way to make Europe’). Moreover, Marc Suárez-Calvet receives the support of a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The CSF p-tau/ß-amyloid 42 ratio correlates with brain structure and fibrillary ß-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer's disease

  • Cacciaglia, Raffaele
  • Shekari, Mahnaz
  • Salvadó, Gemma
  • Milà Alomà, Marta
  • Falcón, Carles
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Fauria, Karine
  • Grau-Rivera, Oriol
  • Molinuevo, José Luis
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Quevenco, Frances-Catherine
  • Suárez-Calvet, Marc
  • Gispert López, Juan Domingo
  • ALFA Study
CSF concentrations of β-amyloid 42 (Aβ42) and phosphorylated tau (p-tau) are well-established biomarkers of Alzheimer's disease and have been studied in relation to several neuropathological features both in patients and in cognitively unimpaired individuals. The CSF p-tau/Aβ42 ratio, a biomarker combining information from both pathophysiological processes, has emerged as a promising tool for monitoring disease progression, even at pre-clinical stages. Here, we studied the association between the CSF p-tau/Aβ42 ratio with downstream markers of pre-clinical Alzheimer's disease progression including brain structure, glucose metabolism, fibrillary Aβ deposition and cognitive performance in 234 cognitively unimpaired individuals, who underwent cognitive testing, a lumbar puncture, MRI, 18F-fluorodeoxyglucose and 18F-flutemetamol PET scanning. We evaluated both main effects and interactions with Alzheimer's disease risk factors, such as older age, female sex and the apoliporoptein E (APOE)-ɛ4 allele, in a priori defined regions of interest and further examined the associations on the whole-brain using voxel-wise regressions. In addition, as the association between CSF Alzheimer's disease biomarkers and brain structure and function may be non-linear, we tested the interaction between the CSF p-tau/Aβ42 ratio and stages of pre-clinical Alzheimer's disease defined using the amyloid (A) and tau (T) classification. We found significantly positive associations between CSF p-tau/Aβ42 and both cortical Aβ deposition and regional grey matter volume while no effect was observed for brain metabolism. A significant interaction with age indicated that, for the same level of CSF p-tau/Aβ42, older individuals displayed both increased Aβ deposition and lower grey matter volume, in widespread cortical areas. In addition, we found that women compared with men had a greater Aβ fibrillary accumulation in midline cortical areas and inferior temporal regions, for the same level of the CSF biomarker. The impact of CSF p-tau/Aβ42 on grey matter volume was modulated by AT stages, with A+T+ individuals displaying significantly less positive associations in areas of early atrophy in the Alzheimer's continuum. Finally, we found that sex and APOE-ɛ4 modulated the association between the CSF biomarker and episodic memory as well as abstract reasoning, respectively. Our data indicate that the CSF p-tau/Aβ42 ratio is strongly associated with multiple downstream neuropathological events in cognitively unimpaired individuals and may thus serve as a potent biomarker to investigate the earliest changes in pre-clinical Alzheimer's disease. Given that its impact on both Aβ deposition and grey matter volume is modulated by specific risk factors, our results highlight the need to take into account such predisposing variables in both clinical practice and prevention trials., The research leading to these results has received funding from ‘la Caixa’ Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. R.C. receives funding from ‘Ministerio de Ciencia, Innovación y Universidades—Agencia Estatal de Investigación’ MCIN/AEI/10.13039/501100011033/FEDER, EU, through project PID2021-125433OA-100 and support from grant RYC2021-031128-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/Plan de Recuperación, Transformación y Resiliencia (PRTR). H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Union’s Horizon Europe research and innovation programme under grant agreement no. 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694) and the UK Dementia Research Institute at University College London (UCL) (UKDRI-1003). K.B. is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the Avtal om Läkarutbildning och Forskning (ALF) agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Programme for Neurodegenerative Disorders (JPND2019-466-236), the National Institutes of Health (NIH), USA, (grant #1R01AG068398-01), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495) and the Alzheimer’s Association 2022–25 Grant (SG-23-1038904 QC). M.S.-C. receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 948677), Project ‘PI19/00155’, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 847648 (LCF/BQ/PR21/11840004). O.G.-R. is supported by the ‘Ministerio de Ciencia, Innovación y Universidades' (IJC2020-043417-I) and receives funding from the Alzheimer’s Association (2019-AARF-644568) and the Instituto de Salud Carlos III (PI19/00117).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individuals

  • López-Martos, David
  • Suárez-Calvet, Marc
  • Cacciaglia, Raffaele
  • Shekari, Mahnaz
  • González Escalante, Armand
  • Brugulat Serrat, Anna, 1986-
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
Alzheimer's disease (AD) diagnostic guidelines emphasize subjective cognitive decline (SCD) preceding mild cognitive impairment (MCI), implicitly assuming awareness of cognitive decline (ACD) is preserved in preclinical AD. This study aimed to characterize a discrete clinical profile consistent with subtle amnestic anosognosia: decreased ACD, evaluating its association with multimodal core AD biomarkers in cognitively unimpaired (CU) individuals. We analyzed data from CU individuals with baseline CSF biomarkers and 3-year longitudinal neuropsychological assessment (ALFA+ cohort). Decreased ACD was defined by concurrent decline in episodic memory and cognitive awareness using robust longitudinal references (Free and Cued Selective Reminding Test, Memory Binding Test, Wechsler Memory Scale, and Subjective Cognitive Decline Questionnaire). Biomarker outcomes included plasma p-tau181, p-tau181/Aβ42, p-tau217; CSF p-tau181, Aβ42/40, p-tau181/Aβ42, p-tau217; Aβ ([¹⁸F]flutemetamol) and tau PET ([¹⁸F]RO948). Associations of ACD with AD biomarkers were evaluated using linear regression models. Sensitivity analysis was restricted to individuals with memory decline. 350 CU individuals were included (mean age 61 years; 60% female; mean education 14 years; 35% CSF Aβ-positive). Memory decline was identified in 61 (17%) individuals, of whom 25 (41%) exhibited concurrent awareness decline; meeting criteria for decreased ACD. This group demonstrated higher levels of AD pathology compared to the remaining sample. Among fluid biomarkers, CSF p-tau217 showed the strongest association. Neuroimaging revealed elevated frontoparietal Aβ PET, alongside temporal, insular, and frontal tau PET deposition. Sensitivity analysis confirmed that, although less pronounced, this pattern persists at the same threshold of memory decline. This study suggests that assessment of ACD may provide a crucial extension of current AD clinical frameworks., The research leading to these results has received funding from “la Caixa” Foundation under agreement LCF/PR/SC22/68000001, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa−17–519007). RC received funding from the MCIN/AEI/10.13039/501100011033/FEDER, EU, through the project PID2021–125433OA−100 and from the grant RYC2021–031128-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR; MS-C received funding from the ERC under the EU’s Horizon 2020 research and innovation program (grant no. 948677), ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project no. SLD077/21/000001, projects PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the EU (FEDER), and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 847648 (LCF/BQ/PR21/11840004)); AB-S received funding from the Alzheimer's Association Clinician Scientist Fellowship (AACSF) Program, through the grant AACSF−23–1145154; HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023–00356, #2022–01018 and #2019–02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG−71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809–2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF−21–831376-C, #ADSF−21–831381-C, #ADSF−21–831377-C, and #ADSF−24–1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Familjen Beiglers Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022–0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021–00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI−1003), and an anonymous donor; KB is supported by the Swedish Research Council (#2017–00915 and #2022–00732), the Swedish Alzheimer Foundation (#AF−930351, #AF−939721, #AF−968270, and #AF−994551), Hjärnfonden, Sweden (#ALZ2022–0006, #FO2024–0048-TK−130 and FO2024–0048-HK−24), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG−965240 and #ALFGBG−1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019–466–236), the Alzheimer’s Association 2021 Zenith Award (ZEN−21–848495), the Alzheimer’s Association 2022–2025 Grant (SG−23–1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden, and an anonymous philanthropist and donor; JDG was supported by the Spanish Ministry of Science and Innovation (RYC‑2013–13054), received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018–102261); OG-R received support from the grant IJC2020–043417-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR, and receives funding from Instituto de Salud Carlos III (ISCIII) through the projects "PI19/00117" and "PI24/00116", co-funded by the European Union/FEDER, and through the project "CB16/10/00417"; GS-B receives support from the grant CP23/00039 (Miguel Servet), funded by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union/FSE + , and receives funding from the MCIN/AEI/10.13039/501100011033 through the project PID2020–119556RA-I00 and through the project PID2024–163071OB-I00, funded by MICIU/AEI/10.13039/501100011033 and by the European Union FEDER.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Immune cell subpopulations and serum neurofilament light chain are associated with increased risk of disease worsening in multiple sclerosis

  • Brune-Ingebretsen, Synne
  • Høgestøl, Einar A.
  • de Rosbo, Nicole Kerlero
  • Berg-Hansen, Pål
  • Brunborg, Cathrine
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Paul, Friedemann
  • Uccelli, Antonio
  • Villoslada, Pablo
  • Harbo, Hanne F.
  • Berge, Tone
Changes is lymphocyte subpopulations in peripheral blood have been proposed as biomarkers for evaluation of disease activity in multiple sclerosis (MS). Serum neurofilament light chain (sNfL) is a biomarker reflecting neuro-axonal injury in MS that could be used to monitor disease activity, response to drugs and to prognosticate disease course. Here we show a moderate correlation between sNfL and lymphocyte cell subpopulations, and our data furthermore suggest that sNfL and specific immune cell subpopulations together could predict future disease worsening in MS., This work was supported by the European Commission (ERACOSYSMED ERA-Net program, Sys4MS project, id:43), Instituto de Salud Carlos III, Spain (AC1500052), the Italian Ministry of Health (WFR-PER-2013-02361136), the German Ministry of Science (Deutsches Teilprojekt B “Förderkennzeichen”: 031L0083B), the Norwegian Research Council (project 257955), the South-Eastern Norway Regional Health Authority (project 2019111) and Biogen Norway. Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, and Swedish State Support for Clinical Research (#ALFGBG-71320).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Longitudinal interplay between subclinical atherosclerosis, cardiovascular risk factors, and cerebral glucose metabolism in midlife: results from the PESA prospective cohort study

  • Tristão Pereira, Catarina
  • Fuster, Valentín
  • Oliva, Belén
  • Moreno Arciniegas, Andrea
  • Garcia-Lunar, Ines
  • Perez-Herreras, Cristina
  • Schöll, Michael
  • Suárez-Calvet, Marc
  • Moro, Maria Angeles
  • Garcia-Alvarez, Ana
  • Fernández Ortiz, Antonio
  • Sánchez González, Javier
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Ibáñez, Borja
  • Gispert, Juan Domingo
  • Cortes-Canteli, Marta
Background: Cardiovascular disease and dementia often coexist at advanced stages. Yet, longitudinal studies examining the interplay between atherosclerosis and its risk factors on brain health in midlife are scarce. We aimed to characterise the longitudinal associations between cerebral glucose metabolism, subclinical atherosclerosis, and cardiovascular risk factors in middle-aged asymptomatic individuals. Methods: The Progression of Early Subclinical Atherosclerosis (PESA) study is a Spanish longitudinal observational cohort study of 4184 asymptomatic individuals aged 40-54 years (NCT01410318). Participants with subclinical atherosclerosis underwent longitudinal cerebral [18F]fluorodeoxyglucose ([18F]FDG)-PET, and annual percentage change in [18F]FDG uptake was assessed (primary outcome). Cardiovascular risk was quantified with SCORE2 and subclinical atherosclerosis with three-dimensional vascular ultrasound (exposures). Multivariate regression and linear mixed effects models were used to assess associations between outcomes and exposures. Additionally, blood-based biomarkers of neuropathology were quantified and mediation analyses were performed. Secondary analyses were corrected for multiple comparisons using the false discovery rate (FDR) approach. Findings: This longitudinal study included a PESA subcohort of 370 participants (median age at baseline 49·8 years [IQR 46·1-52·2]; 309 [84%] men, 61 [16%] women; median follow-up 4·7 years [IQR 4·2-5·2]). Baseline scans took place between March 6, 2013, and Jan 21, 2015, and follow-up scans between Nov 24, 2017, and Aug 7, 2019. Persistent high risk of cardiovascular disease was associated with an accelerated decline of cortical [18F]FDG uptake compared with low risk (β=-0·008 [95% CI -0·013 to -0·002]; pFDR=0·040), with plasma neurofilament light chain, a marker of neurodegeneration, mediating this association by 20% (β=0·198 [0·008 to 0·740]; pFDR=0·050). Moreover, progression of subclinical carotid atherosclerosis was associated with an additional decline in [18F]FDG uptake in Alzheimer's disease brain regions, not explained by cardiovascular risk (β=-0·269 [95% CI -0·509 to -0·027]; p=0·029). Interpretation: Middle-aged asymptomatic individuals with persistent high risk of cardiovascular disease and subclinical carotid atherosclerosis already present brain metabolic decline, suggesting that maintenance of cardiovascular health during midlife could contribute to reductions in neurodegenerative disease burden later in life. Funding: Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III, Santander Bank, Pro-CNIC Foundation, BrightFocus Foundation, BBVA Foundation, "la Caixa" Foundation., We thank the PESA participants and the imaging, administrative, and medical PESA teams. The PESA study is equally co-funded by the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and Santander Bank (Madrid, Spain) and also receives funding from the Instituto de Salud Carlos III (ISCIII), Madrid, Spain (PI15/02019), the European Regional Development Fund (ERDF—A Way to Build Europe), and the European Social Fund (ESF—Investing in Your Future). CNIC is a Severo Ochoa Center of Excellence (CEX2020-001041-S) and is supported by the ISCIII, the Spanish Ministry for Science and Innovation, and the Pro-CNIC Foundation. CT-P was supported by a “la Caixa” Foundation fellowship (ID 100010434, LCF/BQ/DI19/11730052). MC-C was supported by a Miguel Servet type II research contract (ISCIII, CPII21/00007) and the Fondo de Investigación Sanitaria (ISCIII, PI20/00819). We acknowledge the Sephardic Foundation on Aging and other donors of the Alzheimer's Disease Research (grant number A2022034S), a programme of the BrightFocus Foundation, for support of this research. This work was also partially produced with the support of a 2021 Leonardo Grant for Researchers and Cultural Creators from the BBVA Foundation awarded to MC-C (the Foundation takes no responsibility for the opinions, statements, and contents of this project, which are entirely the responsibility of its authors). BI was supported by the European Research Council (ERC-2018-CoG 819775-MATRIX). MS is supported by the Knut and Alice Wallenberg Foundation (Wallenberg Centre for Molecular and Translational Medicine; KAW2014.0363), the Swedish Research Council (2017-02869, 2021-02678, 2021-06545), the Swedish state under the agreement between the Swedish Government and the County Councils, the ALF-agreement (ALFGBG-813971, ALFGBG-965326), the Swedish Brain Foundation (FO2021-0311), and the Swedish Alzheimer Foundation (AF-740191). MS-C receives funding from the European Research Council (grant agreement number 948677), project “PI19/00155”, funded by ISCIII and co-funded by the EU, and a fellowship from “la Caixa” Foundation (ID 100010434) and from the EU's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement number 847648 (LCF/BQ/PR21/11840004). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018), the EU's Horizon Europe research and innovation programme under grant agreement number 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation, USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the EU's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement number 860197 (MIRIADE), the EU Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#2017-00915, #2022-00732), the Swedish state under the agreement between the Swedish Government and the County Councils, the ALF-agreement (#ALFGBG-715986, #ALFGBG-965240), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270), Hjärnfonden, Sweden (#FO2017-0243, #ALZ2022-0006), the Alzheimer's Association 2021 Zenith Award (ZEN-21-848495), and the Alzheimer's Association 2022–2025 grant (SG-23-1038904 QC).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Plasma p-tau212 identifies cognitively unimpaired individuals with emerging amyloid-ß pathology

  • Kac, Przemysław R.
  • González Escalante, Armand
  • Milà Alomà, Marta
  • Ashton, Nicholas J.
  • Shekari, Mahnaz
  • Ortiz Romero, Paula, 1994-
  • Turton, Michael
  • Harrison, Peter
  • Zetterberg, Henrik
  • Gispert, Juan Domingo
  • Karikari, Thomas K.
  • Suárez-Calvet, Marc
  • Blennow, Kaj
Plasma phosphorylated-tau (p-tau) biomarkers show high performance as first-in-line tests in the evaluation of patients with cognitive symptoms and have also found utility in clinical trials for anti-amyloid drug therapies for Alzheimer¿s disease (AD). Plasma p-tau212 is a novel blood biomarker that can discriminate cognitively unimpaired (CU) and subjective cognitive decline patients from mild cognitive impairment (MCI)-AD and AD dementia patients in clinical cohorts. Using Simoa technology, we evaluated plasma p-tau212 for its ability to detect emerging amyloid-beta (Aß) pathology in CU individuals with brain amyloidosis from CSF Aß42/40 ratio (n = 317) or Aß PET scans (n = 277). We benchmarked plasma p-tau212 against p-tau181, p-tau217, and p-tau231 by comparing their accuracies and fold changes for detecting brain amyloidosis. Our results showed that all the plasma p-tau biomarkers are increased in the CU CSF Aß + participants, with the highest median fold change observed for plasma p-tau212. Discrimination performance of the biomarkers to differentiate amyloid PET-positive from amyloid PET-negative participants differed between plasma p-tau biomarkers, being higher for plasma p-tau217 and p-tau212 compared to plasma p-tau181 and p-tau231. Furthermore, plasma p-tau212 was elevated in participants with low Aß burden (CSF Aß-positive, amyloid PET-negative), supporting its potential as a cost-effective, easily implemented biomarker for trial recruitment in early stages. Its further increase in Aß PET-positive participants suggests additional utility for monitoring anti-amyloid therapies., Open access funding provided by University of Gothenburg. Demensförbundet, Anna-Lisa och Bror Björnssons Stiftelse, Alzheimer’s Association, AARF-23-1141384,Marta Milà-Alomà, (#ADSF-21-831376-C,Henrik Zetterberg, #ADSF-21-831381-C, Henrik Zetterberg,#ADSF-21-831377-C, Henrik Zetterberg, #ADSF-24-1284328-C, Henrik Zetterberg, ZEN-21-848495, Kaj Blennow, #AARF-21-850325, Thomas K. Karikari, Vetenskapsrådet, #2023-00356, Henrik Zetterberg, #2022-01018, Henrik Zetterberg, #2019-02397, Henrik Zetterberg, #ALFGBG-71320, Henrik Zetterberg, #2017-00915,Kaj Blennow, (#ALFGBG-715986, Kaj Blennow, #ALFGBG-965240, Kaj Blennow, 2021-03244, Thomas K. Karikari, HORIZON EUROPE Reforming and enhancing the European Research and Innovation system, 101053962, Henrik Zetterberg, 948677, Marc Suárez-Calvet, Alzheimer’s Drug Discovery Foundation, 201809-2016862, Henrik Zetterberg, #RDAPB-201809-2016615, Kaj Blennow, European Partnership on Metrology, NEuroBioStand,Henrik Zetterberg, #22HLT07, Henrik Zetterberg, the Bluefield Project, Cure Alzheimer’s Fund, Olav Thon Stiftelsen, Familjen Erling-Perssons Stiftelse, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, #FO2022-0270, Henrik Zetterberg, #FO2017-0243,Kaj Blennow, #ALZ2022-0006, Kaj Blennow, HORIZON EUROPE Marie Sklodowska-Curie Actions, 860197 (MIRIADE), Henrik Zetterberg, No 847648 LCF/BQ/PR21/11840004, Marc Suárez-Calvet, EU Joint Programme – Neurodegenerative Disease Research, JPND2021-00694, Henrik Zetterberg, University College London Hospitals Biomedical Research Centre, UK Dementia Research Institute, UKDRI-1003, Henrik Zetterberg, Departament de Salut, Generalitat de Catalunya, SLD077/21/000001,Marc Suárez-Calvet, PI19/00155,Marc Suárez-Calvet, PI22/00456, Marc Suárez-Calvet,’la Caixa’ Foundation, ID 100010434, Marc Suárez-Calvet, Instituto de Salud Carlos III, Alzheimerfonden, #AF-930351, Kaj Blennow, #AF-939721,Kaj Blennow, #AF-968270, Kaj Blennow, European Union Joint Program for Neurodegenerative Disorders, JPND2019-466-236, Kaj Blennow, National Institute of Health (NIH), #1R01AG068398-01, Kaj Blennow, 1 RF1 AG052525-01A1, Thomas K. Karikari, 5 P30 AG066468-04, Thomas K. Karikari, 5 R01 AG053952-05, Thomas K. Karikari, 3 R01 MH121619-04S1, Thomas K. Karikari, 5 R37 AG023651-18, Thomas K. Karikari, 2 RF1 AG025516-12A1, Thomas K. Karikari, 5 R01 AG073267-02, Thomas K. Karikari, 2 R01 MH108509-06, Thomas K. Karikari, 5 R01 AG075336-02,Thomas K. Karikari, 5 R01 AG072641-02, Thomas K. Karikari, 2 P01 AG025204-16, Thomas K. Karikari, WaAina (Ann) llströms and Mary-Ann Sjöbloms stiftelsen, Emil och Wera Cornells Stiftelse.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts

  • Lantero Rodríguez, Juan
  • Vrillon, Agathe
  • Fernández-Lebrero, Aida
  • Ortiz Romero, Paula, 1994-
  • Snellman, Anniina
  • Montoliu-Gaya, Laia
  • Brum, Wagner S.
  • Cognat, Emmanuel
  • Dumurgier, Julien
  • Puig-Pijoan, Albert
  • Navalpotro-Gómez, Irene
  • García-Escobar, Greta
  • Karikari, Thomas K.
  • Vanmechelen, Eugeen
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Suárez-Calvet, Marc
  • Paquet, Claire
  • Blennow, Kaj
Background Cerebrospinal fluid (CSF) p-tau235 is a novel biomarker highly specific of Alzheimer’s disease (AD). However, CSF p-tau235 has only been studied in well-characterized research cohorts, which do not fully reflect the patient landscape found in clinical settings. Therefore, in this multicentre study, we investigated the performance of CSF p-tau235 to detect symptomatic AD in clinical settings and compared it with CSF p-tau181, p-tau217 and p-tau231. Methods CSF p-tau235 was measured using an in-house single molecule array (Simoa) assay in two independent memory clinic cohorts: Paris cohort (Lariboisière Fernand-Widal University Hospital Paris, France; n=212) and BIODEGMAR cohort (Hospital del Mar, Barcelona, Spain; n=175). Patients were classified by the syndromic diagnosis (cognitively unimpaired [CU], mild cognitive impairment [MCI] or dementia) and their biological diagnosis (amyloid-beta [Aβ]+ or Aβ ). Both cohorts included detailed cognitive assessments and CSF biomarker measurements (clinically validated core AD biomarkers [Lumipulse CSF Aβ1–42/40 ratio, p-tau181 and t-tau] and in-house developed Simoa CSF p-tau181, p-tau217 and p-tau231). Results High CSF p-tau235 levels were strongly associated with CSF amyloidosis regardless of the clinical diagnosis, being significantly increased in MCI Aβ+ and dementia Aβ+ when compared with all other Aβ− groups (Paris cohort: P ˂0.0001 for all; BIODEGMAR cohort: P ˂0.05 for all). CSF p-tau235 was pronouncedly increased in the A+T+ profile group compared with A−T− and A+T− groups (P ˂0.0001 for all). Moreover, CSF p-tau235 demonstrated high diagnostic accuracies identifying CSF amyloidosis in symptomatic cases (AUCs=0.86 to 0.96) and discriminating AT groups (AUCs=0.79 to 0.98). Overall, CSF p-tau235 showed similar performances to CSF p-tau181 and CSF p-tau231 when discriminating CSF amyloidosis in various scenarios, but lower than CSF p-tau217. Finally, CSF p-tau235 associated with global cognition and memory domain in both cohorts. Conclusions CSF p-tau235 was increased with the presence of CSF amyloidosis in two independent memory clinic cohorts. CSF p-tau235 accurately identified AD in both MCI and dementia patients. Overall, the diagnostic performance of CSF p-tau235 was comparable to that of other CSF p-tau measurements, indicating its suitability to support a biomarker-based AD diagnosis in clinical settings., Open access funding provided by University of Gothenburg. This study was funded by the Swedish Research Council (#2017-00915 and #2022-00732), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236) and the National Institute of Health (NIH), USA, (grant #1R01AG068398-01). AV is supported by Fondation Ophtalmologique Adolphe de Rothschild and Fondation Vaincre Alzheimer. AES was supported by the Paulo Foundation, the Orion Research Foundation sr, and currently holds a postdoctoral fellowship from the Academy of Finland (#341059). TKK was funded by the Swedish Research Council (Vetenskapsrådet #2021-03244), the Alzheimer’s Association Research Fellowship (#AARF-21-850325), the Aina (Ann) Wallströms and Mary-Ann Sjöbloms stiftelsen and the Emil och Wera Cornells stiftelsen. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694) and the UK Dementia Research Institute at UCL (UKDRI-1003). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Multimodal biomarker characterization of amnestic objective subtle cognitive decline in aging and preclinical Alzheimer's disease

  • López-Martos, David
  • Cacciaglia, Raffaele
  • Suárez-Calvet, Marc
  • Salvadó, Gemma
  • Shekari, Mahnaz
  • González Escalante, Armand
  • Milà Alomà, Marta
  • Brugulat Serrat, Anna, 1986-
  • Minguillón, Carolina
  • Tonietto, Matteo
  • Borroni, Edilio
  • Klein, Gregory
  • Quijano-Rubio, Clara
  • Kollmorgen, Gwendlyn
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • Sánchez Benavides, Gonzalo
  • ALFA Study
Background The objective of this study was to provide a multimodal biomarker characterization of amnestic objective subtle cognitive decline (obj-SCD) in aging and preclinical Alzheimer's disease (AD). Methods Prospective observational study; data from the Alzheimer's and Families+ (ALFAs+) cohort, including cognitively unimpaired (CU) individuals with available baseline CSF biomarkers (normal or AD continuum profiles) and longitudinal neuropsychological assessment (2 time points, 3-year follow-up). Amnestic obj-SCD was defined using robust longitudinal neuropsychological references with multivariate base rate thresholds of significant decline (Free and Cued Selective Reminding Test, Memory Binding Test, Wechsler Memory Scale IV: Logical Memory). Study outcomes included plasma p-tau217, NfL, and GFAP; CSF p-tau181/Aß42, NfL, and GFAP; Aß and tau PET; and MRI Grey Matter volume (GMv). The associations of amnestic obj-SCD with fluid (plasma and CSF) and neuroimaging biomarkers (PET and GMv) were evaluated using mixed-effects and voxel-wise linear regression models, respectively. Results 350 CU individuals were included (mean age 61 years; 60% female; mean education 14 years; 35% CSF Aß-positive). Amnestic obj-SCD was identified in 10% of the sample, associated with greater AD pathology (higher plasma p-tau217, CSF p-tau181/Aß42, global Aß PET, medial temporal tau PET), neurodegeneration (higher plasma and CSF NfL, reduced GMv in cingulate cortex, longitudinal GMv reductions in hippocampus) and inflammation (higher plasma and CSF GFAP, longitudinal GMv increases in neocortical brain regions). Discussion These findings highlight the need for standardized clinical staging criteria to enhance early detection and risk stratification in aging and preclinical AD., The research leading to these results has received funding from “la Caixa” Foundation under agreement LCF/PR/SC22/68000001, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). R.C. received funding from the MCIN/AEI/10.13039/501100011033/FEDER, EU,through the project PID2021-125433OA-100 and from the grant RYC2021-031128-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR; M.S.-C. received funding from the ERC under the EU’s Horizon 2020 research and innovation program (grant no. 948677), ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project no. SLD077/21/000001, projects PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the EU (FEDER), and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 847648 (LCF/BQ/PR21/11840004)); A.B.-S. received funding from the Alzheimer's Association Clinician Scientist Fellowship (AACSF) Program, through the grant AACSF-23-1145154; H.Z. is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356, #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Familjen Beiglers Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI-1003), and an anonymous donor; K.B. is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#ALZ2022-0006, #FO2024-0048-TK-130 and FO2024-0048-HK-24), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-965240 and #ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden, and an anonymous filantropist and donor; J.D.G. was supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054), received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018‑102261); O.G.-R. was supported by the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva program IJC2020-043417-I), funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR, Instituto de Salud Carlos III (ISCIII) through the projects "PI19/00117" and "PI24/00116" and co-funded by the European Union/FEDER. OG-R also receives funding from F. Hoffmann-La Roche Ltd, and has given lectures in symposia sponsored by Roche Diagnostics, S.L.U; G.S.-B. was supported by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union/FSE+, supported by MCIN/AEI/10.13039/501100011033, through the project PID2020-119556RA-I00 and grant CP23/00039.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A blood-based multi-pathway biomarker assay for early detection and staging of Alzheimer's disease across ethnic groups

  • Jiang, Yuanbing
  • Ortiz Romero, Paula, 1994-
  • Puig-Pijoan, Albert
  • Fernández-Lebrero, Aida
  • Contador, José
  • Suárez-Calvet, Marc
  • Ip, Nancy Y.
Introduction: Existing blood-based biomarkers for Alzheimer's disease (AD) mainly focus on its pathological features. However, studies on blood-based biomarkers associated with other biological processes for a comprehensive evaluation of AD status are limited. Methods: We developed a blood-based, multiplex biomarker assay for AD that measures the levels of 21 proteins involved in multiple biological pathways. We evaluated the assay's performance for classifying AD and indicating AD-related endophenotypes in three independent cohorts from Chinese or European-descent populations. Results: The 21-protein assay accurately classified AD (area under the receiver operating characteristic curve [AUC] = 0.9407 to 0.9867) and mild cognitive impairment (MCI; AUC = 0.8434 to 0.8945) while also indicating brain amyloid pathology. Moreover, the assay simultaneously evaluated the changes of five biological processes in individuals and revealed the ethnic-specific dysregulations of biological processes upon AD progression. Discussion: This study demonstrated the utility of a blood-based, multi-pathway biomarker assay for early screening and staging of AD, providing insights for patient stratification and precision medicine. Highlights: The authors developed a blood-based biomarker assay for Alzheimer's disease. The 21-protein assay classifies AD/MCI and indicates brain amyloid pathology. The 21-protein assay can simultaneously assess activities of five biological processes. Ethnic-specific dysregulations of biological processes in AD were revealed., This study was supported in part by the National Key R&D Program of China (2021YFE0203000); the Areas of Excellence Scheme of the University Grants Committee (AoE/M-604/16); the Research Grants Council of Hong Kong (the Collaborative Research Fund [C6027-19GF] and the Theme-Based Research Scheme [T13-605/18 W]); the Innovation and Technology Commission (InnoHK; ITCPD/17-9, INNOHK18SC01, ITS/207/18FP, MRP/042/18X, and MRP/097/20X); Chow Tai Fook Charity Foundation (CTFCF18SC01); the Guangdong Provincial Key S&T Program Grant (2018B030336001); the Guangdong Provincial Fund for Basic and Applied Basic Research (2019B1515130004); and the Fundamental Research Program of Shenzhen Virtual University Park (2021Szvup137). Yuanbing Jiang is a recipient of the Hong Kong Postdoctoral Fellowship Award from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. HKUST PDFS2324-6S04). Marc Suárez-Calvet received funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (Grant Agreement No. 948677); Project “PI19/00155,” co-funded by Instituto de Salud Carlos III (ISCIII) and the European Union; and a fellowship from “La Caixa” Foundation (ID 100010434); and a fellowship from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie Grant Agreement (No. 847648; LCF/BQ/PR21/11840004). Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union's Horizon Europe Research and Innovation Programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Sex/gender effects of glial reactivity on preclinical Alzheimer's disease pathology

  • Vila-Castelar, Clara
  • Akinci, Muge
  • Palpatzis, Eleni
  • Aguilar Dominguez, Pablo
  • Operto, Grégory
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Falcón, Carles
  • Fauria, Karine
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Glial reactivity may contribute to sex/gender differences in Alzheimer's disease (AD) pathophysiology. Here, we investigated the differential effect of cerebrospinal fluid (CSF) glial markers on AD pathology and neurodegeneration by sex/gender among cognitively unimpaired older adults at increased risk of developing AD. We included 397 participants from the ALFA+ cohort with CSF Aβ42/40, p-tau181, sTREM2, YKL40, and GFAP, magnetic resonance imaging-based hippocampal volume (n = 299), and amyloid burden (centiloids) measured with [18F] flutemetamol positron emission tomography (n = 341). We ran multiple linear regression models to assess the association between glial markers, AD pathology and hippocampal volumes and their interaction with sex/gender, using False Discovery Rate to correct for multiple comparisons. Glial markers significantly contributed to explain amyloid burden, tau pathology, and hippocampal volumes, beyond age and/or primary AD pathology in a sex/gender-specific manner. Compared to men, women showed increased amyloid burden (centiloids) and CSF p-tau181 with increasing levels of sTREM2 and YKL40, and YKL40 and GFAP, respectively. Compared to women, men with greater tau burden showed lower hippocampal volumes as CSF YKL40 levels increased. Overall, our findings suggest that glial reactivity may contribute to sex/gender differences in AD progression, mostly, downstream amyloid. Further research identifying sex/gender-specific temporal dynamics in AD development is warranted to inform clinical trials., This publication is part of the ALFA study (ALzheimer and FAmilies). The authors would like to express their sincerest gratitude to the ALFA project participants, without whom this research would have not been possible. Collaborators of the ALFA study are: Federica Anastasi, Annabella Beteta, Anna Brugulat-Serrat, Raffaele Cacciaglia, Irene Cumplido-Mayoral, Alba Cañas, Marta del Campo, Carme Deulofeu, Ruth Dominguez, Maria Emilio, Ana Fernández-Arcos, Sherezade Fuentes, Patricia Genius, Armand González-Escalante, Laura Hernández, Felipe Hernández-Villamizar, Jordi Huguet, David López-Martos, Ferran Lugo, Paula Marne, Tania Menchón, Carolina Minguillon, Paula Ortiz, Wiesje Pelkmans, Albina Polo, Sandra Pradas, Blanca Rodríguez-Fernandez, Gonzalo Sánchez-Benavides, Mahnaz Shekari, Anna Soteras, Laura Stankeviciute, Marc Vilanova and Natalia Vilor-Tejedor. The authors would like to thank Jordi Huguet (Barcelonaβeta Brain Research Center, Barcelona) and Robin de Flores (INSERM, Caen, France) for their contributions to hippocampal subfield segmentation with Automated Segmentation of Hippocampal Subfields (ASHS). The Roche NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use. Elecsys β-amyloid (1–42) CSF, Elecsys Phospho-Tau (181P) CSF and Elecsys Total-Tau CSF assays are approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. The research leading to these results has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID) to EMA-U. EMA-U is supported by the Spanish Ministry of Science and Innovation - State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EMA-U receives support from EU Joint Programme-Neurodegenerative Disease Research J(PND2022-138). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). OG-R is supported by the Spanish Ministry of Science and Innovation –State Research Agency (IJC2020-043417-I/MCIN/AEI/10.13039/501100011033) and the European Union laquoNextGenerationEUraquo/PRTR. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) “A way to make Europe”), and receives the support of a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). CV-C is supported by a grant from the National Institute on Aging (K99AG073452).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Associations between objective sleep metrics and brain structure in cognitively unimpaired adults: interactions with sex and Alzheimer's biomarkers

  • Stankeviciute, Laura
  • Tort-Colet, Núria
  • Fernández-Arcos, Ana
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Fauria, Karine
  • Holst, Sebastian Camillo
  • Garcés, Pilar
  • Mueggler, Thomas
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Iranzo, Álex
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
INTRODUCTION: Sleep disturbances are prevalent in Alzheimer's disease (AD), probably emerging during its preclinical stage. Poor subjective sleep quality is linked to reduced brain volume and cortical thickness (CTh), but associations with objective sleep measures, particularly regarding sex and AD pathology, remain unclear. METHODS: We characterized 171 cognitively unimpaired adults from the ALzheimer and FAmilies (ALFA) Sleep study using actigraphy, MRI, amyloid beta 42/40, and phosphorylated tau at threonine 181 in cerebrospinal fluid. RESULTS: Lower sleep efficiency, higher wake after sleep onset (WASO), and sleep fragmentation were associated with lower CTh in the medial temporal lobe and other regions linked with AD and sleep disruption, even after adjusting for AD biomarkers. Sex and AD biomarkers modified these associations, with longer WASO showing a stronger correlation with lower CTh in females. DISCUSSION: Disrupted sleep may reduce cortical integrity independently of AD biomarkers, suggesting alternative pathways. Females appear more vulnerable to impaired sleep, and AD pathology may exacerbate AD-related changes in CTh. Highlights: Poor sleep efficiency, increased WASO, and sleep fragmentation are associated with reduced CTh in regions vulnerable to early AD, independently of amyloid and tau pathology. In the presence of AD pathology, this relationship is altered, with A+T+ individuals exhibiting increased CTh associated with sleep disruption. Sex-specific effects suggest females are more vulnerable to sleep-related cortical thinning. These findings highlight the potential of targeting sleep as a secondary prevention strategy to preserve brain integrity and mitigate neurodegenerative processes in AD-vulnerable regions., The ALFA+ study receives funding from ‘la Caixa’ Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an anonymous international charity foundation through the TriBEKa Imaging Platform project (TriBEKa‑17‑519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under Grant 2017-SGR-892. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (2022-01018 and 2019-02397), the European Union's Horizon Europe Research and Innovation Programme under Grant Agreement 101053962, Swedish State Support for Clinical Research (ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (201809-2016862), the AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270), the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie Grant Agreement 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). K.B. is supported by the Swedish Research Council (2017‑00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (RDAPB‑201809‑2016615); the Swedish Alzheimer Foundation (AF‑742881); Hjärnfonden, Sweden (FO2017‑0243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALF‑agreement (ALFGBG‑715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019‑466‑236); the National Institutes of Health (NIH), USA (Grant 1R01AG068398‑01); and the Alzheimer's Association 2021 Zenith Award (ZEN‑21‑848495). M.S.C. receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (Grant Agreement 948677), the Instituto de Salud Carlos III (PI19/00155, PI22/00456), and from the ERC under the EU's ‘la Caixa’ Foundation (ID 100010434) and from the EU's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant (847648, LCF/BQ/PR21/11840004). J.D.G. is supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054). J.D.G. has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (Grant Agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (Grant Agreement RTI2018‑102261). G.S-B. receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. O.G.R. receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme IJC2020-043417-I).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Differential effects of sleep on brain structure and metabolism at the preclinical stages of AD

  • Stankeviciute, Laura
  • Falcón, Carles
  • Operto, Grégory
  • Garcia, Marina
  • Shekari, Mahnaz
  • Iranzo, Álex
  • Niñerola-Baizán, Aida
  • Perissinotti, Andrés
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Cacciaglia, Raffaele
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
Introduction: Poor sleep quality is associated with cognitive outcomes in Alzheimer's disease (AD). We analyzed the associations between self-reported sleep quality and brain structure and function in cognitively unimpaired (CU) individuals. Methods: CU adults (N = 339) underwent structural magnetic resonance imaging, lumbar puncture, and the Pittsburgh Sleep Quality Index (PSQI) questionnaire. A subset (N = 295) performed [18F] fluorodeoxyglucose positron emission tomography scans. Voxel-wise associations with gray matter volumes (GMv) and cerebral glucose metabolism (CMRGlu) were performed including interactions with cerebrospinal fluid (CSF) AD biomarkers status. Results: Poorer sleep quality was associated with lower GMv and CMRGlu in the orbitofrontal and cingulate cortices independently of AD pathology. Self-reported sleep quality interacted with altered core AD CSF biomarkers in brain areas known to be affected in preclinical AD stages. Discussion: Poor sleep quality may impact brain structure and function independently from AD pathology. Alternatively, AD-related neurodegeneration in areas involved in sleep-wake regulation may induce or worsen sleep disturbances. Highlights Poor sleep impacts brain structure and function independent of Alzheimer's disease (AD) pathology. Poor sleep exacerbates brain changes observed in preclinical AD. Sleep is an appealing therapeutic strategy for preventing AD., This publication is part of the ALFA study (Alzheimer and Families). The authors would like to express their most sincere gratitude to the ALFA project participants and relatives, without whom this research would have not been possible. The authors thank Roche Diagnostics International Ltd. for providing the kits to measure CSF biomarkers and GE Healthcare for providing the doses for [18F]flutemetamol PET. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712 and #101053962), Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). Collaborators of the ALFA Study are Müge Akinci, Annabella Beteta, Alba Cañas, Irene Cumplido, Carme Deulofeu, Ruth Dominguez, Maria Emilio, Karine Fauria, Sherezade Fuentes, Oriol Grau-Rivera, Laura Hernandez, Gema Huesa, Jordi Huguet, Eider M. Arenaza-Urquijo, Paula Marne, Tania Menchón, Carolina Minguillon, Eva M. Palacios, Eleni Palpatzis, Cleofé Peña-Gómez, Albina Polo, Sandra Pradas, Blanca Rodríguez-Fernández, Aleix Sala-Vila, Gemma Salvadó, Mahnaz Shekari, Anna Soteras, Laura Stankeviciute, Marc Vilanova, and Natalia Vilor-Tejedor. This work was supported by a grant from the Alzheimer's Association (2019-AARF-644568) awarded to O.G.-R. The ALFASleep study also receives funding from the Instituto de Salud Carlos III through the project PI19/00117 (co-funded by European Regional Development Fund; “A way to make Europe”) awarded to OG-R. The ALFA+ study is funded by the “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). O.G.-R. is supported by the Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform

  • Palmqvist, Sebastian
  • Anastasi, Federica
  • Puig-Pijoan, Albert
  • Fernández-Lebrero, Aida
  • Contador, Jose
  • Suárez-Calvet, Marc
  • Hansson, Oskar
Global implementation of blood tests for Alzheimer's disease (AD) would be facilitated by easily scalable, cost-effective and accurate tests. In the present study, we evaluated plasma phospho-tau217 (p-tau217) using predefined biomarker cutoffs. The study included 1,767 participants with cognitive symptoms from 4 independent secondary care cohorts in Malmö (Sweden, n = 337), Gothenburg (Sweden, n = 165), Barcelona (Spain, n = 487) and Brescia (Italy, n = 230), and a primary care cohort in Sweden (n = 548). Plasma p-tau217 was primarily measured using the fully automated, commercially available, Lumipulse immunoassay. The primary outcome was AD pathology defined as abnormal cerebrospinal fluid Aβ42:p-tau181. Plasma p-tau217 detected AD pathology with areas under the receiver operating characteristic curves of 0.93-0.96. In secondary care, the accuracies were 89-91%, the positive predictive values 89-95% and the negative predictive values 77-90%. In primary care, the accuracy was 85%, the positive predictive values 82% and the negative predictive values 88%. Accuracy was lower in participants aged ≥80 years (83%), but was unaffected by chronic kidney disease, diabetes, sex, APOE genotype or cognitive stage. Using a two-cutoff approach, accuracies increased to 92-94% in secondary and primary care, excluding 12-17% with intermediate results. Using the plasma p-tau217:Aβ42 ratio did not improve accuracy but reduced intermediate test results (≤10%). Compared with a high-performing mass-spectrometry-based assay for percentage p-tau217, accuracies were comparable in secondary care. However, percentage p-tau217 had higher accuracy in primary care and was unaffected by age. In conclusion, this fully automated p-tau217 test demonstrates high accuracy for identifying AD pathology. A two-cutoff approach might be necessary to optimize performance across diverse settings and subpopulations., We would like to express our gratitude to the participants, and relatives, in all studies, without whom this research would have not been possible. In addition, we thank B. Arslan for analyzing plasma Aβ in the Gothenburg cohort. The BioFINDER group was supported by the National Institute of Aging (grant no. R01AG083740 to O.H., S.P., R.O. and S.J.), Alzheimer’s Association (grant nos. SG-23-1061717 and ZEN24-1069572 to O.H.), GHR Foundation (O.H. and S.P.), European Research Council (ERC, grant no. ADG-101096455 to O.H.), Swedish Research Council (grant nos. 2023-00356 to O.H., 2021-02219 to N.M.-C. and 2018-02052 to S.P.), ERA PerMed (grant no. ERAPERMED2021-184 to O.H.), the Knut and Alice Wallenberg Foundation (grant no. 2022-0231 to O.H.), the European Union’s (EU’s) Horizon Europe research and innovation program under grant agreement no. 101053962 (to O.H.), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University (to O.H.), the Swedish Alzheimer Foundation (grant nos. AF-1011949 and AF-994075 to S.P., AF-994229 to N.M.-C. and AF-981132 to S.P.), the Swedish Brain Foundation (grant nos. FO2023-0163 to N.M.-C., FO2024-0284 and FO2022-0204 to S.P. and FO2021-0293 to O.H.), the family Rönström’s Foundation (grant nos. FRS-0003 to N.M.-C. and FRS-0004 and FRS-0011 to S.P.), the Berg Family Foundation (O.H.), the Parkinson Foundation of Sweden (grant no. 1412/22 to O.H.), the Cure Alzheimer’s fund (O.H.), the Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (O.H.), the Skåne University Hospital Foundation (grant no. 2020-O000028 to S.P.), EU Joint Programme Neurodegenerative Diseases (grant no. 2019-03401 to N.M.-C.), WASP and DDLS Joint call for research projects (grant no. WASP/DDLS22-066 to N.M.-C.), Regionalt Forskningsstöd (grant no. 2022-1346 to S.P.) and the Swedish Federal Government under the ALF-agreement (grant nos. 2022-Projekt0107 to N.M.-C., 2022-Projekt0080 to O.H. and 2018-Projekt0226 to S.P.). The precursor of [18F]flutemetamol was sponsored by GE Healthcare. For the Gothenburg group, S.K. was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (nos. ALFGBG-1005471, ALFGBG-965923, ALFGBG-81392 and ALFGBG-771071), the Alzheimerfonden (grant nos. AF-842471, AF-737641, AF-929959 and AF-939825), the Swedish Research Council (grant nos. 2019-02075 and 2019-02075_15), Stiftelsen Psykiatriska Forskningsfonden and the Swedish Brain Foundation (grant no. FO2024-0097). A.D. was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (grant no. ALFGBG-984092). H.Z. is a Wallenberg Scholar and a distinguished professor at the Swedish Research Council. K.B. is supported by the Swedish Research Council (grant nos. 2017-00915 and 2022-00732), the Swedish Alzheimer Foundation (grant nos. AF-930351, AF-939721, AF-968270 and AF-994551), Hjärnfonden, Sweden (grant nos. ALZ2022-0006, FO2024-0048-TK-130 and FO2024-0048-HK-24), the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (grant nos. ALFGBG-965240 and ALFGBG-1006418), the Alzheimer’s Association 2022–2025 (grant no. SG-23-1038904 QC), the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden and an anonymous philanthropist and donor. The Barcelona group thanks P. Ortiz-Romero, M. de Diego, E. Jiménez, J. Torres and M. del Campo for technical support. F.A. received funding from grant no. JDC2022-049347-I, funded by the MCIU/AEI/10.13039/501100011033 and the EU NextGeneration EU/PRTR. M.S.-C. received funding from the ERC under the EU’s Horizon 2020 research and innovation program (grant no. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project no. SLD077/21/000001; project PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the EU; and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 847648 (LCF/BQ/PR21/11840004)). For the Brescia group, A. Pilotto has beensupported by grants of Airalzh Foundation AGYR2021) Life-BIO grant, the LIMPE-DISMOV Foundation Segala Grant 2021, the Italian Ministry of University and Research PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast (20202THZAW), the H2020 IMI IDEA-FAST (ID853981) and the Italian Ministry of Health, grant/award nos. RF-2018-12366209 and PNRR-Health PNRR-MAD-2022-12376110. V.Q. was supported by the H2020 IMI IDEA-FAST (grant no. ID853981). C.T. was supported by the PRIN 2021 RePlast (grant no. 20202THZAW). A. Padovani has been supported by grants of the Italian Ministry of University and Research PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast (20202THZAW), the H2020 IMI IDEA-FAST (ID853981) and the Italian Ministry of Health, grant/award nos. RF-2018-12366209, RF-2019 RF-2019-12369272 and PNRR-Health PNRR-MAD-2022-12376110. The funders had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review or approval of the paper and decision to submit the paper for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease

  • González Ortiz, Fernando
  • González Escalante, Armand
  • Ortiz Romero, Paula, 1994-
  • Minguillón, Carolina
  • Contador, José
  • Suárez-Calvet, Marc
  • Blennow, Kaj
Introduction: Detection of Alzheimer's disease (AD) pathophysiology among individuals with mild cognitive changes and those experiencing subjective cognitive decline (SCD) remains challenging. Plasma phosphorylated tau 217 (p-tau217) is one of the most promising of the emerging biomarkers for AD. However, accessible methods are limited. Methods: We employed a novel p-tau217 immunoassay (University of Gothenburg [UGOT] p-tau217) in four independent cohorts (n = 308) including a cerebrospinal fluid (CSF) biomarker-classified cohort (Discovery), two cohorts consisting mostly of cognitively unimpaired (CU) and mild cognitively impaired (MCI) participants (MYHAT and Pittsburgh), and a population-based cohort of individuals with SCD (Barcelonaβeta Brain Research Center's Alzheimer's At-Risk Cohort [β-AARC]). Results: UGOT p-tau217 showed high accuracy (area under the curve [AUC] = 0.80-0.91) identifying amyloid beta (Aβ) pathology, determined either by Aβ positron emission tomography or CSF Aβ42/40 ratio. In individuals experiencing SCD, UGOT p-tau217 showed high accuracy identifying those with a positive CSF Aβ42/40 ratio (AUC = 0.91). Discussion: UGOT p-tau217 can be an easily accessible and efficient way to screen and monitor patients with suspected AD pathophysiology, even in the early stages of the continuum., This publication is part of the BBRC's β-AARC study, the MYHAT study, and the Pittsburgh study. The authors would like to express their most sincere gratitude to the project participants, without whom this research would have not been possible. The authors would like to thank Altoida for kindly supporting the CSF AD core biomarker characterisation of β-AARC study participants. F.G.-O. was funded by the Anna Lisa and Brother Björnsson's Foundation and Emil och Maria Palms Foundation. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation ə under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation ə under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). K.B. is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the Alzheimer's Association 2021 Zenith Award (ZEN-21-848495), and the Alzheimer's Association 2022-2025 Grant (SG-23-1038904 QC). M.S.C. receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). T.K.K. was supported by grants 1 R01 AG083874-01 and 1U24AG082930 from the National Institutes of Health (NIH), the Swedish Research Council (Vetenskåpradet; 2021-03244), the Alzheimer's Association (AARF-21-850325), the Swedish Alzheimer Foundation (Alzheimerfonden), the Aina (Ann) Wallströms and Mary-Ann Sjöbloms Stiftelsen, and the Emil och Wera Cornells stiftelsen. M.G. and the MYHAT study were funded by the NIH (grants AG052521 and R37 AG023651). The other Pittsburgh cohorts were financed by the NIH (grants P30 AG066468, P01AG025204, RF1AG025516, RF1AG052525, R01AG052446, and R01AG052446).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic

  • Anastasi, Federica
  • Fernández-Lebrero, Aida
  • Ortiz Romero, Paula, 1994-
  • Torres-Torronteras, Javier
  • González Escalante, Armand
  • Contador, Jose
  • García Escobar, Greta
  • Manero, Rosa María
  • Navalpotro-Gómez, Irene
  • Jiménez-Moyano, Esther
  • Grau-Rivera, Oriol
  • Campo, Marta del
  • Puig-Pijoan, Albert
  • Suárez-Calvet, Marc
Introduction: Blood-based biomarkers for Alzheimer's disease (AD) have been widely studied, but direct comparisons of several biomarkers in clinical settings remain limited. Methods: In this cross-sectional study, plasma biomarkers from 197 participants in the BIODEGMAR cohort (Hospital del Mar, Barcelona) were analyzed. Participants were classified based on AD cerebrospinal fluid (CSF) core biomarkers. We assessed the ability of plasma p-tau181, p-tau217, p-tau231, t-tau, and Aβ42/40 to classify Aβ pathology status. Results: Plasma p-tau biomarkers had a greater diagnostic performance and larger effect sizes compared to t-tau and Aβ42/40 assays in detecting Aβ pathology. Among them, plasma p-tau217 consistently outperformed the others, demonstrating superior area under the curves. Furthermore, p-tau217 showed the strongest correlation between plasma and CSF levels, underscoring its potential as a reliable surrogate for CSF biomarkers. Discussion: Several plasma biomarkers, targeting different epitopes and using different platforms, demonstrated high performance in detecting AD in a memory clinic setting. Highlights: Plasma p-tau biomarkers demonstrated higher diagnostic performance and larger effect sizes than t-tau and Aβ42/40 assays in detecting Alzheimer's disease. Among the p-tau biomarkers, p-tau217 assays consistently outperformed the others, providing superior classification of Aβ pathology status across different phosphorylation sites. p-tau217 assays showed the strongest correlation between plasma and CSF levels, indicating its potential as a reliable surrogate for CSF biomarkers. Several plasma p-tau biomarkers can be used in a specialized memory clinic to accurately detect Alzheimer's disease., Federica Anastasi receives funding from the JDC2022-049347-I grant, funded by the MCIU/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. Henrik Zetterberg is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union's Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through the project SLD077/21/000001; Project “PI19/00155″ and “PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Awareness of episodic memory and meta-cognitive profiles: associations with cerebrospinal fluid biomarkers at the preclinical stage of the Alzheimer's continuum

  • López-Martos, David
  • Suárez-Calvet, Marc
  • Milà Alomà, Marta
  • Gispert, Juan Domingo
  • Minguillón, Carolina
  • Quijano-Rubio, Clara
  • Kollmorgen, Gwendlyn
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Grau, Oriol (Grau Rivera)
  • Sánchez Benavides, Gonzalo
Introduction: The lack of cognitive awareness, anosognosia, is a clinical deficit in Alzheimer's disease (AD) dementia. However, an increased awareness of cognitive function, hypernosognosia, may serve as a marker in the preclinical stage. Subjective cognitive decline (SCD) might correspond to the initial symptom in the dynamic trajectory of awareness, but SCD might be absent along with low awareness of actual cognitive performance in the preclinical stage. We hypothesized that distinct meta-cognitive profiles, both hypernosognosia and anosognosia, might be identified in preclinical-AD. This research evaluated the association between cerebrospinal fluid (CSF) AD biomarkers and the awareness of episodic memory, further exploring dyadic (participant-partner) SCD reports, in the preclinical Alzheimer's continuum. Methods: We analyzed 314 cognitively unimpaired (CU) middle-aged individuals (mean age: 60, SD: 4) from the ALFA+ cohort study. Episodic memory was evaluated with the delayed recall from the Memory Binding Test (MBT). Awareness of episodic memory, meta-memory, was defined as the normalized discrepancy between objective and subjective performance. SCD was defined using self-report, and dyadic SCD profiles incorporated the study partner's report using parallel SCD-Questionnaires. The relationship between CSF Aβ42/40 and CSF p-tau181 with meta-memory was evaluated with multivariable regression models. The role of SCD and the dyadic contingency was explored with the corresponding stratified analysis. Results: CSF Aβ42/40 was non-linearly associated with meta-memory, showing an increased awareness up to Aβ-positivity and a decreased awareness beyond this threshold. In the non-SCD subset, the non-linear association between CSF Aβ42/40 and meta-memory persisted. In the SCD subset, higher Aβ-pathology was linearly associated with increased awareness. Individuals presenting only study partner's SCD, defined as unaware decliners, exhibited higher levels of CSF p-tau181 correlated with lower meta-memory performance. Discussion: These results suggested that distinct meta-cognitive profiles can be identified in preclinical-AD. While most individuals might experience an increased awareness associated with the entrance in the AD continuum, hypernosognosia, some might be already losing insight and stepping into the anosognosic trajectory. This research reinforced that an early anosognosic profile, although at increased risk of AD-related decline, might be currently overlooked considering actual diagnostic criteria, and therefore its medical attention delayed., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The design and execution of the study were independent of any influence from funding sources. This includes data collection, analysis, interpretation, manuscript preparation, review, and approval. The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. DL-M was supported by Instituto de Salud Carlos III through the project PI19/00117 (Co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/”Investing in your future”). MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project “PI19/00155” and “PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). JG receives funding from the European Comission Innovative Health Initiative (Grant Agreement: 101112145), the BrightFocus Foundation (Grant Reference ID: A2022034S), and La Marató de TV3 (Project: 202318 30-31-32). HZ was a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). KB was supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), and the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC). OG-R was supported by the Spanish Ministry of Science and Innovation –State Research Agency (IJC2020-043417-I/MCIN/AEI/10.13039/501100011033) and the European Union laquoNextGenerationEUraquo/PRTR. GS-B was supported by the Agencia Estatal de Investigación AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet contract), co-funded by the European Union (FSE+).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Basal forebrain atrophy along the Alzheimer's disease continuum in adults with Down syndrome

  • Aranha, Mateus|||0000-0001-9594-292X
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Grothe, Michel|||0000-0003-2600-9022
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Padilla, Concepción|||0000-0003-4102-6787
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Fernández, Susana|||0000-0002-9777-1156
  • Ribas, Laia
  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Alcolea, Daniel|||0000-0002-3819-3245
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Bargalló, Núria|||0000-0001-6284-5402
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Blesa, Rafael|||0000-0003-4026-2884
  • Wisniewski, Thomas M.
  • Busciglio, Jorge A.
  • Cuello, AC.|||0000-0003-2143-2745
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
Background: Basal forebrain (BF) degeneration occurs in Down syndrome (DS)-associated Alzheimer's disease (AD). However, the dynamics of BF atrophy with age and disease progression, its impact on cognition, and its relationship with AD biomarkers have not been studied in DS. Methods: We included 234 adults with DS (150 asymptomatic, 38 prodromal AD, and 46 AD dementia) and 147 euploid controls. BF volumes were extracted from T-weighted magnetic resonance images using a stereotactic atlas in SPM12. We assessed BF volume changes with age and along the clinical AD continuum and their relationship to cognitive performance, cerebrospinal fluid (CSF) and plasma amyloid/tau/neurodegeneration biomarkers, and hippocampal volume. Results: In DS, BF volumes decreased with age and along the clinical AD continuum and significantly correlated with amyloid, tau, and neurofilament light chain changes in CSF and plasma, hippocampal volume, and cognitive performance. Discussion: BF atrophy is a potentially valuable neuroimaging biomarker of AD-related cholinergic neurodegeneration in DS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Predicting AT(N) pathologies in Alzheimer's disease from blood-based proteomic data using neural networks

  • Zhang, Yuting
  • Ghose, Upamanyu
  • Buckley, Noel J.|||0000-0003-1152-0653
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Sleegers, Kristel|||0000-0002-0283-2332
  • Frisoni, Giovanni B.|||0000-0002-6419-1753
  • Wallin, Anders|||0000-0001-9506-0513
  • Lleó, Alberto|||0000-0002-2568-5478
  • Popp, Julius|||0000-0002-0068-0312
  • Martinez-Lage, Pablo|||0000-0001-5404-9967
  • Legido-Quigley, Cristina|||0000-0002-4018-214X
  • Barkhof, Frederik|||0000-0003-3543-3706
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Visser, Pieter Jelle|||0000-0001-8008-9727
  • Bertram, Lars|||0000-0002-0108-124X
  • Lovestone, Simon|||0000-0003-0473-4565
  • Nevado-Holgado, Alejo|||0000-0001-9276-2720
  • Shi, Liu|||0000-0003-1752-0419
Background and objective: Blood-based biomarkers represent a promising approach to help identify early Alzheimer's disease (AD). Previous research has applied traditional machine learning (ML) to analyze plasma omics data and search for potential biomarkers, but the most modern ML methods based on deep learning has however been scarcely explored. In the current study, we aim to harness the power of state-of-the-art deep learning neural networks (NNs) to identify plasma proteins that predict amyloid, tau, and neurodegeneration (AT[N]) pathologies in AD. Methods: We measured 3,635 proteins using SOMAscan in 881 participants from the European Medical Information Framework for AD Multimodal Biomarker Discovery study (EMIF-AD MBD). Participants underwent measurements of brain amyloid β (Aβ) burden, phosphorylated tau (p-tau) burden, and total tau (t-tau) burden to determine their AT(N) statuses. We ranked proteins by their association with Aβ, p-tau, t-tau, and AT(N), and fed the top 100 proteins along with age and apolipoprotein E (APOE) status into NN classifiers as input features to predict these four outcomes relevant to AD. We compared NN performance of using proteins, age, and APOE genotype with performance of using age and APOE status alone to identify protein panels that optimally improved the prediction over these main risk factors. Proteins that improved the prediction for each outcome were aggregated and nominated for pathway enrichment and protein-protein interaction enrichment analysis. Results: Age and APOE alone predicted Aβ, p-tau, t-tau, and AT(N) burden with area under the curve (AUC) scores of 0.748, 0.662, 0.710, and 0.795. The addition of proteins significantly improved AUCs to 0.782, 0.674, 0.734, and 0.831, respectively. The identified proteins were enriched in five clusters of AD-associated pathways including human immunodeficiency virus 1 infection, p53 signaling pathway, and phosphoinositide-3-kinase-protein kinase B/Akt signaling pathway. Conclusion: Combined with age and APOE genotype, the proteins identified have the potential to serve as blood-based biomarkers for AD and await validation in future studies. While the NNs did not achieve better scores than the support vector machine model used in our previous study, their performances were likely limited by small sample size.